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Abstract 
The chemokine receptor CXCR3, which has three known variants (CXCR3-A, 
CXCR3-B and CXCR3-Alt), has been implicated in the recruitment of mast cells to 
tissues in many different chronic diseases with its agonists found in elevated levels 
in many pulmonary diseases. All three variants of CXCR3 were detected in cord 
blood-derived mast cells at the mRNA level. Using an antibody that is unable to 
distinguish individual CXCR3 isoforms, we detected a marked down-regulation of 
intracellular protein during maturation from progenitor cells, with no concomitant 
changes in the modest surface expression of CXCR3. The known CXCR3 
agonists CXCL9, CXCL10 and CXCL11 as well as the reported CXCR3-B agonist 
CXCL4, were able to induce Akt and ERK1/2 phosphorylation, as well as partial 
degranulation. Responses to all agonists were inhibited by pre-treatment with 
selective CXCR3 antagonists and pertussis toxin. Use of novel isoform-selective 
inhibitors indicates that the p110γ isoform of PI3K is required for degranulation and 
signalling responses to CXCR3 agonists. Unexpectedly, dual (but not individual) 
isoform inhibition of the class I β and δ isoforms substantially inhibited signalling 
and degranulation responses, indicating a hitherto unrecognised synergy between 
these isoforms, which provide a conduit for CXCR3 signalling in mast cells. 
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Chapter 1 ­ Introduction

1. Introduction 
1.1The Immune System 
The immune system is the body’s defence mechanism which acts to protect the 
body from the potential threats of foreign pathogens. Two main branches of 
immunity are recognised: innate and adaptive immunity. A specific immune 
response — such as a generation of specific antibodies against a specific 
pathogen, for example — is known as an adaptive immune response, occurring 
during the lifetime of an individual as an adaption to infection with that pathogen. 
Adaptive immune responses are capable of generating lifelong protective immunity 
to re-infection of the same pathogen. This is in contrast to innate immunity, which 
is immediately available to combat a wide range of pathogens without requiring 
prior activation. Despite these systems having different immunological profiles, it is 
critical that they interact in such a way so as to initiate the body’s full defence 
system. 
The responses of both the innate and adaptive immunities depend on the activities 
of a group of white blood cells termed leukocytes. Immune responses are 
mediated by leukocytes, which derive from precursors in the bone marrow. A 
pluripotent hematopoietic stem cell gives rise to the lymphocytes responsible for 
adaptive immunity, and also myeloid lineages which participate in both the innate 
and adaptive immunity. 
1.1.1 Innate Responses 
Innate immune responses provide the first line of defence. This is proved by the 
simplest of barrier protection, which is provided by the skin and epithelial of the 
pulmonary and the gut; however, in the instance that these frontline defences are 
breached, the innate immunity then has a second line of defence which largely 
involves granulocytes. These leukocytes are a diverse collection of white blood 
cells whose prominent granules provide their characteristics. These cells are 
comprised of neutrophils and macrophages — the ‘so-called’ eaters of the innate 
immunity due to their ability to phagocytise invading pathogens and dendritic cell, 
and are the sentinels of the immune system. 
1
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The innate immune system discriminates between both self and non-self by 
utilising the receptors which bind features on micro-organisms with regular 
patterns known as Pathogen-Associated Molecular Patterns (PAMPs), which are 
recognised by Pattern-Recognition Receptors (PRRs). Amongst the membrane-
bound PRRs, the best-known PRRs are the Toll-Like Receptors (TLRs) which 
sense a wide array of microbial ligands at the cell surface or within endosomes 
(Kawai and Akira, 2006). At present, 11 TLRs have been discovered in mammals 
(TLR1-TLR11). Interaction of TLRs with their specific PAMP induces NFκB 
signalling and MAP kinase pathways, and therefore the secretion of pro-
inflammatory cytokines and co-stimulatory molecules. Cytoplasmic PRRs include 
the Caspase-Recruiting Domain (CARD) helicases — such as retinoic acid-
inducible protein I and melanoma differentiation- associated protein 5, which are 
involved in antiviral responses (Kawai and Akira, 2006) — and the nucleotide 
binding oligomerisation domain NOD-Like Receptor (NLR) family, which 
recognises primary microbial molecules of bacterial origin (Inohara et al., 2005). 
There are reports of a number of PRRs which do not remain associated with the 
cell that produces them; these include complement receptors, collectins, pentraxin 
proteins and peptidoglycan recognition proteins, all of which are secreted proteins. 
One of the most well-known colectins is mannose-binding lectin, a major PRR 
binding to a wide range of bacteria, fungi and protozoa via sugar groups, 
phospholipids, nucleic acids or non-glycosylated proteins (Dommett et al., 2006). 
These cells of the innate system are specifically inherited in the genome and, 
when fighting against further infection, will generate the same innate 
immunological response. This is in contrast to the adaptive immune response, 
which will adapt their response according to the specific invading particle. 
1.1.2 Adaptive Immunity 
Adaptive immunity is commonly split into two different classes: humoral and cell-
mediated. Humoral responses are generated by B-cells which, upon activation, 
differentiate into plasma cells which secrete antibodies. Cell-mediated responses 
are generated by T-lymphocytes, which are further divided into two different 
subsets: the first, which, upon activation, differentiate into cytotoxic T-cells which 
2
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kill cells infected with viruses; the second, described as T-helper cells, activate 
other cells such as B-cells and those of the innate immunity. 
Innate immunity acts as the activation trigger for the adaptive immune response by 
the production of pro-inflammatory cytokines. This action recruits further 
leukocytes to the point of inflammation. Dendritic cells play the leading role in the 
activation of the adaptive immunity. Immature dendritic cells recognise the 
conserved patterns on pathogens, activating maturation of the dendritic cell and 
expression of a range of co-stimulatory molecules (Akira et al., 2001; Vestweber, 
2003). Subsequently, dendritic cells then migrate and present the processed 
antigen via the major histocompatibility complex to naïve T-lymphocytes, whilst a 
second co-stimulatory signal is received via the binding of B7 to CD28 
(Banchereau and Steinman, 1998; Reis de Sousa et al., 2001). Figure 1.1 
highlights the innate and acquired immune systems’ interaction. 
The complexity of the immune system is achieved by the dynamic and ever-
evolving variety of cells which this system comprises. It is important to orchestrate 
this response in order to achieve a speedy reaction and to accordingly determine 
resolution of inflammation. One such cell which orchestrates the immune response 
is the mast cell. An orchestra comprises many different instruments; however, only 
one conductor directs the music they make. Following this analogy, mast cells are 
few but essential to promoting the immune and inflammatory responses (Kinet, 
2007). 
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Figure 1.1:  Interaction of  the  innate and acquired  immunity. The innate and 
adaptive immune systems are interrelated in ways which have not yet been fully 
established. Antigens are phagocytosed or endocytosed in a non-specific manner 
by neutrophils, subsequently resulting in them being neutralised in the body. 
Alternatively antigens phagocytosed by macrophages can be presented to T-cells, 
generating a highly specific T-cell response. Responses such as these are 
partially dependent on PRRs — such as TLRs and NOD-like receptors — which 
recognise PAMPs presence on a variety of microorganisms. There are also a 
variety of soluble PRRs, such as complement proteins (C1Q), mannose-binding 
protein (MBP), and acute phase reactants, such as C-reactive protein (CRP), all of 
which play a role in innate responses by opsonising microorganisms and 
subsequently binding to apoptotic cellular debris in a non-specific manner. In 
addition, the co-stimulation of B-cells through TLRs (such as TLR9) can result in 
the production of specific antibodies to antigens. Moreover, cytokines such as 
interferons, Tumour Necrosis Factor (TNF), and interleukin 1 (IL1), might stimulate 
the activity of both the innate and adaptive immune responses. Antibody 
production can also reflex back on the innate immunity by activating mast cells, 
thereby resulting in the further recruitment and activation of the innate immunity. 
Adapted from Gregersen and Behrens, (2006). 
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1.1.3 The Inflammatory Response 
The inflammatory response describes the complex biological response of the 
inflammatory tissues to harmful stimuli, such as pathogens or invading bacteria. It 
is the protective mechanism by which an organism attempts to remove potential 
harmful stimuli while, at the same time, inducing the healing process. Both the 
innate and acquired immunity are required in order for an immune response to be 
successful. Inflammatory responses have been classified into two types: acute and 
chronic. 
Acute inflammation is a rapid response to an injurious agent which serves to 
deliver mediators of host defence-leukocytes and plasma proteins to the site of 
injury. The response comprises four components: 
2.	 Alterations in vascular calibre which lead to an increase in blood flow. 
3.	 Structural changes in the microvasculature which permit plasma proteins 
and leukocytes to leave the circulation. 
4.	 Migration of phagocytes out of the venules and into interstitial spaces. 
5.	 Recruitment of lymphocytes to the site of injury by cells of the innate 
immune system. 
Once the inflammatory process has begun, it continues until the infection which 
originally caused the response has been eradicated. Phagocytes continue to 
consume and destroy bacteria whilst the acquired immune system binds and 
disposes of the harmful toxins; this is a fundamental process, as the inflammatory 
response should only last as long as the infection exists. Moreover, prolonged 
inflammatory responses result in chronic inflammation, subsequently leading to 
simultaneous destruction and repair of the infected tissues. Such inflammation 
which operates unchecked can consequently lead to a host of diseases, such as 
asthma, atherosclerosis and rheumatoid arthritis, to which mast cells are heavily 
linked. However, in the absence of the inflammatory response, infections would 
never heal, and the destruction of the infected tissues would seriously compromise 
the health of the individual. 
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1.1.4 The Resolution of Inflammation 
The resolution of inflammation is initiated during the first few hours following the 
initiation of an inflammatory response. After entering tissues, granulocytes 
promote the switch of arachidonic acid-derived prostaglandins and leukotrienes to 
lipoxins, which in turn initiate the termination sequence. Neutrophil recruitment 
thus ceases, and programmed death by apoptosis is subsequently engaged. 
These events coincide with the biosynthesis, from omega-3 polyunsaturated fatty 
acids of resolvins and protectins, which critically shorten the period of neutrophil 
infiltration by initiating apoptosis (Serhan and Savill, 2005). Consequently, 
apoptotic neutrophils undergo phagocytosis by macrophages, thereby leading to 
neutrophil clearance and the release of anti-inflammatory and reparative 
cytokines, such as transforming growth factor- 1. The anti-inflammatory 
programme ends with the departure of macrophages through the lymphatics. 
Stromal cells — such as fibroblasts — also contribute to the resolution of 
inflammation by the withdrawal of survival signals and the normalisation of 
chemokine gradients, thereby allowing infiltrating leukocytes to undergo apoptosis 
or to otherwise leave the tissue through the draining lymphatics (Serhan et al., 
2007). 
1.2Mast Cells 
1.2.1 Historical Background 
Mast cells were first described in the doctoral thesis of Paul Ehrlich in 1878, in 
which he refers to them as Mastzellen, most likely deriving from the German word 
‘mastig’, meaning well-fed. They were initially given this name due to the 
misconception that these cells were over-fed due to their unique staining 
characteristics and large granules. The large amount of granules present in mast 
cells also accordingly led Ehrlich to the mistaken belief that they exist to nourish 
the surrounding tissue. Furthermore, the name ‘mast cell’ may have also arisen 
from the Greek word ‘masto’, literally meaning ‘to feed’. 
1.2.2 What are Mast Cells? 
Since the first discovery of mast cells, it is now widely believed that mast cells are 
one of the key immune effecter cells in consideration of their primary function in 
host defence against parasites and other invading pathogens. Mast cells are 
6
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members of the innate immune system, and are often considered to be the first-
line responders to immunological insults, simply because of their prevalence in 
areas highly exposed to the external environment. They originate from CD34+ 
hematopoietic pluripotent stem cells but do not mature until leaving the bone 
marrow, and circulate in peripheral blood as mast cell committed progenitors or 
‘immature’ mast cells (Födinger et al., 1994; Kirshenbaum et al., 1991). This 
phenotype is, so far, poorly characterised. Progenitors are isolated from peripheral 
blood express c-Kit+, CD34+, CD117+ but lack expression of FcεRI and FcεRII. 
Studies have shown that CD34+ cells lacking c-Kit or CD13 will not develop into 
mast cells (Agis et al., 1993; Kirshenbaum et al., 1999). 
It is from the peripheral blood that mast cells enter the tissues where the mast cell 
will develop into a fully mature cell. The tissue that a committed mast cell 
progenitor enters will ‘tailor’ the differentiation to distinct phenotypes — a 
phenomenon referred to as mast cell heterogeneity (Enerbäck, 1966). The key 
growth factor for mast cells is Stem Cell Factor (SCF), which will not only guide the 
differentiation of mast cells but also regulate all growth, survival, migration, 
adhesion and degranulation (Galli et al., 1994; Nilsson et al., 1999). Moreover, 
mature mast cells can normally be found widely distributed throughout the 
vascularised tissues, especially with numerous found beneath the epithelial 
surfaces of the skin, the respiratory system, the gastrointestinal and genitourinary 
tracts, and also in the central nervous system (Johnson and Krenger, 1992; 
Nilsson et al., 1999; Silver et al., 1996). These cells can be identified in most 
tissues as relatively large cells which express high levels of c-Kit (the receptor for 
SCF) and FcεRI (the high-affinity IgE receptor). Microscopically, these cells are 
easy to identify with toluidine blue or alcian blue dyes. 
7

Chapter 1 ­ Introduction

Despite being described as having an immobile nature (mature mast cells are 
generally found to be ‘fixed’ in the tissues and not circulating in the blood), mast 
cells are widely distributed throughout the body, therefore allowing them to 
encounter pathogens and environmental antigens invading the body. Mast cells 
are commonly found throughout the skin, mucosa of the genitourinary, respiratory 
and gastrointestinal tracts, as well as most vascularised tissues of mammals, 
including the lymphoid organs (Sayed et al., 2008). 
1.2.3 Mast Cell Subtypes 
Mature human mast cells can be divided into two distinct sub-categories 
depending on variations in the protease composition in the mast cell granules. 
These subsets are therefore defined as mast cells containing tryptase or those 
containing both tryptase and chymase (Irani et al., 1986). The Mast cell subset will 
depend largely on the type of tissue it resides in. Mast cells containing tryptase are 
predominately found in lung tissue and intestinal mucosa while mast cells 
containing both tryptase and chymase are found predominately in the skin and 
intestinal submucosa (Irani et al., 1986; Nilsson and Nilsson, 1995). 
1.2.4 Activation of Mast Cells 
Mast cells are very effective as both effector cells, which amplify inflammation, and 
as regulatory cells, which are able to suppress certain immune responses. Mature 
mast cells are primarily activated by IgE aggregation as a result of an antigen 
binding to a high affinity receptor FcεRI on the mast cell surface. The basic 
structure of an FcεRI receptor present on mast cell consists of four joined subunits 
— α, β and two γ subunits, as shown in Figure 1.2. Moreover, mature human mast 
cells constitutively express high affinity receptor FcεRI, with activation initiated 
when adjacent FcεRIs are cross-linked either by antigens interacting with receptor 
bound IgE or antibodies directed against either receptor bound IgE or the receptor 
itself. The cross-linking of these receptors induces a cascade of intracellular 
signalling events, which subsequently leads to the rapid release and de novo 
synthesis of mediators (Kuehn and Gilfillan, 2007; Nishida et al., 2005; Tkaczyk et 
al., 2002). Over recent years, it has also become clear that degranulation of 
mature mast cells can occur by IgG binding to FcγRI (Tkaczyk et al., 2002; 
Woolhiser et al., 2001). 
8

Chapter 1 ­ Introduction

α 
β γ 
Figure 1.2: 2D Schematic of the FcεRI structure.The FcεRI is a 
heterotetrameric structure containing four polypeptide subunits: one α-chain, one 
β-chain, and two disulphide-linked γ chains. The α-chain provides the ligand-
binding function of FcεRI, and has been recognised as a member of the Ig gene 
superfamily on the basis of its predicted amino acid sequence. The functions of 
the β­ and γ-chains are unclear, although roles in cell surface trafficking and trans-
membrane signalling have been suggested. Adapted from Pang et al., (1993). 
Similar to the two-signal model in the activation of T-cells, antigen signalling 
through the FcεRI is often modified by the co-inhibitory or co-stimulatory signals in 
mast cells. This has been noted in the administration of αCD28 to bone marrow-
derived mast cells, which enhances TNF secretion (Tashiro et al., 1997). TLR 
ligands have also been demonstrated in order to synergise with antigen to 
potentiate cytokine secretions by cross-linking of the FcεRI on mast cells. On the 
other hand, the Ig receptor FcγRIIB (Malbec and Daëron, 2007) and platelet 
endothelial cell adhesion molecule-1 (Wong et al., 2002) utilise the ITIMs present 
on the FcεRIIgE so as to suppress mast cell function. 
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1.2.5 IgE Independent Modes of Mast Cell Activation 
In addition to the activation by IgE/antigen, it is now known that mast cells can be 
stimulated by complementary components by both viral and bacterial pathogens, 
hormones, cytokines and chemokine. Mast cells express a wide range of 
complement receptors, including C3aR, C5aR CR2, CR4, and the recently 
described collectin/C1qR (Edelson et al., 2006; Marshall, 2004). These receptors 
have been highlighted as playing an important role in cecal ligation and the 
puncture model of septic peritonitis in which complement-mediated activation of 
mast cells is essential for the clearance of invading bacteria. Furthermore, the 
range of TLRs present on mast cells have recently been shown to differentially 
activate mast cells through interactions between lipopolysaccharide and 
peptidoglycan (Prodeus et al., 1997). Moreover, mast cells are directly activated 
through this mechanism by different bacteria, and act as a first-line defence 
against bacterial infections (Tkaczyk et al., 2002). Other IgE independent 
mechanisms of mast cell activation by hormones include oestrogen inducing mast 
cell degranulation in vitro studies or the inhibition of histamine release 
(Theoharides et al., 2006). Importantly, mast cells influence immune responses via 
the release of a wide range of mediators from within the granules store in the 
cytoplasm, whether their activation method is by IgE cross-linking of the FcεRI 
receptor or the IgE independent mechanisms, such as those highlighted above. 
1.2.6 Mediator Release from Mast Cells 
Mast cells are involved in a variety of biological processes, and their anatomical 
location close to epithelial surfaces in the skin, the respiratory system and 
gastrointestinal tract, makes mast cells a key frontline defence against invasion. In 
studies carried out by Malaviya et al. (1994) and Echtenacher et al. (1996), mast 
cells are described as having a key role in innate immunity. The primary way in 
which mast cells can modulate immune responses is their capacity to produce and 
secrete a large array of inflammatory mediators upon activation. The mediators 
which are released from mast cells stem from three different categories, as shown 
in Figure 1.3. 
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Figure  1.3:  Variety  of mast  cell mediators. Mature mast cells release a wide 
range of mediators at different stages. The first mediators released are the 
preformed granule mediators, followed by the newly-formed mediators and, thirdly, 
the release of cytokines. 
 
The three categories are:  
1. Preformed secretary granule-associated mediators, such as histamine and 
heparin: these mediators are the first released by a mast cell following 
activation, and are of great importance during the early phases of acute 
allergic inflammatory reactions.  
2. Newly-formed lipid mediators: these products result from the arachidonic 
acid metabolism following the activation of mature mast cells, and include 
the formation of leukotriene C4 and prostaglandin D2. These mediators are 
synthesised within minutes of activation, and their production may persist 
for 30 minutes or longer, thereby playing an important role in the acute 
inflammatory response (Secor et al., 2000).  
3. Cytokines, chemokines and growth factors: these are synthesised and 
secreted by the mast cells at a later stage, approximately 4-12 hours after 
initial activation. The formation of these mediators is critical when 
orchestrating the late phase response, which develops within a couple of 
hours of the induction of the inflammatory response. The sheer variety of 
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mediators can then be released from mast cells following activation, which 
allows mast cells to be versatile in the modulation of different immune 
responses. 
1.2.7 Modulation of Immune Responses by Mast Cells 
The key role of mast cells in innate immunity was first highlighted in studies on 
mast cell-deficient mice, therein demonstrating defective clearance and survival 
during bacterial infections. The possible role of mast cells in innate immunity was 
further suggested by evidence of complement fragment 3-induced degranulation of 
mature mast cells, and that the resulting release of TNF-a was a key factor in the 
recruitment of neutrophils and subsequent bacterial clearance (Prodeus et al., 
1997). 
Our current understanding of how mast cells interact with micro-organisms by 
either direct or indirect interaction is that it most likely involves different receptors 
expressed on the surface of mast cells. These include CD48 recognising Fim H (a 
29-kDa mannose binding lectin expressed by E.coil and other enterobacteria) 
(Malaviya et al., 1994), toll-like receptors (Varadaradjalou et al., 2003), and 
complement receptors (Prodeus et al., 1997). The interaction between mast cells 
and micro-organisms induces the activation of mast cells and mediator release, 
inducing inflammatory responses or a direct killing of the pathogen, thereby 
resulting in bacterial clearance. The effects which mediators have on different cells 
of the innate immune system are highlighted in Figure 1.4. 
This emerging evidence points to a pivotal role which mast cells play in innate 
immune responses. It has also become clear that mast cells are not limited to the 
innate immune system and are rather initiators of the acquired immune responses. 
As a part of the adaptive immune system, mast cells have the ability to present 
antigens to T-cells via either MHC class I or II molecules (Mekori and Metcalfe, 
1999). A large array of co-stimulatory molecules have been identified on the 
surface of mast over the years, including ICAM-1, ICAM-3, CD43, CD80, CD86 
and CD40L, all of which enable them to interact with a wide range of cells. The 
result of these interactions includes T-cell proliferation and cytokine release, 
immunomodulation towards Th2 phenotype, and the induction of IgE production by 
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B-cells (Gauchat et al., 1993; Mekori and Metcalfe, 1999). Figure 1.4 provides an 
overview of the central role mast cell can play in modulating immune responses — 
both innate and acquired — interacting with a wide range of cell types.  
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Figure 1.4: The role of mast cells in immune system. Mast cells act in such a 
way so as to orchestrate the immune system; this includes the regulation of 
epithelial, smooth muscle, endothelial function, activation of neutrophils, 
eosinophils lymphocytes and many tissue functions, such as wound-healing. 
Adapted from Bischoff, (2007). 
 
Wound-healing or fibrosis is a very complex biological process which results from 
the interplay of different tissue structures and a large number of resident and 
infiltrating cells. It is the body's natural process of regenerating dermal and 
epidermal tissue. When an individual is wounded, a set of complex biochemical 
events takes place in a closely orchestrated cascade with the sole objective to 
repair the damage. These events overlap in time and may be artificially 
categorised into separate phases: inflammatory, proliferative, and remodelling. 
Ultimately, mast cells are considered to be important orchestrators in this whole 
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process by releasing mediators in three different ways and time points. The mast 
cell can orchestrate to limit damage, to re-vascular damaged tissue, to proliferate 
the connective cellular elements, and to remodel the matrix support (Metcalfe et 
al., 1997; Noli and Miolo, 2001). 
1.3How are Mast Cells Implicated in Disease? 
Mast cells can incur negative as well as positive immune responses, such that 
they both enhance and later suppress certain features of an immune response, 
primarily due to the fine balance between beneficial healing or impaired healing 
following the degranulation threshold being exceeded (Christy and Brown, 2007). 
At this point, mast cells turn into damaging effector cells, subsequently impairing 
the protective immune response. 
Figure 1.5 demonstrates how mast cells can be at the centre of influence of many 
responses notable in diseases. Much of what is currently understood regarding the 
role of mast cells in disease comes from studies of hypersensitivity reactions; 
these are a group of pathogenic immune responses eliciting from antigens which 
are not inherently harmful; it is an overeager immune response that induces these 
pathological conditions. Hypersensitivity reactions have been classified into four 
types; type I-IV, determined by the major effecter mechanisms employed. 
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Figure 1.5: Role of mast cells in initiating disease. The activation of mast cells 
not only requires the synthesis of IgE by B-cells but also IL-4 released from T 
helper 2 cells in order to have full mediator release. The release of the newly 
formed mediators results in the early reaction normally seen in the skin and 
mucosal areas affecting blood vessels and sensory nerves resulting in pain. The 
cytokine release initiates the late phase reaction interacting with a wide range of 
cells. Adapted from Bischoff, (2007). 
1.3.1 Type I Hypersensitivity Reaction 
The term ‘hypersensitivity’ normally brings to mind allergic reactions (hay fever, 
atopic dermatitis and systemic anaphylaxis), all of which are classified into the 
Type I reactions. Mast cells are central to these responses. Type I reactions are 
noticeable within minutes of antigen activation of the mast cell due to the robust 
response induced by FcεRI cross-linking. During the initial sensitisation, certain 
individuals develop (for currently unknown reasons) IgE to these antigens, thereby 
upon subsequent re-exposure to the same antigen, robust mast cell responses. 
This includes early symptoms of vascular permeability and local swelling to the 
late phase responses by influx of inflammatory cells, tissue re-modelling, over 
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production of mucus in the airways, and local cutaneous swelling. Allergic 
inflammation is the most common of inflammatory diseases associated with mast 
cells, and is classified under the Type I hypersensitivity reactions. This is caused 
by the prolonged over-production of IgE in response to exposure to certain 
antigens; these can range from harmful antigens, such as venom and bacterial 
products, to harmless antigens, such as pollen, food and dust mites. Binding of 
IgE to these harmless antigens results in the cross-linking of FcεRI, therefore 
initiating a similar response to that of a harmful antigen, initiating the release of 
mediators, resulting in increased permeability of blood vessels, tissue oedema, 
leukocyte recruitment and inflammation. Typical examples of allergy reactions are 
hay fever, allergic asthma, atopic eczema and drug- and food-related allergies. 
These allergic responses are well-characterised in the context of Th2-type 
responses. 
1.3.2 Type II Hypersensitivity Reaction 
Type II hypersensitivity reactions are classical, and defined by interaction of IgG or 
IgM antibody with a cell surface antigen. This can be followed by the binding of 
complement-mediated cell lysis. Mast cells participate in Type II reactions, both 
directly though the binding of complement proteins, or otherwise via IgG antibody-
inducing degranulation of mast cells. They can also influence Type II reactions by 
influencing T-cell responses, thereby helping B-cell isotype switching. Mast cells 
have been implicated in the Type II disease bullous pemphigoid, which is a chronic 
subepidermal blistering of the skin, classically characterised by the presence of 
IgG auto-antibodies to hemidesmosomal antigens BP20 and BP180. In the case of 
this disease, mast cells triggered by complement activation are a key source of the 
neutrophil chemoattractant CXCL8 (Nelson et al., 2006). 
1.3.3 Type III Hypersensitivity Reaction 
Antigen-antibody complexes mediate the major immune destruction in Type III 
hypersensitivities by depositing in organs and tissues, binding complement, and 
attracting macrophages and neutrophils. Similar to Type II reactions, there are 
many reports to suggest a role for mast cells in Type III reactions. It has been 
shown that the ability of both antibodies and complement to induce the activation 
of mast cells resulting in the production of different chemoattractants, recruiting 
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pathology-effecter cells. Arthus reactions (a local antibody-mediated 
hypersensitivity reaction involving antibody-antigen complexes which fix 
complement, which is deposited in the walls of small vessels, causing acute 
inflammation with an infiltration of neutrophils), Rheumatoid Arthritis (RA) and 
systemic lupus erythematous, are such diseases classified as Type III reactions. 
The role of mast cells in RA is largely supported by the evidence that mast cell-
deficient mice do not develop RA (Lee et al., 2002). Developments in new 
treatments targeting RA are investigating ways in which to reduce the 
inflammation of the joints by reducing the number of mast cells present. 
1.3.4 Type IV Hypersensitivity Reaction 
Delayed-type hypersensitivities are also known as Type IV hypersensitivity 
reactions. These reactions often occur many days following initial exposure to 
antigen and are mediated by antigen-specific CD4+ T-cells. Multiple Sclerosis 
(MS), a CNS-demyelinating disease, is amongst the most widely studied of Type 
IV hypersensitivity reactions. The current evidence of the role of mast cells in MS 
is in both murine and human models, where mast cells accumulate at the site of 
inflammatory demyelination in the brain and spinal cord, and are often found de-
granulated (Ibrahim et al., 1996). High levels of the mast cell-specific protease 
tryptase are found in the cerebrospinal fluid of MS patients, indicating mast cell 
activation (Rozniecki et al., 1995). 
1.3.5 Tumour Development 
Tumour development is a multi-step process, interacting genetically-altered 
malignant cells with the non-neoplastic cells in the surrounding area (Hanahan and 
Weinberg, 2000). A developing neoplasm often contains many different 
leukocytes; for example, macrophages, neutrophils, eosinophils and mast cells. 
The relationship between mast cells and tumours has long been established, since 
Westphal first reported the presence of A large number of mast cells in the 
periphery of tumours in 1891 (Prager and Bearden, 1962). Mast cells were 
originally thought to be a host response to neoplasia; however, evidence gathered 
over recent years has suggested that the actual role of mast cells may support 
tumour development (Dimitriadou and Koutsilieris; Ribatti et al., 2001). 
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1.4 Mast Cell Models 
Human mast cells utilised in studies can develop from heameopotiec progenitor 
cells found in cord blood, foetal liver, peripheral blood and bone marrow. Surface 
expression of the FcεRI receptor occurs constitutively, expressed at low levels in 
mature cells when differentiated from progenitor cells in vitro with recombinant 
human stem cell factor. This occurs in cells obtained from all of the 
abovementioned tissues aside from foetal liver. Addition of IL-4 induces the 
expression of FcεRI in foetal liver, and induces maximum regulation of FcεRI in 
mast cells derived from umbilical cord blood. 
It has been shown that mast cells derived from umbilical cord blood precursors 
express CD13 and CD117. CD13 has been detected on cultured mast cells 
derived from foetal liver and cord blood derived precursors. CD13 is a 150kDa cell 
surface glycoprotein which is identical to the aminopeptidase N — a membrane 
bound glycoprotein thought to be involved in the regulatory metabolism of peptides 
by a wide range of cells; furthermore, it is also known to be expressed on stem 
cells during early stages of myeloid and lymphoid cell development. CD117 is also 
known as c-Kit, which is the receptor for the agonist SCF. Both the human and 
mouse c-Kit ligand induces differentiation of human mast cells in a long-term 
culture of the mononuclear cells of umbilical cord blood. Moreover, human mast 
cells are commonly characterised by the presence of two specific proteases: 
tryptase and chymase. The two subsets comprise mast cells, which just contain 
trypase, and those which contain both tryptase and chymase. Evidence suggests 
that it is possible to switch from single- to double-positive with prolonged culture 
with IL-4 (Toru et al., 1998). It is thought that, in the majority of mast cells cultured 
under SCF conditions, the granule content will just develop tryptase. 
The study of mast cells is challenging for a wide variety of reasons. Firstly, mast 
cells are found in the body in small numbers in both humans and experimental 
animals, and so it is difficult to obtain large numbers of such cells for experimental 
purposes. One solution for overcoming these problems is the development of mast 
cell culture systems. It was discovered that a large number of mast cells could be 
grown from the bone marrow of mice or rats by addition of IL-3 (Razin and Marx, 
1984). This was the first reported mast cell model which enabled large-scale 
18

Chapter 1 ­ Introduction

experiments. There were, however, drawbacks to the system. Despite the 
expression of FcεRI, the cells generated only developed immature phenotypic 
characteristic. Furthermore, over time, there have been many other different 
methods of generating mast cells from many different sources, including foetal 
liver (Irani et al., 1992b), bone marrow (Kirshenbaum and Metcalfe, 2006),cord 
blood (Durand et al., 1994), as well as CD34+ peripheral blood (Kirshenbaum and 
Metcalfe, 2006). Additional to the development of these primary mast cells models, 
many mast cell line models exist; for example, HMC-1 (Butterfield et al., 1990), 
LAD-2 (Kirshenbaum et al., 2003) and the widely used rat mast cell line RBL-2H3 
(Oliver et al., 1988). 
The utilisation of these primary mast cell models and mast cell lines has 
accordingly enabled the discovery of how mast cells respond to a wide range of 
different physiological and pathological mediators. These models have also 
subsequently enabled deeper understanding of the role of mast cells in 
inflammatory responses. 
1.4.1 The Cytokine Milieu at the Precursor Stage 
A previous study (Mitsui et al., 1993) indicates that human mast cells differentiated 
from cord blood and developed by cytokine control are similar to human mast cells 
in the lung and gut mucosa according to similarities in sub-structural granule 
patterns of the cells. The majority of these cells contained only tryptase — unlike 
skin mast cells, which contain both tryptase and chymase (Mitsui et al., 1993). 
Other studies, on the other hand, reveal that levels of chymase are almost doubled 
per individual mast cell in bone marrow derived compared to cord blood-derived 
mast cells (Shimizu et al., 2002). This would indicate that the mast cell receptor 
profile is most likely shaped by the cytokines milieu present at the relevant 
progenitor stage. 
Over the last decade and from a wide variety of sources, many studies have 
developed methods with the aim of culturing mast cells. Progenitor cells derived 
from cord blood are amongst the most widely studied. According to their neutral 
protease contents, two subtypes of human mast cells have so far been identified; 
those which are tryptase positive and those that are both chymase and tryptase 
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positive (Beil and Pammer, 2001; Craig and Schwartz, 1990; Forsythe and Ennis, 
2000). There is the possibility that a third sub-set of mast cells exist which are 
chymase positive but tryptase negative (Li et al., 1996). It is thought that mast cells 
derived from cord blood are believed to be predominately only tryptase positive, 
with low levels of mast cells containing both tryptase and chymase (Irani et al., 
1992a). Moreover, previous studies suggest that the majority of mast cells cultured 
under SCF will only develop tryptase (Mitsui et al., 1993). 
1.4.2 The Importance of IL­4 Addition of Mast Cell Development 
The mast cells used in this study and the subsequent studies were generated from 
human cord blood derived CD133+ progenitors by culturing these cells in the 
presence of SCF and IL-6 in a serum-free medium for 8 weeks, with additional 
supplementing mature mast cells with serum and IL-4. The late addition of IL-4 is 
to maximise the expression of FcεRI and to enhance degranulatory responses 
when FcεRI becomes aggregate (Dahl et al., 2002; Sayama et al., 2002). Studies 
have revealed that addition of IL-4 in culture medium up regulates FcεRI (Kinet, 
1999). 
1.5Chemokines and Chemokine Receptors 
1.5.1 A Brief History of Chemokine/Chemokine Receptor System 
The coordinated movement of the leukocytes is critical to both innate and adaptive 
immune systems, and is primarily mediated by the chemokine system. The history 
of chemokines first began in 1977, when the secreted platelet factor 4 
(PF4/CXCL4) was purified without actual knowledge of its function or receptor 
(Walz et al., 1977; Wu et al., 1977). It was not until a decade later that the next 
chemokine (interleukin-8 (IL-8/CXCL8) was discovered, which showed 
chemotactic activity for neutrophils, establishing that chemokines are key elements 
in the control of leukocyte migration (Yoshimura et al., 1987). It was not until 1992 
at the 3rd International Symposium on Chemotactic Cytokines at Baden, Austria, 
that the term ‘chemokines’ was proposed and the name has remained. The next 
major finding in the chemokine field came with certain chemokines functioning as 
HIV-suppressive factors in vitro by blocking viral interaction with specific 
chemokine receptors, and that some chemokine receptors act as co-receptors for 
viral entry (Bleul et al., 1996; Cocchi et al., 1995; Feng et al., 1996; Oberlin et al., 
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1996). One year later, it followed with the discovery that CCR5 was a major co-
receptor for the entry of HIV (Deng et al., 1996). This research formed the initial 
foundation that would subsequently lead to the release of the first pharmaceutical 
chemokine target-based drug being approved for medical use — maraviroc, a 
CCR5 inhibitor used in the treatment of HIV — which has subsequently led the 
way for development of more chemokine-based treatments. The next reported 
chemokine target-based treatment is Schering-Plough's vicriviroc, which is 
showing potent antiretroviral activity in clinical trials, which is targeted against 
CCR5. 
1.5.2 Nomenclature and Structural Characteristics of Chemokines 
Following the first chemokine being discovered, their role became am interesting 
topic for investigation and debate as to their role and function in inflammatory 
responses (Thelen, 2001). Chemokines or chemotactic cytokines, as they are still 
sometimes referred to, are small secretary or membrane-bound proteins with 
molecular masses of 6-14kDa. There are around 50 chemokines which have been 
discovered to date, all of which have been traditionally divided into two major 
groups based upon their sequence homology and the position of the first two 
cysteine residues at the NH2 terminus, C-X-C chemokines (or α chemokines) and 
CC (or β chemokines). The CXC chemokines contain a single non-conserved 
amino acid between the first two cysteines of this motif, whereas the CC 
chemokines have these residues juxtaposed. Two other minor groups of 
chemokines exist — C and CX3C, both having so far only one member per group. 
The former one lacks cysteines one and three of the typical chemokine structure 
(Kelner et al., 1994), whereas the latter exhibits three amino acids between the 
first two cysteines and is also the only membrane-bound chemokine through a 
mucin-like stalk (Bazan et al., 1997). 
The expression profile of chemokines in a particular inflammatory site ultimately 
determines the type of infiltrating leukocyte; therefore, recruiting the correct cells to 
the right areas is done in order to reduce inflammation. As such, chemokines have 
been further characterised by their physiological features, considering the 
conditions and locations of chemokine production, as well as the cellular 
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distribution of chemokine receptors, subsequently leading to the separation of

chemokines into so-called inflammatory (or alternatively called inducible) 
chemokines and homeostatic (or constitutive, housekeeping, or lymphoid) 
chemokines (Moser and Loetscher, 2001) (Figure 1.6). 
Figure 1.6: Characterisation of chemokine receptors by the role in immune 
responses. Chemokines are classified into three different charactertories: 
homeostatic, inflammatory and non-signalling. The classification depends on their 
characteristic features. 
Inflammatory chemokines are expressed in inflamed tissues by resident and 
infiltrated cells on stimulation by pro-inflammatory cytokines or during contact with 
pathogenic agents. In contrast, homeostatic chemokines and their receptors are 
produced in discrete microenvironments within lymphoid or non-lymphoid tissues, 
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such as the skin and mucosa (Moser and Loetscher, 2001). These chemokines 
are involved in creating the directional map which the adaptive immune system 
follows during antigen surveillance. 
Throughout history, many of these chemokines have had many different names 
assigned to them. It was the consensus of opinion within the field that their 
nomenclature be standardised based on their structure and how they were 
traditionally considered. The proposed chemokine nomenclature is based on the 
chemokine receptor nomenclature currently in use, utilising CC, CXC, XC or CX3C 
followed by an R (representing it is a receptor) followed by a number, therefore 
generating the current chemokine receptors known as CCR1-9, CXCR1-7, XCR1 
and CX3CR1. The new nomenclature for chemokines follows a similar pattern, 
replacing the R with an L with the view of representing the fact that this is a ligand, 
not a receptor. Figure 1.7 highlights the old and new nomenclature of the human 
chemokine systems along with their respective receptor and genomic locations. 
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Systematic Human Chemokine 
name Chromosome Human Ligand receptor(s) 
CXCL1 4q12-q13 GROα/MGSA-α CXCR2 > CXCR1 
CXCL2 4q12-q13 GROβ/MGSA-β CXCR2 
CXCL3 4q12-q13 GROγ/MGSA-γ CXCR2 
CXCL4 4q12-q13 PF4 Unknown 
CXCL5 4q12-q13 ENA-78 CXCR2 
CXCL6 4q12-q13 GCP-2 CXCR1, CXCR2 
CXCL7 4q12-q13 NAP-2 CXCR2 
CXCL8 4q12-q13 1L-8 CXCR1, CXCR2 
CXCL9 4q21.21 Mig CXCR3 
CXCL10 4q21.21 IP-10 CXCR3 
CXCL11 4q21.21 I-TAC CXCR3 
CXCL12 10q11.1 SDF-1α/β CXCR4 
CXCL13 4q21 BLC/BCA-1 CXCR5 
CXCL14 Unknown BRAK/bolekine Unknown 
CXCL15 Unknown Unknown (Lungkine 
in mouse) Unknown 
Systematic Human Chemokine 
name Chromosome Human Ligand receptor(s) 
CCL1 17q11.2 I-309 CCR8 
CCL2 17q11.2 MCP-1/MCAF CCR2 
CCL3 17q11.2 MIP-1α /LD78α CCR1, CCR5 
CCL4 17q11.2 MIP-1β CCR5 
CCL5 17q11.2 RANTES CCR1, CCR3, CCR5 
(CCL6) Unknown 
(mouse only) Unknown 
CCL7 17q11.2 MCP-3 CCR1, CCR2, CCR3 
CCL8 17q11.2 MCP-2 CCR3 
(CCL9/CCL10) Unknown 
(mouse only) Unknown 
CCL11 17q11.2 Eotaxin CCR3 
(CCL12) Unknown 
(mouse only) Unknown 
CCL13 17q11.2 MCP-4 CCR2, CCR3 
CCL14 17q11.2 HCC-1 CCR1 
CCL15 17q11.2 HCC-2/Lkn-1/MIP-1δ CCR1, CCR3 
CCL16 17q11.2 HCC-4/LEC CCR1 
CCL17 16q13 TARC CCR4 
CCL18 17q11.2 DC-CK1/PARC/AMAC-1 Unknown 
CCL19 9p13 MIP-3β /ELC/exodus-3 CCR7 
CCL20 2q33-q37 MIP-3α /LARC/exodus-1 CCR6 
CCL21 9p13 6Ckine/SLC/exodus-2 CCR7 
CCL22 16q13 MDC/STCP-1 CCR4 
CCL23 17q11.2 MPIF-1 CCR1 
CCL24 7q11.23 MPIF-2/Eotaxin-2 CCR3 
CCL25 19p13.2 TECK CCR9 
CCL26 7q11.23 Eotaxin-3 CCR3 
CCL27 9p13 CTACK/ILC CCR10 
The Human Chemokine/ Chemokine Receptor family 
CXC Chemokine/Receptor family CC Chemokine/Receptor family 
C Chemokine/Receptor family 
CX3C Chemokine/Receptor family 
Systematic Human Chemokine 
name Chromosome Human Ligand receptor(s) 
XCL1 1q23 Lymphotactin XCR1 
XCL2 1q23 SCM-1b XCR1 
Systematic Human Chemokine 
name Chromosome Human Ligand receptor(s) 
CX3CL1 16q13 Fractaline CX3CR1 
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Figure 1.7: Nomenclature of Chemokine Receptors and their agonists. 
Chemokines can be classed according to the number of amino acids separating 
the first two cysteine residues at the NH2 terminal. The receptors for CXC 
subclasses are shown in green; the C-C subclasses are in light blue; and the 
minor subclasses are in blue. The pairing of chemokines to their receptors is 
principally based on receptor-binding assays, and has identified receptors which 
have just one agonist, whereas other receptors have multiple. Each of the agonists 
throughout history has been recorded with a common name and systemic name. 
Adapted from Murphy et al., (2000). 
The chemokine family can be loosely grouped as a group of three gene clusters 
representing duplicated genes with similar function and a smaller number of 
isolated genes representing highly conserved chemokines, with no functional and 
little or no receptor sharing, allowing broad grouping of the chemokines according 
to function. The CXC 4q12-13 cluster chemokines act mainly on neutrophils, while 
the CC 17q11.2 cluster chemokines are predominantly monocyte and effector T-
cell chemoattractants. The CXC chemokines in the 4q21.21 mini-cluster act 
specifically as T-cell chemoattractants, as highlighted in Figure 1.7. 
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1.5.3 Chemokine Receptor Structure 
Chemokines mediate their effects by binding to G-protein coupled, 7-
transmembrane serpentine receptors called chemokine receptors. The classical 
structure of a chemokine receptor is highlighted in Figure 1.8. Studies published in 
1991 describe the first chemokine receptors (CXCR1 and CXCR2) which, like all 
signalling chemokine receptors identified since, belong to the family of G protein-
coupled receptors (Holmes et al., 1991; Murphy and Tiffany, 1991). 
N­terminus
Extracellular Extracellular Extracellular
1 2 3
S­S
1 2 3 4 5 6 7
Cytoplasmic Cytoplasmic Cytoplasmic
1 2 3
C­terminus
Figure 1.8: Schematic depicting a typical GPCR. A representational diagram of 
an unfolded chemokine receptor, highlighting the 7-transmembrane domains, the 
intra and extracellular loops with the second intracellular loop being critical for 
signalling of GPCRs. The N-terminus hangs on the outside of the cell with the C-
terminus stored intracellularly. 
The agonist-receptor network is complex: some chemokine receptors have just a 
single ligand, e.g. CXCR4 only mediates its effect via CXCL12, whereas other 
receptors can have multiple ligands; for example, CXCR3 mediating its effect via 4 
different agonists, CXCL9, CXCL10, CXCL11 and CXCL4. It is common for single 
chemokines to act as ligand for multiple different receptors, and that each receptor 
can bind an array of chemokines. 
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The complexity of the chemokine/chemokine receptor system may provide a very 
complicated but nevertheless effective way of regulating the cellular responses 
and functions of different cell types, thereby creating a robust system of over-
lapping ligands and receptors which protect the host. For example, CXCR3 
agonists CXCL9, CXCL10 and CXCL11 are involved in responses driven by Th1 
cells, and are accordingly reported to be antagonists for CCR2, which is thought to 
play a role in Th-2 driven response (Loetscher and Clark-Lewis, 2001). 
Furthermore, CCL11 as an agonist for CCR3 has been shown to be a partial 
agonist for CCR2 and CCR5 (Martinelli et al., 2001). Cross-reactivity seems to be 
a fundamental property of the chemokine/chemokine receptor system acting as a 
self-regulating system to protect the host. 
Chemokine receptors are expressed on the majority of the cells involved in the 
immune system, with each type of cell having a unique and distinct array of 
chemokine receptors depending on the function of the cell. Chemokine receptors 
share 25-80% identity at an amino acid level, indicating a common ancestor with 
several similar features and motifs shared amongst different chemokine receptors. 
1.5.4 Conserved Motifs in the Chemokine System 
With similar homology throughout the chemokine receptor system, certain key 
motifs have been highly conserved through the evolution of the 
chemokine/chemokine receptor linage. Such important conversed motifs include 
the DRYLAIVHA motif, the NPXXY motif and the Gly at junction of 7th TM and cyto 
domain. 
a) Functional motifs in agonists: 
The CXC chemokines are further sub-classified according to the presence or 
absence of ELR motif in the N-terminal, Glu-Leu-Arg (ELR)+ and Glu-Leu-Arg 
(ELR) -. the ELR+ group of chemokines includes CXCL1, CXCL2, CXCL3, CXCL5, 
CXCL6, CXCL7, CXCL8 and CXCL15, all of which have been shown to have 
angiogenic activity and attract mainly neutrophils and polymorphonuclear (PMN) 
leukocytes to the sites of inflammation. ELR - chemokines — to which CXCL4, 
CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14 and CXCL16 belong — 
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have mainly angiostatic properties and attract lymphocytes and monocytes with 
poor chemotactic ability for neutrophils (Laing and Secombes, 2004). 
b) Receptor signalling motifs 
DRYLAIV: 
The sequence DRYLAIVHA is found at a length of 340 to 370 amino acids — an 
acidic flexible N-terminal segment or a variation n the second extracellular loop. 
This flexible N-terminus is important during activation. The DRYLAIV motif is 
conserved in all signalling chemokine receptors, and is a variant of the acidic 
residue arginine aromatic residue motif found at this position. In all signalling 
chemokine receptors, it is considered necessary for G protein coupling and 
calcium signalling. Exceptions to this rule include the non-signalling promiscuous 
chemokine receptor-like molecules, Duffy Antigen Receptor for Chemokines 
(DARC) and D6, which will be discussed later on in this paper. 
The interaction between R of the DRY motif with its adjacent D/E residue at 
position 3.49 and an additional D/E at position 6.30 near the cytoplasmic end of 
TM6 is known as the ionic lock (Ballesteros et al., 2001). Charge-neutralising 
mutation of D/E6.30 in TM6 results in increased constitutive activity (Ballesteros et 
al., 2001; Montanelli et al., 2004). Another characteristic feature of chemokine 
receptors is the highly conserved NPXXY motif found within TM7, in which N 
residue acts as an on/off switch by adopting two active and inactive conformational 
stages (Govaerts et al., 2001; Urizar et al., 2005). 
NPXXY 
The NPXXY motif (with the X representing amino acid) in the 7th trans-membrane 
domain is highly conserved within the chemokine receptor family. This motif is 
thought to contribute to the internalisation and signal transduction of chemokine 
receptors (He et al., 2001). Positions of Asn, Pro, and Tyr residues are almost 
invariable within the motif. The inner two residues are generally hydrophobic in 
nature, whilst the residues that flank Tyr and Asn may vary (Probst et al.). Asn7.49 
of the highly conserved NPxxY motif in TM 7 acts as an on/off switch by adopting 
alternative conformations in the inactive and active receptor states (Govaerts et al., 
2001; Urizar et al., 2005). Upon receptor activation, N7.49 is proposed to adopt 
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the trans-conformation to interact with D2.50 of the (N/S)LxxxD motif in TM2 
(Remko et al., 2007). The NPXXY motif has been associated with receptor 
trafficking (Barak et al., 1995). 
1.5.5 Silent Chemokine Receptors 
The inflammatory process depends on the precise control of each part. It has been 
long thought that chemokine receptors play a role in the recruitment of 
inflammatory cells to the site of infection or injury; however, not all chemokine 
receptors which have been so-far discovered to date have this function; these are 
so-called atypical chemokine receptors and have apparent non-signalling or ‘silent’ 
properties, and raise the question as to the function of these abundant receptors. 
The chemokine system includes at least three ‘silent’ receptors — DARC, D6 and 
CCX CKR — each of which has distinct specificity and tissue distribution (Locati et 
al., 2005). Mechanistically, DARC and D6 represent a subclass of chemokine 
internalising receptors, ‘interceptors,’ taking chemokines into nucleated cells in the 
apparent absence of signalling (Nibbs et al., 2003). These receptors have 
moderate-to-high homology when compared to classical receptors, but ultimately 
lack in G protein-coupling motifs and are incapable of eliciting chemotactic or 
activating responses to a ligand (Liu et al., 2006). These receptors are different 
from their chemotactic counterparts, as they show a mutation in the second 
intracellular loop. Typically, chemokine receptors display the motif ‘DRYLAIV’ in 
their second intracellular loop, with this motif accordingly acting as a key mediator 
in the coupling to downstream signalling. 
1.5.6 D6 Receptor 
The D6 receptor is a typical chemokine receptor but has a mutation in its 
DRYLAIV motif: it has been mutated to DKYLEIV and also has replaced an 
aspartic acid residue to an asparagine in the second trans-membrane domain — 
both key components of G-protein dependent signalling. The D6 receptor shares 
similarities in terms of structure with other chemokines, binding at least 13 CC 
chemokines (Nibbs et al., 1997), all of which are known to be inflammatory. 
Curiously, D6 has been demonstrated as being unable to bind constitutive 
chemokines (Fra et al., 2003). Chemokines which bind to D6 are also rapidly 
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internalised, followed by dissociation from the receptor, and remain trapped within 
the cell for degradation. Meanwhile, D6 recycles back to the plasma membrane for 
further ligand sequestration (Hansell et al., 2006). 
In vivo studies reveal that deletion of D6 can result in the increased susceptibility 
to skin cancer and inflammatory similar to psoriasis (Nibbs et al., 1997). Anti-
inflammatory tumour suppressor properties of D6 are also supported by in vivo 
with null mice studies (Bonecchi et al., 2004; Jamieson et al., 2005). D6 is 
expressed at low levels by circulating leukocytes (Borroni et al., 2006); however, 
high levels of D6 were found on endothelial cells of lymphatic afferent vessels in 
the skin, gut and lungs (Nibbs et al., 2001) and in the placenta (Bonini et al., 
1997). D6 cannot couple with signalling pathways used by chemokines, but 
instead poses unusual intracellular trafficking properties to mediate repeated 
rounds of chemokine internalisation (Fra et al., 2003; Weber et al., 2004; Bonecchi 
et al., 2004). Moreover, D6 undergoes rapid constitutive ligand-independent 
trafficking both to and from plasma membrane, utilising β-arrestin and clathrin 
dependent route of internalisation; this feature is unique amongst mammalian 
chemokine receptors (Weber et al., 2004). 
1.5.7 DARC 
Similar to the D6 receptor, DARC has its DRYLAIV motif mutated. DARC has the 
motif DRYLGH resulting in the receptor being unable to signal. DARC may act as 
either a reservoir or transporter to both CC and CXC chemokines, maintaining the 
presence of chemokines with the circulation, releasing them when required. This 
mechanism can also aid the desensitisation of leukocytes. DARC also uses 
chemokine sequestration in order to control the CC and CXC chemokines which it 
binds (Nibbs et al., 2003; Rot, 2005; Du et al., 2002); this limits chemokine 
availability and regulates blood chemokine levels (Fukuma et al., 2003; Jilma-
Stohlawetz et al., 2001). Moreover, it has been suggested that DARC promotes 
chemokine transcytosis across blood vessel endothelial cells. Furthermore, whilst 
chemokines internalised by D6 are degraded, the fate of chemokines internalised 
by DARC may be cell context-dependent, and it is further possible that they can 
maintain their biological activities. Therefore, it has been stated that DARC 
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expressed on erythrocytes and vascular endothelial cells may act as either 
biological sink or a transporter for both CC and CXC chemokines, respectively. 
This suggests that, in contrast to chemokine decoy/scavenger D6, DARC plays a 
more complex role in chemokine homeostasis (Pruenster and Rot, 2006). 
1.5.8 CCR11/CCX­CKR 
Recent work carried out by Comerford et al suggests that, along with D6 and 
DARC, CCX-CKR also shows biochemical properties of a chemokine-
sequestrating atypical chemokine receptor (Comerford et al., 2006). In contrast to 
previously described ‘atypical’ receptors, CCX-CKR binds homeostatic 
chemokines, namely CCL19, CCL21 and CCL25, and also exhibits weak 
interactions with human CXCL13 (Gosling et al., 2000). Similar to DARC and D6, 
CCX-CKR does not couple with typical signalling pathways, and displays 
alterations within DRYLAIVHA motif. CCX-CKR has been shown to internalise and 
degrade CCL19 in vitro high efficiency and in β-arrestin independent manner; 
however, in contrast to most chemokine receptors, this process was abolished 
through caveolin-1 manipulations. 
1.5.9 Glycosaminoglycans 
Chemokines do not only bind to GPCRs: they are also known to be capable of 
binding to proteoglycans. This process is facilitated by highly acidic 
glycosaminoglycan (GAG) chains (Handel et al., 2005). The majority of 
chemokines need high (in the micro-molar range) concentrations to bind to GAGs, 
although it has been demonstrated that CXCL4 can bind GAGs in a nano-molar 
range. It is thought that the interaction of chemokines with the endothelial cell-
expressed proteoglycans is to immobilise high concentrations of locally generated 
chemokines on the luminal surface of the microvascular endothelium. It has been 
proposed that chemokines are present on the surface of the endothelial, triggering 
the signalling in leukocytes resulting in the up-regulation of selecting molecules 
resulting in the adhesion and migration of leukocytes through the endothelial 
barrier and into the tissue. 
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1.6The Biological Function of Chemokines 
The immune system of the body is a dynamic system. In order to effectively fight 
infections and diseases, cells must first migrate around the body to the area under 
attack. and not wait until the fight comes to them. Cell movement is not only 
essential for encountering pathogens, but also for initiating the complex 
interactions between different immune cells. Chemokine receptors and their 
agonists create the navigation system of the body and induce the migration of 
immune cells. 
1.6.1 Migration 
Migration is a multi-step process involving the co-ordinated interaction of adhesion 
molecules and chemokines and their receptors between leukocytes and 
endothelial cells, and the regulated migration from the bone marrow to the blood, 
and further from the blood to the tissue. The cytoskeletal re-organisation and 
polarisation of leukocytes requires integrin activation by chemokines, thereby 
allowing firm adhesion and migration. 
There are several defined mechanisms of migration. The term ‘chemotaxis’ is the 
directed migration of a cell towards a chemotactic gradient; similarly, haptotaxis 
also describes the directional movement of a cell towards a chemotactic gradient 
but on an immobilised substrate. Chemokinesis involves the random movement of 
cell which is independent of any chemotactic gradient. Chemofugetaxis is the 
active movement of a cell away from a chemokine source. This phenomenon was 
first described following the observation that high (but not low) concentrations of 
CXC12 has the ability to induce chemofugetaxis in a sub-population of T-cells; 
furthermore, it is also thought to contribute to thymic emigration (Poznansky et al., 
2000). Directional migration requires three distinct features of a cell, including the 
extension of pseudopodia, gradient sensing and polarisation, and directional 
movement. 
1.6.2 Extension of Pseudopodia 
In chemokinesis, pseudopodia are extending and contracting from the cytoplasm 
over the cell surface. Following cell activation, these pseudopodia are focused 
towards the leading edge of a cell due to the accumulation of such signalling 
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molecules; for example, PtdIns (3,4,5)3. This movement and rearrangement of 
signalling molecules is considered critical in the initiation of directional migration. 
1.6.3 Polarisation 
The process of polarisation in directional migration in leukocytes requires the cell 
to be polarised, with the molecular processes at the front (leading edge) of a 
moving cell being distinct from those at the back (uropod) (del Pozo et al., 1995). 
This polarised shape of the cell is the result of a redistribution of F-Actin from a 
fairly uniformed distribution throughout the cell, to being concentrated within the 
leading edge (Coates et al., 1992; Howard and Oresajo, 1985; Parent and 
Devreotes, 1999). Furthermore, it is known that leukocytes do possess some 
intrinsic cell polarity where there is differential sub-cellular localisation of the F-
actin filaments and assembled myosin, thereby allowing rapid responses to 
chemoattractant gradients. 
1.6.4 Actin Polymerisation 
During the process of migration, the polymerisation of actin filaments is critical to 
establishing and maintaining cell polarity. The functional unit of actin is known as 
globular action (G-actin), and is the polymerisation of these intrinsically polarised 
units by the action of ATP. Once bound together, these generate filamentous 
action (F-actin), which is generated by the polymerisation at one end of the 
filament (known as the barbed end), whereas depolymerisation occurs at the 
opposing or pointed end. The formation of F-actin at the leading edge drives the 
plasma membrane forward, subsequently resulting in the protrusion of the cell. 
The growth of F-actin is only halted by the binding of a capping protein on the 
barbed end of the filament, thereby maintaining or stabilising the filament or 
promoting depolymerisation. The phosphorylation and dephosphorylation rates are 
relatively equal, thus ensuring the maintenance of the current filament length. This 
process is known as tread-milling (Revenu et al., 2004; Vicente-Manzanares et al., 
2005). 
Despite the fact that inducing the migration is the primary function of chemokine, 
there is nevertheless increasing evidence for the role of chemokines in non-
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migration responses which are also modulated by chemokines, including 
lymphocyte differentiation and effecter functions (Luther and Cyster, 2001). 
1.6.5 Lymphocyte Modulation by Chemokines 
During T-cell activation, CCR5 and CXCR4 are recruited to the immunological 
synapse and, in this context, as opposed to delivering signals competing with 
those induced by TCR and adhesion molecules, they function as T-cell co-
stimulators (Molon et al., 2005). Indeed, heterodimerisation of CCR5 with other 
chemokine receptors, such as CXCR4 or CCR2, elicit the coupling of Gq to the 
receptor, and this change in G protein results in preferential chemokine-induced 
cell adhesion rather than chemotaxis (Mellado et al., 2001a; Mellado et al., 
2001b). It has also been demonstrated that T-cell chemokine receptors coupled 
with Gq and/or G11 protein are recruited to the immunological synapse by a Gi-
independent mechanism (Molon et al., 2005). CXCR4 has been also shown to be 
physically associated with the T-cell Receptor to induce signalling events in T-cells 
(Kumar et al., 2006). 
Further evidence shows that some chemokines can act as modulators of 
angiogenesis, thereby promoting inflammatory responses, tumour growth or 
interference with angiogenesis, thereby inhibiting tumour growth (Homey et al., 
2002). Furthermore, several chemokines have been shown to be potent activators 
of innate immune cell, such as basophils and eosinophils, mediating different 
release responses (Bischoff et al., 1993; Jinquan et al., 2000; Kampen et al., 
2000). 
Many different molecules can be found in the directed migration of motile cells. 
Several different molecules exist, with the most notable being the chemokine 
family, as described in detail in this study. 
1.6.6 Lipid Chemoattractants 
Mast cells are a key source of other mediators besides chemokines which are able 
to induce migration. These potent mediators of inflammation are derivatives of 
Arachidonic Acid (AA) a 20-carbon unsaturated fatty acid produced from 
membrane phospholipids. 
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The principal pathways of arachidonic acid metabolism are: 
•	 the 5-lipoxygenase pathway, which produces a collection of leukotrienes 
(LT). 
•	 the cyclooxygenase (COX) pathway, which produces prostaglandin H2 
(PGH2). PGH2 serves as the substrate for two enzymatic pathways; one 
leading to the production of several prostaglandins (PG); the other leading 
to the production of thromboxanes (Tx). 
The release of leukotriene B4 — which has been demonstrated as a potent 
mediator of neutrophil chemotaxis and stimulator of leukocyte adhesion to 
endothelial cells — is of particular interest. Leukotriene B4 mediates its effect via 
GPCRs B-LT1 and B-LT2. The receptor B-LT1 has been shown to be restricted to 
leukocytes (Kamohara et al., 2000; Tager et al., 2003). The release of this 
mediator from mast cells has been implicated in a wide range of inflammatory 
diseases; for example, increased levels in murine models of Chronic Obstructive 
Pulmonary Disease (COPD), asthma and RA (Crooks et al., 2000; Montuschi and 
Barnes, 2002). This evidence has since been further backed-up in studies by the 
administration of LTB4 antagonist in models of RA, reducing levels of inflammation 
(Griffiths et al., 1995). 
1.6.7 Neuropeptides and Mast Cells 
Human skin mast cells respond to neuropeptide stimulation with a rapid release of 
histamine and minimal generation of PGD2 and LTC4 (Bischoff, 2004). As such, 
they are uniquely positioned in such a way so as to respond to neuropeptides 
produced by nearby neurons. Mast cells express receptors for neuropeptides, 
such as Substance P (SP), Nerve Growth Factor (NGF), calcitonin gene-related 
peptide (CGRP) and Vasoactive Intestinal Polypeptide (VIP) (Kulka et al., 2008). 
These neuropeptides are believed to activate mast cells either by direct G protein 
binding or by ligating specific surface receptors (Ferry, 2002). The neuropeptide 
activation of human mast cells not only activates degranulation and release of 
preformed granule contained mediators, but can also induce the production of 
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cytokines and chemokines, including GM-CSF, IL-3, MCP-1, IP-10, RANTES and 
IL-8. These mediators can recruit and activate T-lymphocytes, eosinophils and 
other inflammatory cells. 
1.6.8 The Chemokine Expression Profile of Mature Mast Cells 
Many factors can influence the range of chemokine receptors which are expressed 
on the surface of a specific cell. The health and age of the host and anatomical 
location of specific cell types are contributing factors. In the case of in vitro studies, 
the activation and cytokine milieu which are exposed to the cell are also 
considered to be contributing factors that can ultimately determine the chemokine 
profile, as well as the mast cell sub-type that will develop. At least nine chemokine 
receptors (CXCR1, CXCR2, CXCR3, CXCR4, CX3CR1, CCR1, CCR3, CCR4 and 
CCR5) have been described as being expressed by human mast cells of different 
origins (Juremalm and Nilsson, 2005). Moreover, seven chemokines (CXCL1, 
CXCL5, CXCL8, CXCL14, CX3CL1, CCL5 and CCL11) have been shown to act on 
some of these receptors and to induce mast cell migration (Juremalm and Nilsson, 
2005). 
1.6.9 The Role of Chemokines in Disease 
Due to the sheer number and variety of biological functions which involve the 
chemokine system, mis-regulation of this system can result in great harm to the 
host. Chemokines have been implicated in a wide range of inflammatory diseases, 
including autoimmune, cardiovascular, cancer, transplantation, neuro-
inflammation, HIV and allergic inflammatory diseases (Gerard and Rollins, 2001). 
Figure 1.9 provides an overview of certain chemokine receptors involved in the 
case of different diseases. 
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Figure  1.9:  Chemokine  receptors  and  disease. Chemokine receptors can be 
classified according to their function. Homeostatic chemokine receptors are 
responsible for orchestrating trafficking and homing of leukocytes during their 
immune surveillance role. The inflammatory chemokine receptors are important 
components of the immune system. Non-signalling chemokine receptors act as a 
chemokine sink to remove excess chemokines from the system. Adapted from 
Johnson et al., (2004). 
 
One strategy for investigating the role of chemokines in disease is the 
implementation of the knockout murine models. Gene-targeting approaches have 
proved particularly useful when dissecting the role of specific chemokines and 
their receptors in vivo. The ability to remove or alter with precision a single gene 
by gene-targeting or knockout is now a routine technique which is commonly 
adopted when creating animal models that can be used to study the 
pathophysiology of various diseases. The aim of a gene knockout is to ablate the 
function of the targeted gene in order to discern its role in vivo. Table 1.1 provides 
an overview of certain chemokine knockout models which have been developed. 
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Targeted 
Subunit 
Immunological 
Phenotype 
References 
CCR1 Imbalance in Th1/Th2 cytokines. Prolonged Blease et al., 
allograft survival in a transplantation model, 2000b; Gao et al., 
resistance to EAE development and 2000; Gerard et al., 
decreased pancreatitis-associated lung injury. 1997; Khan et al., 
Increased glomerular injury in nephrotoxic 2001; Rottman et 
nephritis and increased susceptibility to A. al., 2000; Topham 
fumigatus and T. gondii infection compared to et al., 1999. 
wild-type mice. 
CCR2 Defects in macrophage recruitment and in the Blease et al., 
production of Th1 cytokines, such as 2000a; Boring et 
interferon-γ (IFNγ). Unable to clear infection al., 1997; Fife et al., 
by Listeria monocytogenes and more 2000; Izikson et al., 
susceptible to the injurious effects of 2000; Kurihara et 
intrapulmonary challenge with Aspergillus al., 1997. 
fumigatus spores. Resistant to experimental 
autoimmune encephalitis induced by the MOG 
peptide. 
CCR3 Eosinophil recruitment to the lung is severely Ma et al., 2002. 
curtailed, with eosinophils remaining in the 
sub-endothelial space; paradoxically, there is 
an increase in airway hyper-responsiveness. 
Eosinophils were absent in the CCR3 
knockout mice, mast cell numbers and IL-4 
expression were normal in allergic skin 
inflammation model. 
CCR4 No effect on Th2 differentiation. Resistant to Chvatchko et al., 
LPS-induced endotoxin shock in both low- and 2000. 
high-dose models. 
CCR5 Impaired macrophage function and reduced Zhou et al., 1998; 
efficiency in the clearance of Listeria infection Zhou et al., 1998; 
as well as enhanced T cell-dependent Tran et al., 2000; 
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immune response (DTH reaction). No Barcellos et al., 
protection against the development of EAE or 2000. 
against the development of multiple sclerosis, 
although they do show delayed disease onset. 
CCR6 2–15-fold increase in specific T cell subsets Cook et al., 2000, 
within the mucosa (CD4+ and CD8+ ah-TCR Varona et al., 2001, 
T cells) Develop more severe and persistent Lukacs et al., 2001. 
inflammation than wild type mice in 2.4-DNFB-
induced contact hypersensitivity. Conversely 
in a DTH model, developed no inflammation. 
Reduced airways resistance, fewer 
eosinophils around the airways, reduced IL-5 
in the lung and reduced serum IgE compared 
to wild type mice. 
CCR7 Severely delayed kinetics regarding antibody Forster et al., 1999. 
responses and lack of contact sensitivity and 
DTH reactions. Due to impaired lymphocyte 
migration, there are profound morphological 
alterations in all secondary lymphoid organs, 
and upon activation, DCs fail to migrate into 
the draining lymph nodes. 
CCR8 Defective Th2 immune responses in models of Chensue et al., 
Schistosoma mansonii-soluble egg antigen 2001. 
(SEA)-induced granuloma formation as well 
as in ovalbumin and cockroach antigen-
induced airways inflammation, resulting in 50– 
80% reduction in eosinophil recruitment. Th2 
cells developed normally, they showed 
aberrant Th2 cytokine production. 
CCR9 Appear phenotypically normal. Wurbel et al., 2001; 
CXCR2 Decreased neutrophil recruitment but also an Cacalano et al., 
increase in the number of B cells, and 1994; Del Rio et al., 
lymphadenopathy and splenomegaly. 2001; Frendeus et 
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Increased susceptibility to Toxoplasma gondii al., 2000; 
infection, urinary tract infection and is Devalaraja et al., 
necessary for normal wound healing. Reduces 2000; Boisvert et 
the progression of atherosclerosis, implying a al., 2000. 
role for this receptor in macrophage 
recruitment to atherosclerotic plaques. 
CXCR3 Resistance to development of acute allograft Hancock et al, 
rejection, and CXCR3 deficient allograft 2000; Widney et al., 
recipients treated with a brief, sub-therapeutic 2005. 
course of cyclosporin A maintained their 
allografts permanently and without evidence 
of chronic rejection. 
CXCR4 CXCR4 embryonic lethal embryo lethal. Ma et al., 2002; 
Tachibana et al., 
1998; 
CXCR5 Altered B cell migration and abnormal Forster et al., 1996. 
germinal centre formation in the spleen, and 
lack of Peyer’s patches. 
CX3CR1 Increased graft survival time. Selective Haskell et al., 2001; 
reduction in natural killer cells. Jung et al., 2000. 
Table 1.1: Examples of chemokine knockout murine model. The table above 
provides certain examples of several different murine models available for each 
chemokine receptor, and the insights which these models have provided into the 
role of their specific receptor. 
Chemokines influence allergic diseases, not only by the recruitment of leukocytes 
but also the activation of different leukocytes, inducing the release of a wide range 
of inflammatory mediators inducing Th2 promotion and IgE synthesis. It was 
originally believed that the CC-chemokines were the primary chemokines involved 
in allergic response, with CCL5 and CCL5 being the best known as chemo-
attractants for inflammatory cells, such as eosinophils, basophils and mast cells. 
Other CC-chemokines, such as CCL3, CCL7 and CCL13, have also been 
associated with leukocyte recruitment in the case of allergic diseases. The majority 
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of these chemokines are known to bind CCR3 — which is expressed on Th2-cells, 
basophils, mast cells — and is a major receptor on eosinophils (Kitaura et al., 
1996). Therefore, this has led to the belief that antagonists against CCR3 may be 
a good target as an alternative approach in the treatment of allergic disorders 
(Pease and Williams, 2001). 
1.6.10 Dimerisation of Chemokine Receptors 
The simplest way to view GPCR signalling is according to the model of a 
monomeric GPCR binding an agonist on the N-terminus side of the receptor. This 
induces conformational change of the receptor, altering the 7 trans-membrane 
domains in such a way so as to allow interaction of the G-proteins (Armbruster and 
Roth, 2005). Signalling is not only restricted to monomeric receptors; these 
receptors will form homodimers and heterodimers with other receptors 
(Breitwieser, 2004). The precise structural characteristics of dimerisation are not 
fully understood, although two models have been proposed: 1) contact 
dimerization; and 2) domain-swapping. For contact dimerisation, each receptor is 
an individual entity, contacting each other by non-covalent interactions between 
trans-membrane helices. Domain-swapping shares helices which form covalent 
links between two polypepetide chains; however, there is no clear evidence to 
support either of these theories with regards to chemokine dimersation, but 
provides useful theoretical knowledge to envisage dimerisation. Hernanz-Falcón et 
al. (2004) have suggested that the trans-membrane domains 1 and 4 are involved 
in the dimerisation of CCR5. Furthermore, dimerisation has also been observed 
between CXCR1 and CXCR2, thereby forming both homo- and heterodimers. Vila-
Coro et al also report CXCL12 stimulated dimerisation of CXCR4 receptor (Vila-
Coro et al., 1999b). Although heterodimerisation can occur with certain chemokine 
receptors, this cannot be a generalisation for all chemokine receptors, but it is 
most likely they can only couple to a few others, indicating the need for each case 
to be individually examined. 
The functional relevance of dimerisation may be important in many aspects of 
leukocyte biology. Chemokines are bound to the surface of the epithelium and 
may induce the characteristic rolling of the cell. Dimerisation of receptors may not 
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only decrease the required threshold for activation, but may also provide increased 
sensitivity and specificity within the system (Rodríguez-Frade et al., 2001). 
1.7 Conformation Changes of the Chemokine Receptor 
There is a two-step model of receptor activation for chemokines. The amino-
terminus of the receptor is thought to tether the chemokine with high affinity, 
following which the chemokine N-terminus activates a ligand-binding pocket with 
the TM helices. The resulting conformational changes result in the recruitment of 
heterotrimeric G proteins and subsequent downstream signalling. 
1.7.1 G­protein Dissociation 
Chemokine receptors — like other members of the GPCR family — transduce 
signals via heterotrimeric G-proteins. The name ‘G-protein’ is short for guanine 
nucleotide-binding proteins, which act as ‘molecular switches’, mediating their 
effects by switching between an inactive Guanosine Diphosphate (GDP) and 
active Guanosine Triphosphate (GTP) bound state. The active state results in the 
activation of many different downstream cell processes. 
The interaction of an agonist with its respective chemokine receptor and the 
alteration of the 7 trans-membrane receptors all occur at the cell’s surface. The 
agonist and receptor complex must undergo a specific process in order to turn this 
into a cellular function. Moreover, activation of the receptor occurs after the 
coupling of an agonist. After activation, the second messenger signalling cascade 
is provided by a heterotrimeric guanine nucleotide binding protein (G-protein) just 
under the surface of the membrane (Neer, 1995). The G-protein accordingly acts 
as the molecular switch to initiate different functions within a cell. The G-protein 
comprises α, β and γ subunits. Activation of a chemokine receptor initiates the 
exchange of GDP for GTP on the α subunit. The result of this exchange removes 
the hydrophobic pocket to which the βγ subunit binds, subsequently reducing the 
affinity between Gα-GTP and βγ-subunit; the result of this is the dissociation of the 
two complexes (Lambright et al., 1994). 
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After the disassociation event, the β-γ subunit is free to activate or inhibit 
downstream signalling molecules. Termination of this response is rapid due the 
GTP being hydrolysed back to GDP through innate GTPase activity, thereby 
allowing the re-association of the α and βγ-complex (Hamm, 1998; Sprang, 1997). 
The specific downstream effectors depend on the G-protein which is activated. G-
proteins are characterised by their G-α subunits. Initial experiments employing 
Pertussis toxin(PTX) blockade suggests that Gαi/O proteins are primarily 
responsible for downstream signalling, as physiological responses — such as 
chemotaxis — were readily inhibited by pre-incubation of cells with the toxin 
(Thelen et al., 1988); however, it is now known that there are three other classes: 
Gs, Gq and G12/13. PTX catalyses the ADP-ribosylation of the α subunits of the G-
proteins Gi, and Go resulting in the inability of the G-protein to interact with the cell 
membrane. All of these subunits and the βγ-subunit couple to and activate many 
different signalling pathways, including PLCβ2 and β3 (Katz et al., 1992), PI3K 
(Stephens et al., 1994; Tang and Downes, 1997), MAPK cascade (Inglese et al., 
1995), adenylyl cyclase (Tang and Gilman, 1991), β-adrenergic receptor kinase, 
and K+ and Ca2+ channels (Cabrera-Vera et al., 2003). 
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1.7.2  Phospholipase C/ Protein Kinase C 
Phospholipase C/Protein Kinase C cascade has been demonstrated to activate 
downstream of many different chemokine receptors. PLC is a crucial modulator of 
phosphoinositides at the plasma membrane. There are 6 different isoforms of 
PLC, β, γ, δ, ε, ζ and η. The structural differences of PLC isoforms are highlighted 
in Figure 1.10.  
 
Class Structure
 
 
δ X Y δ1, δ3, δ4
 
PH EF Catalytic
 
ζ ζ1
 
 SH2 SH2 SH3
 
PH
 
γ γ 1, γ 2
 
η  η1, η2 
 
β tail β1- 4 
ε CDC25
 
 
Figure  1.10:  Structural  differences  of  PLC  isoforms. The four domains of 
PLCδ, the PH domain, EF-hands (EF), catalytic domain (containing highly 
conserved X and Y regions) and the C2 domain (C2) are also present in most 
isoforms of other PLC families. The unique region of PLCγ, inserted through a 
flexible loop of the catalytic domain, includes the second PH domain: two SH2 (Src 
homology 2) regions and one SH3 (Src homology 3) region. PLCε contains the 
domain with a guanyl-nucleotide exchange factor activity (CDC25) and two 
predicted RA (Ras association) domains which are implicated in the binding of 
small GTPases from the Ras family. In PLCβ, the unique region (tail) is present at 
the C-terminus. The sequences unique to PLCη (tail) are, as in PLCβ, located at 
the C-terminus. Adapted from Katan, (2005). 
 
 
 β RA RA ε1
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Most chemokines share the ability to bind to chemokine receptors which trigger 
these downstream cascades, rapidly activating phosphoinositide-specific 
phospholipase C-ß2 (PLC-ß2) and PLC-ß3 isoenzymes, which subsequently leads 
to inositol-1,4,5-triphosphate(IP3) and diacylglycerol (DAG) formation and to a 
transient rise in the concentration of intracellular free calcium (Ca2+) by utilising 
PtdIns(4,5)P2 as a substrate (Hawkins et al., 1984; Cicchetti et al., 2002). In the 
neutrophils of mice that lack the genes encoding PLC-ß2 and PLC-ß3, the 
chemokine-induced calcium elevation is fully suppressed, which further supports 
the conclusion that PLC-ß2 and PLC-ß3 are the sole PLC isoforms activated by 
chemokines in immune cells (Li et al., 2000). 
IP3, by interaction with its receptor, induces the mobilisation of cytosolic calcium. 
This results in the entry of Ca2+ ions through Calcium Release-Activated Channels 
(CRAC channels) (Luik and Lewis, 2007; Luik et al., 2006). The result of these 
channels opening is directly related to reduce the levels of calcium from the 
intracellular stores such as the endoplasmic reticulum. There are two key 
components which are considered critical to mediating this process: firstly, Stromal 
Interaction Molecule 1 (STIM1), which is located in the endoplasmic reticulum and 
acts as a calcium senor; and ORAI1, which is a functional component of the Ca2+ 
release-activated Ca2+ (CRAC) channels (Roos et al., 2005). Furthermore, it is 
believed that the depletion of calcium from the intracellular stores results in the re-
localisation of STIM1 from a diffuse distribution to a focal point near the plasma 
membrane. The redistribution of STIM1 to the plasma membrane allows the 
interaction with the CRAC channels, thereby allowing the replenish of the 
intracellular stores (Figure 1.11) (Luik et al., 2006). 
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Figure  1.11: Overview of PLC activation. The G-protein subunit of the GPCR 
activates phospholipase C (PLC), which cleaves phosphatidylinositol-4,5-
bisphosphate (PtdIns(4,5)P2) to produce inositol-1,4,5-trisphosphate (InsP3) and 
diacylglycerol (DAG). IP3 causes the release of calcium from stores within the 
endoplasmic reticulum, which is detected by STIM1. This causes the opening of 
CRAC channels in the plasma membrane. Adapted from Ley et al., (2007). 
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1.8Phosphoinositide 3­Kinase 
1.8.1 Overview 
The early research on phosphorlayted forms of phosphoinositide lipids focuses on 
the conversion of PIP2 by PLC. In the mid-1980s, researchers discovered that the 
lipid PIP2 can serve as a substrate for the phosphoinositide 3-kinase or PI3K 
family, which is characterised by their ability to catalyse the phosphorylation of D3 
of the inositol ring on membrane-bound phosphoinositide lipids to produce PI-
3,4,5-P3 (PIP3). The first known receptor to associate with and activate PI3K was 
platelet-derived growth factor (Auger et al., 1989; Kaplan et al., 1987). PIP3 acts 
as a secondary messenger, which actively recruits intracellular signalling 
molecules, such as Ser/Thr protein kinase B/Akt, Tec family tyrosine kinases and 
the Grp1/Arf exchange factor to the plasma membrane. 
1.8.2 Classes of PI3K 
Mammals have 8 isoforms of PI3K and are subdivided into three main classes 
according to their varying in vivo substrates and structural characteristics. The 
subset of PI3K enzymes which are acutely activated by membrane bound 
receptors are known as Class 1 PI3Ks. Of these, the Class IA PI3Ks signal the 
downstream of tyrosine kinases and consist of a catalytic subunit, p110α (Hiles et 
al., 1992), p110β (Hu et al., 1993), and p110δ (Vanhaesebroeck et al., 1997), and 
are complexed to one of five regulatory subunits (collectively known as p85s) 
containing a Src homology 2 (SH2) domain (Stoyanov et al., 1995). The p85s are 
encoded by three genes: the first three regulatory subunits are all splice variants of 
the same gene (Pik3r1); the other two are expressed by other genes (Pik3r2 and 
Pik3r3, p85β and p55γ, respectively) (Carpenter et al., 1990; Fruman et al., 1996; 
Inukai et al., 1996; Pons et al., 1995; Skolnik et al., 1991). Of the regulatory 
subunits, p85α is the most highly expressed. The three catalytic subunits are 
expressed by separate genes (Pik3ca, Pik3cb and Pik3cd for p110α, p110β and 
p110δ, respectively). 
The Class 1B family has only one member, p110γ (Krugmann et al., 1999; 
Stoyanov et al., 1995), which can interact with one of two regulatory subunits 
(p84/87 or p101 encoded by the PIK3R6 and PIK3R5 gene respectively) and is 
activated by Gβγ subunits downstream of G-protein coupled receptors. The p110γ, 
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like Class 1A isoform, forms heterodimers but varies from Class 1A isoforms as it 
lacks the N-terminus p85. In vitro Class 1A and 1A isoforms have been shown to 
catalyse PtdIns, PtdIns(4)P and PtdIns (4,5)P2 into their respective products; 
however, in vivo, their preferred substrate is PtdIns (4,5), which is converted into 
PtdIns (3,4,5)P3 (Fruman and Cantley, 2002; Vanhaesebroeck et al., 1999). Most 
of the ligands which activate Class IB PI3K are involved in coordinating the body's 
response to injury and infection. 
Class II PI3Ks are encoded according to three separate genes: PI3K Class II α, β, 
γ. The Class II PI3K α and β are ubiquitously expressed, whereas the Class II γ 
has been shown to be almost solely in the liver. In vitro assays demonstrate that 
the Class II isoforms can bind phospholipids in a calcium-independent manner via 
a C-terminal domain; compared to the Class I PI3Ks, Class II PI3Ks demonstrates 
lipid specificity utilising Ptd to PtdIns(3)P and PtdIns(4)P to PtdIns(3,4)P2 
(MacDougall et al., 1995). It is therefore likely that the Class II PI3Ks will induce 
the accumulation of lipids with a profile distinct from that stimulated by the Class I 
PI3Ks (Vanhaesebroeck and Waterfield, 1999). 
The Class III PI3K is the least well-known and least studied of the isoforms in the 
PI3K family. Class III PI3Ks are only thought to comprise one member — the 
human homologue of the yeast vesicular protein-sorting protein, Vps34 (vascular 
protein sorting 34) — which, both in vitro and in vivo, only catalyses PtdIns and is 
thought to play a role in intracellular trafficking events (Yan and Backer, 2007). 
There structural differences of the different PI3K isoforms are highlighted in Figure 
1.12. 
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Figure  1.12:  The  PI3K  family. Class 1 PI3K are heterodimeric enzymes 

consisting of a catalytic and adaptor subunit. The adaptor subunit comprises a N-

terminal p85-binding domain, which binds a p85 regulator subunit, a RBD (RAS 

binding domain) mediating activation by GTPase RAS, a C2 domain and a helical 

domain. Class 1B PI3Ks is similar to the Class 1A, but lacks the p85 binding 

domain, instead having p101 as its adaptor subunit. P101 subunits enable the 

interaction between p110y and the BY subunits of the G proteins, which are 

activated by G-protein coupled receptors. Class II PI3K comprises three members 

and are similar to Class IB but contain additional PX and C2 domains towards the 

C-terminal. Class III comprise a single member with a Vps34 catalytic subunit. 

Adapted from Bader et al.,(2005). 

 

Mammalian cells express PtdIns(3)P constitutively; however, once these cells are 
stimulated, PtdIns(3,4)P2 and PtdIns(3,4,5)P3 are expressed in abundance. This 
difference in expression profile would suggest that PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 play a role as intracellular mediators (Figure 1.13). 
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Figure 1.13: Pathways of phosphoinositide metabolism. The major routes of 

phosphoinositide metabolism thought to operate in mammalian cells are depicted; 

where known, the main enzyme activities thought to catalyse these conversions 

are also noted. The activation of Class I PI3Ks by cell-surface receptors is shown, 

thus leading to the rapid synthesis of PtdIns(3,4,5)P3 and, via the action of 5 

phosphatases, the synthesis of PtdIns(3,4)P2. Adapted from (Hawkins  et  al., 

2006). 

 

1.8.3  PH Domains 
The activation of PI3K results in the accumulation of PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 at the plasma membrane, which then recruits proteins via the lipid 
binding domains (known as Pleckstrin Homology (PH) domains). A protein domain 
of approximately 120 amino acids occurs in a wide range of proteins involved in 
intracellular signalling or as a constituent of the cytoskeleton. Work from a number 
of different laboratories has built the concept that: (i) some PH domains bind 
phosphoinositides; (ii) a subset of these PH domains bind PtdIns(3,4,5)P3 and/or 
PtdIns(3,4)P2 with high affinity and specificity; and (iii) several proteins which 
contain these PtdIns(3,4,5)P3/PtdIns(3,4)P2-specific PH domains play key roles in 
mediating Class I PI3K-dependent regulations of important cellular responses 
(Hawkins  et  al 2006). However, it is still unclear precisely how 
PtdIns(3,4,5)P3/PtdIns(3,4)P2 engagement with the PH domain of an effector 
protein regulates its activity. This interaction is of sufficient affinity that the target 
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protein undergoes a net change from a predominantly cytosolic to a predominantly 
plasma membrane location.  
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Figure 1.14: Activation of Class 1 PI3K results in binding of PtdIns(3,4,5)P3 to 
a wide  variety  of  PH domains. Phosphorylation of PIP2 to PIP3 culminates in 
increased levels, thus resulting in the sensing by PH domain with appropriate 
affinity and specification, leading to the activation of a wide range of PH domains. 
These PH-domain-containing effectors belong to several different protein families, 
some of which are shown together with specific examples and an indication of the 
downstream responses which they are thought to regulate. Adapted from Hawkins 
et al., (2006). 
 
It is now also thought that PtdIns(3,4,5)P3/PtdIns(3,4)P2 binding to PH domains 
can often derepress an intramolecular inhibition mediated by the PH domain, 
subsequently inducing significant activation of the effector. Examples of this are 
apparent in the activation of GEFs (guanine nucleotideexchange factors) for small 
GTPases. PtdIns(3,4,5)P3 binding is thought to relieve a PH-domain-mediated 
inhibition of the Dbl catalytic domain and to also bring the GEF into proximity with 
its lipid-tethered GTPase (Welch  et  al., 2003). Furthermore, PDK 
(Phosphoinositide-Dependent Kinase)-mediates phosphorylation and activation of 
PKB (also known as Akt) (Komander et al., 2004; McManus et al., 2004; Mora et 
al., 2005). Both PDK and PKB possess PH domains which bind 
PtdIns(3,4,5)P3/PtdIns(3,4)P2, thus allowing an increase in their relative effective 
concentration on Class I PI3K activation. PDK appears to be ‘constitutively active’, 
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and its activity is ultimately considered independent of phosphoinositide/PH 
domain binding. Moreover, it also has a major role to play in PI3K-independent 
phosphorylation of the activation loop in several ‘AGC family’ kinases. In contrast, 
however, the ability of PDK to phosphorylate PKB in its activation loop is highly 
dependent on Class I PI3K activity. PtdIns(3,4,5)P3/PtdIns(3,4)P2 binding to the 
PH domain of PKB is required to make Thr308 in the activation loop available for 
phosphorylation by PDK. Figure 1.14 highlights the PtdIns(3,4,5)P3/PtdIns(3,4)P2 
binding to PH with the wide downstream effectors activated. The PI3K family has 
been implicated in a wide range of biological processes, such as cell survival, 
proliferation, cell migration and degranulation with the signalling pathways 
highlighted in Figure 1.15. 
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Figure 1.15: Signalling events following formation of phosphoinositide lipids 
by  PI3K. Agonist stimulation of chemokine receptor activated class IB PI3K via 
action of Gβγ subunits and the Ras. This leads to accumulation of PI3K products 
PtdIns(3,4,5)P3 and indirectly PtdIns(3,4)P2 in the membrane and interaction with 
variety of effector proteins by binding to the PH domain.  
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1.8.4 Protein Kinase B 
One of the most widely studied molecules phosphorylated by the activation of 
PI3K is the serine/threonine kinase, Protein Kinase B (PKB, also known as Akt) 
(Burgering and Coffer, 1995). There are three known members in the Akt family: 
Aktα, Aktβ and Aktγ, all of which share close homology to the protein kinases A, G 
and C, collectively form the AGC kinase family (Manning and Cantley, 2007). The 
precise activation of the kinases is not yet fully understood; however, 
phosphorylation of Akt is thought to occur at two key sites — the Ser473 in the 
hydrophobic region of the C-terminal regulatory down and Thr308 within the 
kinase activation loop (Toker and Newton, 2000). Alteration of Akt by activation of 
PI3K results in accumulation of PtdIns(3,4,5)P3 at the plasma membrane. After 
relocation to the plasma membrane, this lipid recruits Akt via its PH domain. Upon 
reaching the plasma membrane, it is thought that PDK-1 induces the 
phosphorylation of the Thr308, whereas the rictor-mTOR complex directs 
phosphorylates Ser473 in the hydrophobic region of Akt (Sarbassov et al., 2005). 
In order for Akt to be fully active, both of these residues have to become 
phosphorylated. Moreover, the regulation of Akt activation has been shown to be 
controlled by the dephosphorlaytion of PtdIns(3,4,5)P3 by the cellular phosphatase 
SHIP, resulting in decreased levels of PtdIns (3,4,5)P3 at the cellular membrane 
leaving the remaining Akt in its inactive form in the cytoplasm (Stambolic et al., 
1998). Moreover, activation of Akt is known to induce the phosphorylation of a 
number of proteins further downstream of itself, particularly those involved in the 
regulation of glucose metabolism and cell survival (Wymann et al., 2000). Further 
downstream signalling pathways include mTOR. 
A role for Akt activation within the degranulation of mast cells has appeared over 
the last decade, and is currently being investigated (Ali et al., 2008; Wymann et 
al., 2003). Akt can be directly dephosphorylated, thus inactivating Akt; this is 
induced by the PH domain leucine-rich repeat protein phosphatase (PHLPP), 
which specifically dephosphorylates the hydrophobic motif of Akt (Ser473 in Akt1) 
(Gao et al., 2005). PHLPP levels are markedly reduced in the instance of several 
colon cancers and glioblastoma cell lines, which have elevated Akt 
phosphorylation, induced apoptosis and restricted tumour growth. Moreover, the 
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reintroduction of PHLPP into a glioblastoma cell line causes a dramatic 
suppression of tumour growth (Gao et al., 2005). 
1.9Assessing the Role of PI3K 
Many different approaches have been studied through PI3K in order to assess the 
role of a particular gene. Each of the methods has its advantages and 
disadvantages, all of which will be discussed in the following section. The use of 
antibodies or inhibitors has been used to block the function of proteins by affecting 
the proteins from binding. Other studies have utilised the use of knock-in/knock-
out animal models. Further studies, in the middle of these two extremes in order to 
try and utilise RNA interference against specific isoforms of interest — transcribed 
but degraded before generation of the protein. 
1.9.1	 Pharmacological Intervention: first generation ‘dirty’ PI3K 
inhibitors 
The PI3K family comprises a group of enzymes possessing several structural 
elements and binding domains. Studies aiming to reveal the role of the PI3K family 
have utilised pharmacological inhibitors. Moreover, the majority of studies have 
used the broad-spectrum isoform PI3K inhibitors Wortmannin and LY294002. 
Wortmannin, a metabolite of Penicillium funiculosum, is one such molecule. 
Wortmannin’s anti-inflammatory actions were first recognised in 1974 by 
Wiesinger et al. (1974) and, approximately a decade later, it was described as a 
potent inhibitor of the respiratory burst in neutrophils and monocytes (Baggiolini et 
al., 1987). It was not until 1993 that PI3K was recognised as one of the many 
molecular targets of Wortmannin (Arcaro and Wymann, 1993). The action of 
Wortmannin involves interacting with the ATP-binding pocket by forming a 
covalent interaction with the catalytic lysine residue, and it is likely that the reactive 
nature of the Wortmannin structure makes it prone to forming unexpected and 
possibly hazardous combinations with other biological molecules (Wymann et al., 
1996). 
LY294002 was first described as a PI3K inhibitor by the Lilly Research Laboratory, 
in 1994. LY294002 is ATP-competitive, has low molecular weight and planar with 
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relatively low potency against the PI3Ks. Moreover, it has been found to inhibit — 
or at least interact with — a plethora of other intracellular targets at concentrations 
little removed from those required for PI3K inhibition (Gharbi et al., 2007). Despite 
the limitations of these first generation PI3K inhibitors — such as poor selectivity, 
toxic effects and the inability to distinguish between specific PI3K isoforms, for 
instance — they have nevertheless been proven as pivotal tools in research when 
striving to fully understand the role of PI3K (Rommel et al., 2007; Ward and Finan, 
2003). The pre-treatment of murine T and B lymphocytes, freshly isolated T 
lymphocytes with LY294002 or Wortmannin demonstrates a role for PI3K in the 
peak chemotactic response (Reif et al., 2004; Sotsios et al., 1999). Moreover, in 
recent years, a new general broad-spectrum inhibitor, ZSTK474, is reported to 
lack the off-target limitations of the widely used inhibitors LY294002 and 
Wortmannin (Kong and Yamori, 2007). Similar to LY294002, ZSTK474 is also an 
ATP-competing inhibitor of PI3K. The chemical structure of each of the three PI3K 
general inhibitors is highlighted in Figure 1.16. 
ZSTK474LY294002 Wortmannin 
1st 
Generation 
PIK75 TGX­221 IC87114 AS605240 
2nd 
Generation 
Figure 1.16: Chemical structure of PI3K inhibitors. 
The use of these inhibitors is limited due to their broad-spectrum nature, which has 
consequently led to confusion as to which specific PI3K isoforms are involved in 
different cellular functions. This has subsequently led to questions posed 
concerning exactly which class of PI3K can be involved, and therefore underplays 
the contribution of these family members within different models. In more recent 
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years, however, there has been much excitement concerning the development of 
PI3K isoform specific inhibitors — the so-called second-generation inhibitors. 
1.9.2 Second­Generation Inhibitors 
Given the high degree of similarity that exists between the amino acids forming the 
ATP-binding pockets of the four class I PI3Ks, it was expected that isoform 
selective inhibitors with at least 50-fold difference in potency would be difficult to 
obtain; this, however, was disproved with the discovery of the quinazolinone 
purine series, exemplified by IC87114 and described by the ICOS Corporation 
(Sadhu et al., 2003). Although only these compounds have been used within the 
last decade, they have already significantly contributed to the current body of 
knowledge regarding the different isoform specific functions. PIK75 has been 
noted as a class 1α inhibitor, and has accordingly demonstrated a role in insulin-
signalling (Knight et al., 2006). IC87114 and AS605240 are selective inhibitors for 
the δ and γ isoforms respectively, and have accordingly highlighted a role for 
these isoforms in the case of neutrophil trafficking (Camps et al., 2005; Puri et al., 
2004). Moreover, each of these inhibitors appears to mediator their effect by 
competitively binding at the ATP binding site. The advancement of PI3K isoform-
specific inhibitors has subsequently allowed, and is continuing to be critical in, 
unravelling the roles of each of the specific isoforms. 
1.9.3 Genetic Approaches 
The contribution of knock-out and knock-in mice models has greatly increased our 
knowledge regarding many different systems and their particular isoforms, each 
with many different signalling pathways. The PI3K family is just one of these. In 
order to produce knockouts using recombinant DNA technology, the normal DNA 
sequence of the gene being studied is altered so as to prevent the synthesis of a 
normal gene product. Cloned cells in which this DNA alteration is successful are 
then injected into mouse embryos in order to produce chimeric mice; the chimeric 
mice are then bred with the aim of yielding a strain in which all the cells of the 
mouse contain the disrupted gene. 
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The advantages of knockout mice are: 
•	 The ability to study gene function in a living animal; 
•	 The ability to test drugs and therapies; and 
•	 Ease of breeding and maintaining. 
Disadvantages: 
•	 15% of gene knockouts are lethal; 
•	 There is only the ability to study embryonic development, as genes may 
have different functions in adults; 
•	 The knockout may produce no observable change(s); and 
•	 The knockout may illustrate no correlation with human gene activity. 
The kinase dead or knock-in models, at which point mutation within the gene of 
interest, is generated resulting in the transcription of the isoform and production of 
protein but yet it provides no functional signals. The knock-in method was 
developed in which a mutated DNA sequence was exchanged for the endogenous 
sequence without any other disruption of the gene. Some knock-in strategies rely 
on the use of gene vectors with flanking sequences — termed loxP — which, upon 
exposure to an enzyme called Cre recombinase, undergoes reciprocal 
recombination, subsequently leading to the deletion of the intervening DNA. With 
this method, it is possible to replace a gene sequence with a sequence of the 
investigator’s choice and to accordingly delete unnecessary sequences. The 
advantages of knock-in mice are: 
•	 Specific integration site; 
•	 The transgene genetic environment is totally controlled; and 
•	 Only one transgenic line is necessary. 
The major drawback of this method is that the molecular biology work is 
considered to be significantly more complex and can take longer to perfect. 
However, it is worth noting that compensatory mechanisms in protein expression 
by other PI3K isoforms exist. In an attempt to overcome this, these knock-in 
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murine models have needed to maintain protein stoichiometry. A list of some of 
the PI3K murine models are summarised in Table 1.2. 
Targeted 
Subunit 
Genetic 
Approach 
Viability Immunological 
Phenotype 
References 
P110α KO	 Embryonic Not applicable 
lethal 
P110β KO	 Embryonic Not applicable 
lethal 
P110δ KO Viable	 ↓ neutrophil tethering 
and trafficking across 
inflamed venules. ↓ B 
cell number and 
proliferation 
P110δ KI Viable	 ↓ neutrophil migration 
and PIP3 generation. ↓ 
B and T cell number and 
proliferation 
P110γ KO Viable	 ↓ neutrophil and 
macrophage migration 
in vivo and in vitro. ↓ T 
proliferation 
P110γ KI Viable	 ↓ Decrease in vivo and 
in vitro chemotaxis 
Bi et al., 1999.

Bi et al., 2002.

Puri et al., 
2004; 
Jou et al., 
2002; Clayton 
et al., 2002. 
Okkenhaug et 
al., 2002. 
Hirsch et al., 
2000; Li et al., 
2000; 
Rodriguez-
Borlado et al., 
2003. 
Patrucco et 
al., 2004. 
Class II α Not yet Not Not applicable 
generated applicable 
Class II β KO Viable Wound healing Harada et al., 
unaffected 2005. 
Class III Not yet Not 
generated applicable 
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Table 1.2: Phenotypes of mice that have PI3K catalytic subunit genetically 
targeted. Adapted from Vanhaesebroeck et al., (2005). 
A review reports that the use of knock-out murine models allows a potential 
functional redundancy between the PI3K isoforms (Vanhaesebroeck and 
Waterfield, 1999). The variation in species used to generate these murine models 
also has drawbacks; this is where the ‘middle ground’ in studying PI3K becomes 
an invaluable tool, as it allows specific targeting on gene function in humans. 
1.9.4 RNA Interference 
Murine models are not perfect and, like any technique implemented, have 
disadvantages. One problem which has been associated with knockout models is 
functional redundancy between particular isoforms. If one particular gene is knock-
out, other isoforms within this family subsequently compensate for the absence of 
this gene and may artificially drive functionality through other members. Moreover, 
RNA interference could potentially overcome this problem as it has only a of 
knockdown 80-90% of normal levels, thereby allowing background function of the 
selected isoforms; therefore, any potential compensatory mechanisms by other 
isoforms with the same family may not become active. 
RNA interference is a naturally occurring event in which double-stranded RNA 
molecules induce the degradation of the corresponding mRNA. This, in turn, 
inhibits the translation of mRNA. RNA interference is the silencing of gene by 
target messenger RNA, and this technique has been used in research for many 
years, initially being utilised in plants, followed in the 1990s in invertebrates. The 
switch to mammalian systems has proved a much bigger challenge: the biggest 
problem was the struggle to introduce long, double-stranded RNA in mammalian 
cells. As a result of this, the cells’ initiation interferon response led to wide protein 
inhibition (Bass, 2001); however, this issue has been overcome during the last 
decade as a result of the utilisation of small double-stranded RNA molecules, 
normally 21-23 base pairs long. These small double-stranded RNA molecules 
(siRNA) have been utilised in order to decrease target mRNA levels correlating to 
a decrease in protein expression of up to 90% (Gresch et al., 2004). The 
mechanism of siRNA action is highlighted in Figure 1.17. 
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Figure 1.17: Schematic representation of siRNA mediating complementary 
mRNA degradation. Long dsRNA are introduced into the cell and are cleaved by 
enzymes, known as Dicers, into siRNA of 21-23 nucleotides in length. These 
siRNAs are then incorporated into the RISC complex, where the two strands are 
unwound, thereby allowing one strand to bind to complementary mRNA within the 
cells. The mRNA is then cleaved and degraded by nucleases, with the RISC free 
to bind further siRNAs. Abbreviations of dsRNA — double-stranded RNA, siRNA 
— short interfering RNA, RISC — RNA-induced silencing complex. Adapted from 
Sioud and Sørensen, (2004). 
The principle that RNA interference is based upon is that only specific target gene 
will be down-regulated. The majority of studies focus on one target gene and 
several additional genes; however, recent data suggests that care must be taken 
in order to avoid off-target effects. Furthermore, it is possible to knock-down genes 
with homology similar to the target gene, and they are therefore knocked down as 
so-called off-target (Jackson and Linsley, 2004). 
There are several methods available in order to facilitate the entry of siRNA into 
mammalian cells in vitro; lipid based carriers and viruses, for instance, have been 
used with varying success. Moreover, the direct application of siRNAs onto 
mucosal membranes has been demonstrated to be an efficient up-take of siRNA, 
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thereby helping to explain why the lung has shown the most successful application 
of siRNA technology in vivo to date. 
The application of siRNA possesses many challenges, especially in the case of 
humans; lipid-based carriers and viruses, for example, have been used with 
varying success. It has been demonstrated in Phase I results of the first two 
therapeutic siRNA trials demonstrated that siRNAs are well-tolerated and have 
suitable pharmacokinetic properties. Moreover, Kumar et al. (2008) demonstrate 
that siRNA treatment can dramatically suppress HIV infection in T-cells, which 
therefore highlights the importance of siRNA as a potential powerful therapeutic 
target over the next decade. 
1.10 Mitogen­Activated Protein Kinase 
The Mitogen-Activated Protein Kinase (MAPK) pathway is made up of many 
different subunits. The most widely studied of these is the ERK (extracellular 
signal regulated kinase), JNK (c-jun-NH2-terminal kinase), and the p38 kinases. 
These different subunits each plays a key role in signal transduction from the 
plasma membrane to the nucleus. Moreover, MAPKs primarily reside in the 
cytoplasm; however, upon activation, these molecules have the capacity to 
phosphorylate nuclear substrates, such as protein kinases, cell-cycle regulators 
and transcription factors. Furthermore, activation of MAPKs induces a cascade of 
phosphorylation events via proteins kinases. Numerous protein kinases are 
involved in different stages of this process, each regulated through G-proteins, 
scaffolds, substrates, adaptors and regulator proteins. This, in turn, induces a wide 
range of cellular functions, including differentiation, cell proliferation, inflammatory 
responses and apoptosis (Weston et al., 2002). 
1.10.1 Extracellular Signal Regulated Kinase 
ERK is the most well-known member of the MAPK family. Activation of this protein 
is carried out after stimulation via receptor tyrosine kinases, GPCRs and integrins. 
The subsequent activation of ERK is catalysed upstream by the kinases MEK1 or 
MEK2, subsequently resulting in the homodimerisation of ERK1/2 and 
translocation to the nucleus where they can further stimulate other kinases and 
transcription factors (Kolch, 2005). CXCR3 agonists demonstrate the ability to 
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activate the MAPK pathway, utilising the ERK1/2 response as a read-out for 
MAPK activation (Figure 1.18) (Smit et al., 2003). 
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Figure 1.18: Simplified GPCR activation of MAPK pathway. The activation of 
GPCR accordingly activates the MAPK family, which subsequently results in the 
activation of the three main MAPK families — ERK, JNK and p38. The primary but 
overlapping responses include cell growth and differentiation (ERK), matrix 
regulation (JNK), and inflammatory cytokine production (p38). Adapted from 
Sweeney and Firestein, (2007). 
 
1.10.2  Rho in Cell Polarisation 
Cell polarity is essential for the process of cell migration and degranulation, and is 
regulated by conserved protein complexes, including the Par complex, Rho 
GTPases and their regulators. Increasing evidence indicates that differential sub-
cellular localisation and activity of the Par complex — consisting of Par3, Par6, 
and atypical protein kinase C (aPKC) — are critical for polarisation (Kraynov et al., 
2000). 
 
It is also known that the spatial coordination of Rac and Rho activity is essential for 
degranulation. The molecular mechanisms regulating these GTPases during 
degranulation are unknown. Members of the Rho family of GTPases are emerging 
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as key regulators of cell migration; specifically, Rac activity is increased at the 
leading edge of a migrating cell (Wang et al., 2002). Depending on the 
physiological context, Rac and Cdc42 can function as mediators and/or regulators 
of the Par complex. Moreover, PI3K has been shown to predominantly activate 
Rac or Cdc42 (Raftopoulou and Hall, 2004; Srinivasan et al., 2003; Weiner, 2002). 
This activity drives the actin polymerisation which underlies lamellipodia formation 
and subsequent forward protrusions (Xu et al., 2003). Rac activity leads to 
lamellipodia formation and forward protrusion. Moreover, rho activity is 
hypothesised to be required later in order to stabilise the cell during the contractile 
events of migration. 
A large body of evidence has indicated that Rac proteins, and/or components of F-
actin networks which are dependent on Rac activity, may form part of a positive-
feedback loop, capable of stimulating PtdIns(3,4,5)P3 production preferentially at 
the leading edge (Park et al., 2004; Sasaki et al., 2004). It has been further 
demonstrated that RhoA and its downstream effector ROCK regulates the 
assembly and activity of the Par complex during cell migration. 
1.11 Mast Cell Signalling 
Antigen-dependent mast cell activation is regulated by a complex series of 
intracellular signalling processes which are activated following antigen/IgE cross-
linking to FcεRI. The proximal-signalling events required to release the mediators 
seem to be common for all categories of mediator, whereas the distal signalling 
events diverge to regulate different mechanisms, by which the mediators are then 
released (Gilfillan and Tkaczyk, 2006). 
One of the main families of kinases which are involved in mast cell signalling is the 
SRC family kinases which, during the initial stages, is LYN and mainly resides in 
lipid rafts (Kovarova et al., 2006). The exact involvement of LYN is unclear; 
however, it has been reported that antigen-mediated allergic reactions are absent 
in LYN-/- mice (Hibbs et al., 1995). One possibility for the involvement of LYN in 
activating both positive and negative pathways for FcεRI mediated degranulation, 
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with the negative pathways being mediated by the PI3K regulator SHIP 
(Hernandez-Hansen et al., 2004). 
The activation of LYN has been shown to phosphorylate the tyrosine residues in 
the FcεRI β and γ-chains. Following phosphorylation, the immunoreceptor 
tyrosine-based activation motifs (ITAMs) of the FcεRI β and γ-chains provide 
docking sites for the SH2 domains of LYN and ZAP70-related tyrosine kinase SYK 
(spleen tyrosine kinase) (Chen et al., 1996; Furumoto et al., 2004). The activation 
of SYK and/or LYN induces the phosphorylation of the trans-membrane adaptor 
molecule LAT (Linker for the Activation of T-cells), and is critical for the guidance 
and direction of downstream signalling (Saitoh et al., 2000). 
Phosphorylation of LAT results in the recruitment of several molecules such as 
cytosolic adaptor molecules; for example, GRB2 (growth-factor-receptor-bound 
protein 2), GADS (GRB2-related adaptor protein), SHC (SH2-domain-containing 
leukocyte protein C), and SLP76 (SH2-domain-containing leukocyte protein of 
65kDa); guanine-nucelotide-exchange factors and adaptor molecules, such as 
SOS (Son of Sevenless homologue) and VAV; and signalling enzymes, such as 
phospholipase Cγ1 (PLCγ1). The results of all the molecules being recruited 
subsequently enables the formation of macromolecules through either direct or 
indirect binding to LAT, thereby allowing diversification of the downstream 
signalling required for the release of all the various mediators stored in the 
cytoplasm of mast cells. 
The crucial residues of LAT involved in regulating signalling and degranulation are 
Y132, Y171, Y191 and Y226; these 4 residues interact though direct or indirect 
interaction with the signalling enzyme PLCγ, the result of which induces the 
mobilisation of intracellular calcium and activation of PKC. There are two forms of 
PLC expressed within mast cells: PLCγ1 and PLCγ2; both of these require re-
localisation to the plasma membrane prior to their activation. The precise role of 
PLCγ has been difficult to assess in the case of mast cells, as knock-out of PLC in 
mice is lethal (Ji et al., 1997). However, a study suggests that, in bone marrow-
derived mast cells in PLC-deficient mice, reduced degranulation response when 
challenged with antigen has been observed (Wang et al., 2000). LAT is now 
63

Chapter 1 ­ Introduction

known to be not the only adaptor molecule required for mast cell activation. 
Studies in LAT-deficient bone marrow-derived mast cells still demonstrate residual 
calcium mobilisation and degranulation, (Saitoh et al., 2000). 
Another trans-membrane adaptor molecule, Non-T-cell Activation Linker (NTAL) 
— sometimes referred as LAT2 due to the structural similarity to LAT — has been 
identified as a key component for mast cell activation by providing key docking 
sites. NTAL has been shown to rapidly phosphorylate tyrosine residues in an LYN-
and SYK-dependent manner following FcεRI activation (Brdicka et al., 2002; 
Tkaczyk et al., 2004). However, it is believed that NTAL has a role to play in the 
negative regulation of mast cell induced degranulation due to the increased 
capacity to signal and de-granulate in NTAL knock-out mice (Volná et al., 2004). 
Moreover, it is also believed that NTAL and LAT compete for the same pool of 
associating signalling molecules in lipid rafts (Tkaczyk et al., 2004). NTAL 
functions in a similar way to LAT by recruiting GRB2. Despite the similarity 
between LAT and NTAL, they do not bind to exactly the same molecules. LAT has 
a site (Y132) which, when phosphorylated, allows binding of PLCy, whereas 
NTAL, on the other hand, has a region between 104 and 114, containing the 
sequence YIDP allowing the binding of SRC-family kinases such as LYN and FYN 
(Linnekin, 1999). 
Studies reveal that the absence of the FceRI β chain only partially limits mast cell 
activation, whereas knock-out of the γ chain completely abolishes mast cell 
activation. This has subsequently led to the conclusion that the γ chain is required 
for degranulation, whereas the β chain is involved in the amplification of the 
signals (Ra et al., 1989; Repetto et al., 1996; Takai et al., 1994). This amplification 
pathway is thought to involve another SRC-family kinase FYN, which doesn’t 
activate LAT but another kinase family — the PI3Ks (Gu et al., 2001; Parravicini et 
al., 2002). An overview of mast cell signalling is highlighted in Figure 1.19. 
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Figure  1.19:  Brief  overview  of  signalling  molecules  involved  in  mast  cell 
degranulation. Activation of FcεRI and c-Kit result in the activation of both the 
principle signalling pathways (red arrows) and the complementary pathways (black 
arrows). The role that NTAL might have to play in these pathways is yet to be 
confirmed experimentally. The blue and green arrows indicate the activation of 
downstream signalling pathways, which subsequently leads to degranulation 
(adapted from Gilfillan and Tkaczyk, 2006). 
 
PI3K provides a docking site for PH domains of several signalling molecules which 
are considered important for mast cell activation containing these PH domains, 
including PLCγ 1 and 2, VAV and Burtons tyrosine kinase (BTK), (Iwaki  et  al., 
2005; Salojin  et  al., 2000). There have been many different approaches utilised 
over the years with the aim of deciphering the role of PI3K in mast cell activation 
and subsequent degranulation. Initial studies began with the broad-spectrum PI3K 
inhibitors, Wortmannin and LY294002, which were observed to inhibit both 
antigen-mediated calcium mobilisation and degranulation (Barker  et  al., 1995; 
Barker et al., 1998). Moreover, it is widely recognised that these inhibitors have a 
wide range of off-target effects hitting other kinases. Genetic approaches have 
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generated mice lacking the p85α or p85β subunits individually, mice lacking 
catalytic p110γ, p110δ subunits, or mice with a knock-in point mutation of 
p110δD910A, thereby revealing the involvement of p110δ but not p110γ as the 
key PI3K isoform involved in mast cell activation. Mast cells derived from the bone 
marrow of p85α and p85β knock-out mice show normal antigen mediated calcium 
flux and degranulation. 
PI3K plays a multiple role in mast cells — not only in terms of the release of 
mediators but also in chemotaxis, adhesion and homeostasis. As with all PI3K-
induced responses, specific isoforms are responsible for mediating different 
reactions. Examples of this are in p110δ-deficient bone marrow-derived mast cells, 
where chemotaxis and adhesion are severely diminished compared to wild type 
mast cells (Jolly et al., 2004). In vivo studies also demonstrate the loss of 
peritoneal and gastrointestinal mast cells in p85α-deficient mice (Kim et al., 2004). 
1.12 CXCR3 
Historically, CD183 was the third CXC chemokine receptor discovered and was 
subsequently given the name CXCR3 as it is now more commonly known. CXCR3 
is a PTX-sensitive, seven-transmembrane domain-spanning G protein-coupled 
receptor which binds the pro-inflammatory non-ELR motif CXC chemokines: 
monokine, induced by human IFN-γ (Mig)/CXCL9, IFN-inducible 10-kDa protein 
(IP-10)/CXCL10 and IFN-inducible T-cell α chemo-attractant (I-TAC)/CXCL11. 
CXCL9, CXCL10 and CXCL11 (Loetscher et al., 2000; Murphy et al., 2000; Zlotnik 
et al., 1999);(Khan et al., 2000). CXCR3 was cloned and identified as a receptor 
for CXCL9 and CXCL10 by Loetscher et al. (1996) and was subsequently 
identified as a receptor for CXCL11 (Cole et al., 1998). CXCL9, CXCL10 and 
CXCL11 are selective, potent agonists of CXCR3 (Kd 0.1–5 nM) (Cole et al., 1998; 
Loetscher et al., 1996). Additional chemokines have been reported to bind to 
CXCR3 (e.g., CXCL13 (Jenh et al., 2001) and CCL11 (Xanthou et al., 2003). 
Notably, the reported affinities are generally weak and the biological significance 
of the interactions is questionable. Similarly, the agonists for CXCR3 have been 
reported to be antagonists of CCR3 (Loetscher et al., 2001) and CCR5 (Petkovic 
et al., 2004), but high concentrations of the CXCR3 ligands are required to achieve 
inhibition of CCR3 or CCR5 biological functions. CXCL11 has a higher binding 
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affinity for CXCR3 than either CXCL9 or CXCL10 and is a more potent activator of 
CXCR3 (Clark-Lewis et al., 2003; Meyer et al., 2001; Sauty et al., 2001). Similarly, 
CXCL11 is a more potent antagonist to CCR3 than CXCL9 or CXCL10 (Loetscher 
et al., 2001). 
Recent studies show that different CXCR3 ligands exhibit unique temporal and 
spatial expression patterns, suggesting that they have non-redundant functions in 
vivo. Moreover, the CXCR3 ligands share low sequence homology (around 40% 
amino acid identity) and exhibit differences in their potencies and efficacies at 
CXCR3, with CXCL11 being the dominant ligand in several assays (Cole et al., 
1998; Meiser et al., 2008). CXCR3 is expressed in a wide variety of cells, including 
activated T lymphocytes, NK cells, malignant B lymphocytes, endothelial cells, and 
thymocytes (Loetscher et al., 1996; Loetscher et al., 1998; Qin et al., 1998; 
Romagnani et al., 2001; Trentin et al., 1999; Van Der Meer et al., 2001). 
The binding of chemokines to CXCR3 induces cellular responses which are 
involved in leukocyte traffic, most notably integrin activation, cytoskeletal changes 
and chemotactic migration (Loetscher et al., 2000; Murphy et al., 2000; Zlotnik et 
al., 1999). Signal transduction has not been further analysed but may include the 
same enzymes (including phospholipases, protein kinase B and C, PI3K, MAP 
kinases, G protein-coupled receptor kinases, and small GTPases) identified in the 
signalling cascade as induced by other chemokine receptors (Loetscher et al., 
2000; Murphy et al., 2000; Zlotnik et al., 1999). 
In recent years, however, two main variants of CXCR3 receptor have been 
identified, namely CXCR3-B (Lasagni et al., 2003) and CXCR3-alt (Ehlert et al., 
2004). Both variants are generated via alternative splicing of mRNA, encoding the 
original CXCR3 receptor (henceforth referred to as CXCR3-A). In the case of 
CXCR3-B, alternative splicing results in the translation of CXCR3-B mRNA 
generating a 416–amino acid receptor containing a longer NH2-terminal 
extracellular domain different from the CXCR3-A sequence in the first 52 amino 
acid residues; the remaining receptor at a protein level, on the other hand, was 
identical (Lasagni et al., 2003). Moreover, it has also been reported that CXCR3-B 
could be bound to a G protein that is not Gαi as CXCR3-B is not pertussis toxin-
sensitive. Pertussis toxin insensitive hetrotrimetric G proteins include members of 
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the Gα12 and Gq families and the Gi family member Gz, although the latter is 
predominately expressed in neurons and platelets (Kouroumalis  et  al., 2005). 
CXCR3-B is expressed at a lower concentration than CXCR3-A, but has been 
shown to be functional against all classical CXCR3 ligands, CXCL9, CXCL10 and 
CXCL11. This form of receptor has been shown to bind Platelet Factor 4 
(PF4/CXCL4) in addition to the three classical CXCR3 agonists (Lasagni  et  al., 
2003). Figure 1.20 highlights the structural differences between the CXCR3 
isoforms. 
 Extra 52 
aa 
 

 

 

N­terminus N­terminus N­terminus
 

 

 

 

 

 

C­terminus C­terminus C­terminus


 CXCR3A CXCR3B CXCR3­Alt
 
  
Figure  1.20:  2D  Schematic  of  the  CXCR3  variants. The three variants of 
CXCR3 have structure differences. CXCR3B has a slightly longer NH2 terminus, 
by 52 aa when compared to CXCR3A. CXCR3 is the truncated form of CXCR3, 
and has a predicted four, possibly five, transmembrane spanning domains. 
 
In contrast, CXCR3-alt is a truncated version of CXCR3 (lacking 101 amino acids), 
which consequently exhibits a dramatically altered C terminus and has a predicted 
4-5 transmembrane domain structure (Ehlert et al., 2004). Despite this drastically 
modified structure, CXCR3-alt has nevertheless been shown to bind and respond 
to CXCL11, yet is unresponsive to CXCL9 and CXCL10. In addition, CXCL11 — 
but not other CXCR3 agonists — also binds to CXCR7; a receptor which has been 
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associated with increased adhesiveness, invasiveness and reduced apoptosis of 
human umbilical vein endothelial cells and tumour cells (Burns et al., 2006). 
1.12.1 CXCR3 and its Agonists on Mast Cells 
Previous studies carried out on mast cells reveal that CXCR3 is the most 
abundantly expressed, functional chemokine receptor on human lung mast cells. 
In contrast, CXCR3 expression by bone marrow mast cells is low (Brightling et al., 
2005). It is thought from this study that the CXCR3 activation may facilitate the 
migration of mast cells within tissue, and may therefore be important in the micro-
localisation of mast cells within specific tissue structures. However, although 
CXCR3 was the chemokine receptor most highly expressed, human lung mast 
cells is also expressed in the chemokine receptors CCR3, CXCR1, and CXCR4 in 
more than 10% of cells (Brightling et al., 2005). 
It has been widely reported that CXCR3 agonists play a key role in the recruitment 
of CXCR3 positive mast cells to the tissues in many diseases (Ruschpler et al., 
2003; Wardlaw et al., 1986; Yousem, 1997). Such diseases include Rheumatoid 
Arthritis, (Ruschpler et al., 2003), post-lung transplant bronchiolitis obliterans 
syndrome (Belperio et al., 2003), and sarcoidosis (Miotto et al., 2001). ASM 
bundles are contracted in asthma and is predominately mediated by activation of 
mast cell CXCR3 by ASM-derived CXCL10, but not CXCL9 or CXCL11, therefore 
suggesting a different role for the various CXCR3 agonists in diseases. 
1.12.2 Therapeutic Potential of CXCR3 
Studies using CXCR3-KO (CXCR3-/-) show a delayed acute or chronic rejection of 
cardiac or pancreatic allograft in murine models of transplant rejection. In some 
cases — especially in combination with immunosuppressive therapy — CXCR3-/-
mice were able to maintain the allograft. Moreover, in the case of similar models, 
treatment with an antibody directed against either CXCR3 or CXCL10 significantly 
prolongs allograft survival. In addition, anti-CXCL10 antibodies inhibited chronic 
experimental colitis, and a Phase II clinical trial has been launched with the aim of 
further studying the effects of one of the antibodies (MDX1100) in the treatment of 
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ulcerative colitis. The same antibody will also be tested in a Phase II trial for 
rheumatoid arthritis. 
Disease References 
Multiple sclerosis	 Sorensen et al., 1999. 
Rheumatoid arthritis	 Qin et al., 1998. 
Atherosclerosis	 Mach et al., 1999. 
Chronic obstructive pulmonary disease	 Saetta et al., 2002. 
Inflammatory bowel disease	 Yuan et al., 2001. 
Psoriasis	 Rottman et al., 2001. 
Hepatitis C	 Shields et al., 1999. 
Sarcoidosis	 Agostini et al., 1998. 
SARS	 Glass et al., 2004; Danesh et al., 
2008. 
Transplant rejection	 Hancock et al., 2000; Hancock et al., 
2001; Inston et al., 2007. 
Metastasis of melanoma and colon	 Kawada et al., 2004; Kawada et al., 
cancer cells to the lymph nodes	 2007. 
Metastasis of breast cancer cells to the	 Walser et al., 2006. 
lungs 
HIV	 Hatse et al., 2007. 
Table 1.3: Involvement of CXCR3 in human disease. Adapted from Wijtmans 
et al., (2008). 
Use of protein-based CXCR3 antagonists also confirms that the blocking of this 
receptor helps to reduce skin inflammation (Proudfoot and Kosco-Vilbois, 2003) 
and neuro-inflammation in mice model (Vergote et al., 2006). 
A hallmark of CXCR3 is its prominent expression in in vitro cultured 
effector/memory T-cells, and in T-cells present in many types of inflamed tissues. 
In addition, CXCL9, CXCL10 and CXCL11 are commonly produced by local cells 
in inflammatory lesion, therefore suggesting that CXCR3 and its chemokines 
participate in the recruitment of inflammatory cells. Therefore, CXCR3 is a target 
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for the development of small molecular weight antagonists which may be used in 
the treatment of diverse inflammatory diseases. Essentially, a better 
understanding of all the CXCR3 variants is needed in order to fully develop any 
therapeutic potential of CXCR3. CXCR3 and its agonists have been implicated in 
several immune-mediated inflammatory diseases, and, similarly, a few reports 
describe the vast differences in potencies of the three CXCR3 ligands (Heise et 
al., 2005). Most of the therapeutic studies based around CXCR3 concentrate on 
the therapeutic potential of CXCR3 within tumours. Moreover, studies have looked 
at CXCR3 ligands as potent inhibitors of tumour growth in mice (Arenberg et al., 
2001) to the attraction of CD8+ T-lymphocytes by CXCR3 ligands as potent anti 
tumour activities (Hensbergen et al., 2005). A number of studies also consider the 
development of CXCR3-antagonists, as a high prevalence of CXCR3 ligand 
expression is usually observed, especially in inflamed joints of RA patients 
(Wedderburn et al., 2000) in MS lesions (Balashov et al., 1999) during pancreatitis 
in Type 1 diabetes (Frigerio et al., 2002) and during allograft rejection in animal 
models and transplantation patients (Agostini et al., 2001). Table 1.3 highlights 
some of the diseases which have been linked with CXCR3 involvement. 
1.12.3 CXCR7 
CXCR7 is a 7-transmembrane receptor member of the G-protein coupled receptor 
family. It was previously thought that this protein was a receptor for VIP and was 
considered to be an orphan receptor (Law and Rosenzweig, 1994). CXCR7 is 
encoded in humans in the second chromosome — the same chromosome where 
the genes to CXCR1, CXCR2 and CXCR4 are encoded. The binding of the 
chemokines CXCL12/SDF-1 and CXCL11 has been demonstrated by various 
scholars, including Balabanian et al. (2005) and Burns et al. (2006). Recent 
findings in zebra fish suggest that CXCR7 primarily functions by sequestering the 
chemokine CXCL12. Membrane-associated CXCR7 has also been found to be 
expressed on many tumour cell lines, on activated endothelial cell, and on foetal 
liver cells. Unlike many other chemokines receptors, CXCR7 has not yet been 
shown to induce cell migration or to otherwise induce the mobilisation of 
intracellular calcium (Dambly-Chaudière et al., 2007). Furthermore, it has been 
recently demonstrated that CXCR7 also regulates the expression of the pro-
angiogenic factors interleukin-8 or vascular endothelial growth factor, which are 
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likely to participate in the regulation of tumour angiogenesis and the activation AKT 
pathways (Wang et al., 2008). 
1.13 Regulation of GPCR Signalling 
The expression of GPCRs on the cell surface is a finely controlled process. The 
first step is the generation of a receptor in the endoplasmic reticulum, where the 
GPCR is assembly-ready for transportation to the cellular membrane. The newly 
assembled glycosylated receptor is then considered ready to interact with its 
specific agonist. Signalling via GPCRs is very sensitive following activation. 
Moreover, the sensitivity or negative regulation has been termed desensitisation. 
Desensitisation occurs very quickly following activation by its agonist. This 
activation event reduces the responsiveness of the receptor to further stimulation. 
The reduction in responsiveness is due to the G protein-coupled receptor kinases 
phosphorylating the receptor induced conformational changes, which results in the 
binding of inhibitory β-arrestin protein that induces the dissociation of the G-protein 
(Pao and Benovic, 2002; Vroon et al., 2006). The disassociation of the G-proteins 
can also occur via second messenger-dependent kinases; for example, protein 
kinase A and C. In contrast to the G-protein receptor kinases, this disassociation 
occurs in the presence or absence of agonist, and has been named heterologous 
desensitisation. This type of desensitisation is responsible for cellular hypo-
responsiveness (Kristiansen, 2004). Moreover, GPCR signalling is further 
controlled by the internalisation of the receptor; this control process of GPCR 
signalling is longer than desensitisation and can take up to several minutes 
(Luttrell and Lefkowitz, 2002). 
Once a GPCR has been internalised, there are two resulting outcomes: recycling 
of the receptor back to the surface, or degradation of the receptor. Recycling of the 
receptor back to the surface requires the receptor to undergo dephosphorylating 
and the removal of the β-arrestin, thereby allowing the resensitation of the receptor 
to its appropriate agonist. Use of modified chemokines demonstrates longer 
recycling times, thereby indicating different rates depending on the agonist 
stimulating the receptor (Pastore et al., 2003). Degradation of the receptor is via a 
lysomal degradation pathway. 
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1.13.1 Chemokine Receptor Internalisation and Intracellular Trafficking 
The expression of the chemokine receptor on the surface is a balance between 
the rate of internalisation and the rate of replacement (recycling or synthesis of 
new protein) (Mueller et al., 2002). Chemokine receptors undergo a basal level of 
internalisation and the degradation or recycling in the absence of the agonist. 
Agonist-binding can enhance the internalisation and trafficking of these receptors, 
and can accordingly increase the rate of receptor sensitisation versus 
desensitisation, and recycling versus degradation (Neel et al., 2005). Two major 
routes of receptor trafficking exist: clathrin-mediated endocytosis, and lipid 
raft/caveolae dependent internalisation. Moreover, it is possible that certain 
receptors can internalise via both pathways whilst others may utilise one preferred 
pathway. The pathway of internalisation selected by a particular receptor will 
partially depend on the specific cell type and the different expression of specific 
adaptor proteins, membrane lipid composition in close location to the receptor or 
other unknown factors (Neel et al., 2005). 
1.13.2 Pathways for Internalisation of Chemokine Receptors 
The internalisation of the receptor and its agonist by clathrin-coated pits is the best 
characterised endocytic process (Mukherjee et al., 1997). Activation of a receptor 
by its agonist induces a phosphorylation of Ser and Thr residues in intracellular 
loops and C-terminus of the receptor due to action of GRKs (G protein-coupled 
receptor kinases, which are activated by the kinase activity of second messengers, 
such as PKC) which subsequently leads to the uncoupling of the G protein from 
the receptor and, in some cases, the receptor desensitisation. Receptor 
phosphorylation and/or presence of di-leucine motif in the C-terminus of 
chemokine receptor are crucial for the binding of adaptor proteins which link the 
receptor to a lattice of clathrin that ultimately facilitates its internalisation (Neel et 
al., 2005). Adaptin-1 and β-arrestin have been found to play an important role in 
chemokine receptor internalisation. β-arrestin binding to receptor occurs through 
phosphorylated residues in the C-terminus, but can also occur through the 
intracellular loops. Furthermore, it has also been reported that CXCR4 β-arrestin 
binds to both carboxyl-terminus and the third intracellular loop (Cheng et al., 
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2000). AP-2 binds to some chemokine receptors, including CXCR2 and CXCR4, 
via highly conserved Leu-Leu, Ile-Leu and Leu-Ile motif within the C-terminus 
(Heilker et al., 1996; Fan et al., 2001). Association of the adaptor proteins is 
required for the recruitment of clathrin and through action of dynamin, formation of 
clathrin-coated vesicles (Mousavi et al., 2004). Following receptor internalisation, 
clathrin-coated vesicles are uncoated and receptor-ligand complexes are directed 
to the early endosomal compartment. The receptor can then be directed to the 
perinuclear recycling compartment and can be recycled back to the plasma 
membrane or can otherwise enter the late endosomal compartment and be 
directed to the lysosomal compartment for degradation. 
An alternative pathway for the internalisation of a chemokine receptor may occur 
via lipid rafts or through cholesterol enriched structures, called caveolae (Parton 
and Simons, 2007; Palade, 1953). Caveolae are stabilised by caveolin-1 (CAV-1) 
and CAV-2 cholesterol-binding proteins and form characteristic flask-shape 
structures with no obvious coat (Stan, 2005). Once internalised, some receptors 
can enter the compartment, known as caveosome, and fuse with early endosomes 
also used in clathrin-dependent pathways (Sharma et al., 2003). Despite some 
reports that chemokine receptors — such as CCR5 and CXCR4 (Manes et al., 
1999; Manes et al., 2000; Nguyen and Taub, 2002) — have been found to some 
degree in lipid rafts; coveolae/lipid rafts-dependent internalisation does not appear 
to be a common feature for the chemokine receptors. 
1.13.3 Regulation of Chemokine Receptor Trafficking by Rab GTPases 
Rabs are small GTPases which are involved in the regulation of a variety of 
cellular trafficking events. The exchange of GDP for GTP, GTP hydrolysis w and 
GDP displacement are regulated by Guanine nucleotide Exchange Factors 
(GEFs), GTPase-Activating Proteins (GAPs) and GDP Dissociation Inhibitors 
(GDIs), respectively. Rab5 mediates early endocytic responses which are required 
for the fusion of early endosomes (Rybin et al., 1996). Moreover, Rab5 interacts 
with Class I of PI3K and induces the production of PI3P. Rab5 and PI3P recruit 
EEA-1 (Early Endosomal Antigen) and other proteins involved in fusion with early 
endosomes. Furthermore, the internalisation of CXCR2, CXCR4 and CCR5 
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requires activity of Rab5 and is significantly blocked by expression of Rab5 
dominant negative mutant (Fan et al., 2003; Venkatesan et al., 2003). 
There are two types of endocytic recycling — rapid and slow pathway — to which 
Rab4 and Rab11a contribute respectively (Ullrich et al., 1996; Sheff et al., 1999; 
Sonnichsen et al., 2000). The slow recycling pathway involving localised on 
perinuclear compartment Rab11a seems to be important in the case intracellular 
trafficking of chemokine receptors. This is shown for the case of CXCR2 which, 
upon agonist-induced internalisation, localises to Rab11a-containing compartment 
(Fan et al., 2003). Rapid recycling pathway through Rab4 positive endosomes 
bypasses the perinuclear endosomes and occurs in PI3K-dependent manner 
(Hunyady et al., 2002). It is not known which mechanisms regulate these different 
recycling pathways. Rab7 is involved in the directing of late endosomes to the 
lysosomal compartment. Prolonged exposure of chemokine receptor to ligand may 
result in their degradation in lysosomes. Moreover, Rab7 is thought to be 
important in the process of lysosomal sorting. Involvement of Rab7 is shown for 
the CXCR2 receptor where the blocking of Rab7 activity results in the decreased 
localisation of this receptor to the lysosomal compartment, and its accumulation in 
early and recycling endosomes (Fan et al., 2003). 
1.13.4 Regulation and Functional Consequences of Internalisation 
Receptor internalisation following ligand-binding is most likely the reason for down-
regulation of most chemokine receptors (Neel et al., 2005). The rate of this 
process can be dependent on multiple factors involving C-terminus of receptor, the 
type of ligand, cell type or phosphorylation status. Phosphorylation of Ser and Thr 
residues and presence of di-leucine motif in the carboxyl-terminus is shown to be 
required for the internalisation of some chemokine receptors. This has been 
reported for CXCR4 receptor, for example (Neel et al., 2005). In contrast, the 
internalisation of CXCR3 by any of its ligands is not affected by the mutational 
change in the LLLRL motif located in the C-terminus. However, mutational change 
of C-terminal Ser and Thr residues inhibited CXCL9- and CXCL10-nduced 
internalisation with no effect of CXCL11, whereby action was dependent on the 
third intracellular loop of CXCR3 in 300-19 cells (Colvin et al., 2004). The rate of 
internalisation also depends on the type of ligand. Most chemokine receptors bind 
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with high affinity more then one chemokine, and these chemokines may 
differentially induce the internalisation of the receptor. This situation is observed 
for CXCR2, which binds two ligands — CXCL6 and CXCL8 — with high affinity; 
however, the latter is more efficacious in inducing internalisation of CXCR2 
(Feniger-Barish et al., 2000). Similar findings have been reported for the CXCR3 
receptor, which becomes internalised by CXCL9, CXCL10 and CXCL11, with 
CXCL11 being the principal chemokine responsible for CXCR3 internalisation 
(Sauty et al., 2001). Cell context may also affect the rate of internalisation and the 
pathway through which a receptor becomes internalised; this may be due to the 
availability of different endocytic compartments, such as caveolae, and the 
expression of various proteins, such as β-arrestin and other adapt proteins. For 
example, CXCL11 reduces surface expression of endogenous CXCR3 in T-cells 
down to 20% whereas, in transfected L1.2 cells, only 50% reduction of basal 
expression of surface CXCR3 is detected (Meiser et al., 2008). Moreover, the 
internalisation of some receptors — such as CCR5 — has been reported to occur 
via both clathrin and caveolae-dependent pathway. However, in some cell types, 
such as Chinese Hamster Ovary (CHO), CCR5 internalises mainly clathrin-
dependent endocytosis (Signoret et al., 2005); in other cell types, on the other 
hand, namely Human Embryonic Kidney cells (HEK293), the dominant pathway for 
CCR5 internalisation is via caveoli (Venkatesan et al., 2003). 
The factors which mediate the fate of internalised receptors are largely unknown. 
They possibly include the duration and concentration of ligand stimulation, and 
different sorting motifs present within intracellular domains of the receptor. As is 
the case of the CCR5 receptor, short stimulation leads to the direction of recycling 
endosomes, whereas longer stimulation cause its localisation to late endosomal 
compartment (Signoret et al., 2000). Similarly, at the early time of stimulation with 
CXCL8, CXCR2 enters recycling endosomes while the extended stimulation time 
leads to its direction to the lysosomes (Fan et al., 2003). Moreover, intracellular 
trafficking is an important aspect of the chemokine receptor function, and has been 
studied for multiple receptors. Some findings suggest the role of internalisation of 
chemokine receptors in trans-endothelial migration (Sauty et al., 2001). However, 
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the requirements for internalisation in chemotaxis and signalling remain 
controversial and still need to be addressed. 
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1.14 Hypothesis and Aims 
The aims of the first part of this thesis were as follows: 
•	 To establish the expression of CXCR3 on the human mast cell line, HMC-1, 
and the primary mast cell model derived from cord blood mast cells, and to 
determine their suitability as a mast cell model. 
Hence, the following hypotheses were proposed: 
•	 All variants of CXCR3 will be expressed on HMC-1 and will induce 
migration of the HMC-1 cell line. 
•	 The primary mast cell model will mirror more closely mast cells in the 
human body than the cell line, HMC-1. 
The following objectives were established in order to test these hypotheses: 
•	 Examine the expression of CXCR3 variants on the HMC-1 cell line by 
investigating expression at the mRNA and protein level. 
•	 Investigate the signalling profile of CXCR3 agonists in the HMC-1 cell line. 
•	 Analyse functional responses of CXCR3 on the HMC-1 cell line by 
examining chemotactic responses. 
•	 Examine cell surface markers on primary mast cell models so as to ensure 
correct differentiation from precursors to mature mast cells. 
•	 Establish the mast cell phenotype generated in the primary model and 
check if the function mirrors the current understanding. 
•	 Analyse certain signalling pathways involved in FcεRI via western blotting, 
and utilise available inhibitors to establish their importance in mast cell 
degranulation. 
The second aim of this thesis was to establish the role of CXCR3 on the 
primary mast cell model derived from cord blood. As such, the following 
hypotheses were proposed: 
•	 CXCR3 variants will all be expressed on the primary mast cell model, and 
will augment sub-optimal FcεRI induced degranulation. 
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•	 CXCR3 activation will induce PI3K and PLC activation, which will be critical 
to the release of mediators from mast cells. 
The following tasks were subsequently established to test these hypotheses: 
•	 Examine CXCR3 at mRNA and protein levels. 
•	 Induce the degranulation of primary mast cell models utilising sub-optimal 
antigen concentration, then stimulate with CXCR3 agonists. 
•	 Examine any augmentation of degranulation by CXCR3 in order to 
determine if this response is CXCR3-specific, utilising small molecular 
CXCR3 antagonists. 
•	 Investigate the pathways activated by CXCR3, and accordingly examine 
their involvement in degranulation of these pathways, utilising specific 
isoform inhibitors. 
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2. Methods and Materials 
2.1Methods 
2.1.1 Cell Types and Culture Conditions 
The focus of this work was to characterise the signalling and function of CXCR3 
and its variants in human mast cells. The models that were used were mast cells 
differentiated and matured for CD133+ precursor cells derived from human cord 
blood or the human leukemic mast cell line, HMC-1. Furthermore, the THP-1 cell 
line was utilized to investigate the presence of variants of CXCR3 in other 
leukocytes. All primary cells and cell lines were routinely maintained in their 
respective media supplemented with antibiotics and 10% foetal bovine serum as 
described in detail below. Cells were cultured ever 3-4 days as required and 
maintained at 37oC and 5% CO2. Prior to experimental procedures, cell viability 
was determined using trypan blue to stain any dying cells. 
2.1.2 Cord Blood Derived CD133+ Precursors 
CD133+ progenitor cells (Stem Cell Technologies) were grown in presence of 
Stem Cell Factor (SCF) (100 ng/ml); IL-6 (100 ng/ml) and IL-3 (30 ng/ml). 
Cytokines were applied in Stem pro serum-free medium containing 50U/ml 
penicillin, 50µg/ml streptomycin and 1% l-glutamine. Cultures were maintained at 
37 °C and 5% CO2 in 6-well plates at cell density 0.5 × 10
6/ml. Cells were fed 
twice per week during the first 4 weeks of culturing, and thereafter once per week 
by removing half of the volume of the cytokine-supplemented medium and adding 
fresh medium containing 2× cytokine cocktail. After 8 weeks, cultures were 
supplemented with 5% FCS and IL-4 (10ng/ml) (Mirkina et al., 2007). 
2.1.3 THP­1 
THP-1 cells(Sigma-Aldrich, Poole, UK) were maintained in 175cm2 tissue culture 
flask in RPMI 1640 medium supplemented with 10% foetal bovine serum (FBS), 
50U/ml penicillin and 50µg/ml streptomycin. Cells were grown to a maximum of 1.5 
x 106 cells and diluted with fresg complete medium to 5x105 cells every 3-4days. 
THP-1 cells were maintained in a humidified incubator at 37oC and 5% CO2. 
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2.1.4 HMC­1 
HMC-1 cells (Mayo Foundation for Medical Education and Research, Rochester, 
USA, MMV-88-049) were maintained in 175cm2 tissue culture flask in Iscove's 
modified Dulbecco's medium(IMDM) without phenol red medium supplemented 
with 10% foetal bovine serum (FBS), 50U/ml penicillin, and 50µg/ml streptomycin. 
Cells were grown to a maximum of 1.5 x 106 cells and diluted with fresh complete 
medium to 5x105 cells every 3-4days. HMC-1 cells were maintained in a 
humidified incubator at 37oC and 5% CO2. 
2.1.5	 Evaluation of CD133+ Precursor Differentiation in to Immature Mast 
Cells. 
In order to verify that the differentiation procedure was successful, cells off all ages 
were routinely stained for the presence of the mast cell specific marker tryptase. 
1 x 105 of primary mast cells were washed twice in RPMI and centrifuged onto 
polylysine-coated glass slides in a Cytospin3 cytocentrifuge at 250g. The resulting 
smears were then air-dried and fixed by submersion in an acetone: methanol 
solution (1:1) for 1 minute. The smears were then carefully washed in TBS buffer 
(pH 7.6) and a circle drawn around the outside of the smear using a SuperPap pen 
to create a hydrophobic ring around the smear in order to generate a concentrated 
pool of antibody over the smear. 100µl of anti-human mast cell tryptase mAb or 
isotype matched control was added to the appropriate smear and incubated at 4oC 
overnight. 
To visualise the presence of tryptase within human mast cells, prepared smears 
were stained using the alkaline phosphatase/anti-alkaline phosphatase (APAAP) 
method according to the manufacturer's (DAKO) instructions, briefly outline as 
follows. After incubation overnight, excess anti-human tryptase antibody was 
washed away using TBS buffer (pH 7.6) and then a drop of Dako REAL™ Link, 
Secondary Antibody (LINK) (Bottle A) was added to each smear and left at room 
temperature for 30 minutes. After incubation, excess secondary antibody was 
washed off and a drop of Dako REAL™ APAAP Immunocomplex (APAAP) (Bottle 
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B) was added to each smear for 30 minutes at room temperature. During this time 
the Chromogen Red-containing Substrate Working Solution (CHROM) was 
prepared by mixing thoroughly 750µL AP Substrate Buffer (Bottle F) with 30 µL 
Chromogen Red 1 (Bottle C), 30µL Chromogen Red 2 (Bottle D) and 30 µL 
Chromogen Red 3 (Bottle E) in that exact order and with thorough mixing after the 
addition of each chromogen. Use CHROM within 20 minutes. Any volume of 
CHROM that was not used was discarded. Smears were rinsed again in TBS 
(pH7.6) to remove the excess APAAP and a drop of CHROM was added to each 
smear for 20 minutes at room temperature. Slides were then washed again in 
TBS (pH 7.6) and air dried then analysed microscopically. 
2.1.6 Evaluation of Mast Cell Maturity. 
1 x 105 of primary mast cells were washed twice in RPMI and centrifuged onto 
polylysine-coated glass slides in a cytospin3 cytocentrifuge at 250g. The resulting 
smears were then air-dried and fixed by submersion in an acetone: methanol 
solution (1:1) for 1 minute. Smears were then air-dried before submersion in May-
Grunwald’s eosine-methylene blue solution modified for 1 minute. Smears were 
rinsed with dH2O and air-dried. Smears were then submersed in Giemsa’s azur 
eosin methylene blue solution for 1 minute. After incubation period, excess stain 
was washed off using dH2O and again left to air dry. 
Slides were then analysed microscopically. 
2.1.7 Transmission Electron Microscopy (TEM) 
TEM is a microscopy technique whereby a beam of electrons is transmitted 
through an ultra thin specimen, interacting with the specimen as it passes through 
it. An image is formed from the electrons transmitted through the specimen, 
magnified and focused by an objective lens and appears on an imaging screen, a 
fluorescent screen in most TEMs, plus a monitor, or on a layer of photographic 
film, or to be detected by a sensor such as a CCD camera. 
A biocompatible surfactant-n-dodecylammonium α-glutamate was diluted to a 
2.5% final concentration in complete culture medium. 1x106/ml were re-suspended 
in this medium to fix the cells at room temperature over a two hours period then 
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stored overnight at 4oC. Samples were washed three times, each for a period of 5 
minutes in 0.1 Sodium Cacodylate buffer. Samples were post fixed in 1% Osmium 
Tetroxide + 1% Potassium Ferrocyanide for 1 hour before washed three times with 
dH2O. After post fixation, each sample was encapsulated in 3% agarose and cut 
into cubes. Each cube was subsequently washed in dH2O twice each for a period 
of five minutes. 1% aqueous Uranyl Acetate was applied to each cube before 
stored at room temperature in the dark for one hour. The cubes were then 
dehydrated using increasing concentrations of acetone – 50, 70, 90 and 95% at 
4oC, cubes were treated with each dilution twice over a period of ten minutes per 
concentration before final dehydration in 100% dry acetone at room temperature. 
This final dehydration with 100% acetone was applied to each cube 4 times over a 
period of twenty minutes. After dehydration samples were infiltrated in Spurrs 
Epoxy Resin: 100% dry acetone 1:1 for a period of 1-2 hours then 100% Spurrs 
Epoxy resin for 2 hours then fresh resin overnight. Each sample was then 
embedded in moulds and cured in a 70oC oven for 8 hours. 
2.1.8 Freezing/Thawing of Cells 
For storage, 1x106 cells/ml in exponential growth were re-suspended in freeze 
medium containing 10% dimethyl sulpohoxide (DMSO), and 90% foetal calf 
serum. The cell suspension was transferred to cryotube (1ml/tube), cooled 
overnight at 1oC/minute in isopropanol to -80oC and transferred to liquid nitrogen 
tanks for long-term storage. For resuscitation of cells from liquid nitrogen, cells 
were rapidly defrosted for one-minute in a 37oC water bath, washed once in RPMI-
1640 and re-suspended in correct medium and volume and cultured as previously 
stated. 
2.1.9 Degranulation 
Mature mast cells were passively sensitised overnight in culture media containing 
chimeric human Fc anti-4-hydroxy-3-nitrophenylacetyl (NP)-specific IgE (1 µg/ml). 
The mature mast cells were then washed twice in RMPI-1640 without phenol red, 
0.1% BSA and re-suspended at 1x106/ml in RPMI-1640 without phenol red, 0.1% 
BSA. 90µl of cell suspension was added to each well. Degranulation was induced 
by addition of 10x NP-BSA or specific chemokine. When the effects of inhibitors 
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were examined, these, or controls, were added 30 min prior to the addition of NP-
BSA or specific chemokine. Degranulation was performed at 37oC, 5% CO2 for 
150 minutes, after which β-hexosaminidase release was measured as a readout of 
degranulation. To measure total β-hexosaminidase release, control well were 
treated with 1% TRITON-X solution. 
To measure β-hexosaminidase release, 90 µl of cell supernatants were transferred 
to 96-well flat bottom plates and mixed with 90 µl of chromogenic β-
hexosaminidase substate p-nitrophenyl-N-acetyl-β-d-glucosaminide (1.3 mg/ml in 
0.1 M sodium citrate buffer, pH 4.5). Incubation of supernatant and substrate took 
place at 37oC, 5% CO2 for 90 minutes. After incubation for 1.5 h at 37 °C, the 
reaction was stopped by the addition of 90 µl of 2M NaOH, and the release of the 
product p-nitrophenol was determined by monitoring the O.D. at 405 nm in an 
ELISA reader. 
2.1.10 Determination of Protein Expression 
Immunoblotting and flow cytometry are techniques which can be utilised to 
facilitate the detection of a protein of interest. As the techniques are also used in 
the analysis of signalling pathways and functional studies, these topics will be 
discussed in much greater detail in the section below with specifics to this study, 
however, a brief overview of these techniques will be presented here. 
Immunoblotting uses whole cell lysates which are then analysed for the expression 
of a particular protein using electrophoresis to separate the proteins according to 
their size. The transfer of these proteins onto a nitrocellulose membrane facilitates 
their detection by incubating this membrane in the presence of antibodies against 
the protein of interest which can be detected by the use of HRP-secondary 
antibody. Flow cytometry also uses whole cells which has the advantage as the 
antibodies can be added directly to the sample without the need for protein 
separation. 
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2.1.11 Immunoblotting 
Immunoblotting or western blotting is a technique that facilitates the detection of a 
protein of interest or the phosphorylated form of that protein. Within this study, 
cells were stimulated with numerous chemokines triggering downstream signalling 
events characterised by the phosphorylation of proteins within that pathway. By 
lysing the cells, the mixture of proteins contained within the cell can be extracted. 
The whole cell lystates are then dispensed into wells within a polyacrylamide gel. 
Upon applying an electrical current across the gel, the proteins separate according 
to their molecular weight, with smaller proteins migrating the furthest. These 
separated proteins are then transferred onto a nitrocellulose membrane which can 
be ‘probed’ using an antibody against a protein of interest. Following incubation 
and binding of the primary antibody to the protein of interest, a secondary antibody 
is applied which is coupled to a horseradish peroxidise tag. Upon delivering a 
chemiluminescent agent there is a reaction which produces luminescence that is 
in relation to the amount of protein detected. This luminescence is detected using 
a sensitive photographic film, allowing visualisation of the protein of interest. 
Immunoblotting was utilised in this study to allow the visualisation of the 
phosphorylation of Akt, ERK1/2 and S6.This phosphorylation was used as a 
readout of chemokine stimulation (CXCL4, CXCL9, CXCL10, CXCL11, CXCL12, 
CXCL16 and CCL2) in mature mast cells and THP-1 cell line. This method was 
also used to visualise the variants of CXCR3 and CXCR7. Furthermore, to 
determine the involvement of different proteins involved in mast cell signalling 
needed for a functional response, we utilised this method to indentify key 
components of this signalling pathway through inhibition of specific molecules. 
2.1.12 Stimulation of Cells and Collection of Whole Cell Extracts 
1 x 106 of primary mast cells or THP-1 cells per point were washed twice in RPMI 
1640 and incubated at 37oC in serum free RMPI 1640 for 60 minutes. Cells were 
or were not stimulated with specific chemokine diluted in RPMI 0.1% BSA. 
Stimulations were terminated by aspiration of the supernatant followed by the 
addition of ice cold lysis buffer (50mM Tris-HCL ph 7.5, 150mM sodium choride, 
1% Nonidet P40, 10% Glycerol, 5mM EDTA, 1mM sodium vanadate, 1mM sodium 
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molybdate, 10mM sodium fluoride, 40µg/ml PMSF, 0.7µg/ml Pepstatin A, 10µg/ml 
aprotinin, 10µg/ml leupeptin, 10µg/ml soyabean trypsin inhibitor). Lysates were 
rotated at 4oC for fifteen minutes, followed by centrifugation at 17,500g. The 
protein rich supernatant were diluted in 5x loading buffer (10% SDS, 50% glycerol, 
200mM Tris HCL pH 6.8, Bromophenol blue) heated to 95oC for 5 mins and stored 
at -20oC. 
2.1.13 Electrophoretic	 Separation, Transfer and Immunoblotting of 
Cellular Proteins 
Solubilised proteins were electrophoresed on a one dimensional 10% sodium 
dodecyl sulphate-polyacrlamide gel (SDS-PAGE). This was carried out using the 
Bio-Rad Mini Protean II system. Samples were loaded into a stacking gel and run 
at 80V in running buffer containing 25mM Tris base, 192 mM Glycine and 
0.1%(w/v) SDS. Upon reaching the resolving gel, samples were electrophoresed 
at 180V. The proteins were transferred by electoblotting for 60 minutes at 40mV 
onto nitrocellulose membrane 0.45µM soaked in semi-dry transfer buffer (70% 
H2O, 20% methanol and 10% blot buffer (39mM Glycine, 48M Tris base and 
0.0375% SDS)). Membranes were incubated for 60 minutes at room temperature 
in block buffer (TBS-tween containing 5% milk), with slight agitation and rinsed 
three times for five minutes in TBS-tween. The membrane was incubated in the 
specified 1o antibody dilution 1:1000 in TBS-tween supplemented with 0.01% 
sodium azide and 5% milk overnight with slight agitation. The membrane was 
washed three times for five mintues in TBS-Tween and incubated in the 2o 
antibody couple to horse radish peroxidise (HRP) diluted 1:10,000 in block buffer 
for 60minutes at room temperature and washed in TBS-Tween three times for five 
minutes. Visualisation of the protein was performed by incubating the membrane 
in 5ml of Enhanced Chemiliminescent reagent (ECL), for one minute and exposing 
to Fuji medical x-ray film. 
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2.1.14 Membrane Stripping and Reprobing 
In order to verify whether the samples were equally loaded the membranes were 
stripped of antibody and reprobed with a pan antibody that detects absolute levels 
of protein. Firstly the membrane was rehydrated in TBS for 10 minutes and then 
placed in 100mls of stripping buffer to remove bound antibody, (100mM 2-
Mecaptoethanol, 2% SDS, 62.5mM Tris-HCL pH 6.7) and incubated at 60oC for 30 
minutes. After extensive washing with TBS-Tween, the membrane was incubated 
for 60 minutes at room temperature in block buffer, washed three times in TBS-
Tween. Blots were re-probed with a different primary antibody and the 
immunoblotting procedure is carried out as described above. 
2.1.15 Flow Cytometry 
Flow cytometric analysis is a highly selective technique used to count, examine 
and sort single cells with use of a laser. Within this study this technique was 
utilised to determine the expression of cell surface receptors and also used to 
investigate proteins levels at an intracellular level. 
The sample being analysed is directly into a stream of fluid that passes through a 
number of detectors, which can analyse the properties of the particles that pass 
through it, such as size and granularity. With the use of fluorescently labelled 
antibodies surface receptors or intracellular proteins can be detected and the 
expression levels compared to other samples. For example, incubation with a 
specific anti-human CXCR3 can be compared to its specific isotype control to 
determine the proteins levels of CXCR3 on the cell. 
2.1.16 Determining Expression of Cell Surface Receptors 
Mast cell models and THP-1 cell line were washed twice in PBS 5% BSA and re-
suspended in 100µl. 5µl of PE-conjugated anti-human antibodies against the 
receptor of interest or the respective immunoglobulin isotype control was added 
and incubated on ice and darkness for 30mins. Cells were washed twice in PBS 
5% BSA and re-suspended in 300µl for analysis. 
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2.1.17 Determination of Expression Levels of Intracellular Proteins 
1 x 106 mast cell models or THP-1 cell line were incubated at 37oC in serum free 
RPMI for 30 minutes. Cells were centrifuged at 17,500g, and fixed by aspiration of 
the supernatant and addition of 2% formaldehyde in PBS for 10 minutes at room 
temperature followed by 1 min on ice. Cells were washed in PBS and 
permeabilised by the addition of 90% methanol at –20oC, which slowly vortexing 
followed by incubation at 4oC for 30minutes. Cells were washed, re-suspended in 
100µl of PBS 0.1% BSA and blocked for 10 minutes at room temperature. 5µl of 
specific PE-conjugated antibody or appropriate PE-conjugated isotype control 
added (1 in 20 dilution) and incubated at on ice and in the dark for 30minutes. 
Cells were washed twice and re-suspended in 400µl PBS, for flow cytometric 
analysis using a Becton Dickinson FACS Canto flow cytometer and analysed 
using FACSDiva software. 
2.1.18 RNA Extraction with Trizol 
10x106 were homogenised with 1ml of Trizol tm in a sterile RNAase free microfuge 
tube by pipetting vigorously up and down. RNA was then extracted according to 
the Trizol manufacturer’s instructions. In brief, samples were incubated at room 
temperature for 5 mins, spun at 17,500g for 10 minutes at 4oC and the top layer 
collected and placed in a fresh tube. 0.2 chloroform was added to samples which 
where then shaken vigorously for 15 seconds and incubated at room temperature 
for 2 minutes. Samples were then centrifuged in a chilled microfuge for 15 minutes 
at 17,500g before the upper layer carefully removed and placed in fresh tube. 
0.5ml of propan-2-ol was added to each sample which were then incubated at 
room temperature for 10 minutes to allow nucleic acid precipitation. Samples were 
then centrifuged at 9000g, for 10 minutes at 4oC. RNA pellets were washed in 
75% EtOH, air dried and re-suspended in the RNA storage solutions. The optical 
absorbance at 260nM and 280nM was measured using a spectrophotometer and 
used to determine the RNA concentration. Purity was estimated from the 
OD260/OD280. 
RNA samples were DNAase treated using the DNA-freeTM kit according to the 
manufacturer’s instructions (Invitrogen). In brief, 5µg of each RNA sample was 
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diluted in 1xDNAaseI buffer containing 1µl of DNAaseI with the total volume made 
up to 50µl with diethylpyroCarbonate (DEPC) treated water. Sample were mixed 
and incubated at 37oC for 30 minutes. 5µl of DNAase inactivation reagent was 
then added and samples mixed thoroughly during incubation at room temperature 
for 2 minutes. Samples were centrifuged at 6000g for 1.5 minutes and the 
supernatant containing DNAase treated RNA, placed in a fresh tube. 
2.1.19 cDNA Synthesis from RNA 
cDNA was reversed transcribed from DNAase-treated RNA using the superscript 
TM first strand synthesis system for RT-PCR according to manufacturer’s 
instructions (Qiagen). Briefly, 5µg of each RNA sample was mixed with 10µg/ml 
Oligo(dT)12-18, 200nM dNTP mix and the volume made up to 10µl with DEPC 
treated water. Samples were incubated at 65oC for 5 minutes then placed on ice 
for ~1 minute. To each sample, 9µl of a mixture containing the following 
components (final concentrations) was added: 1xRT-buffer, 5mM MgCl2, 10nM 
DTT, and 1µl of RNaseOUT TM recombinant Rnase inhibitor. Samples were 
incubated at 42oC for 2 minutes and then 1µl (50 units) of superscript TM II 
reverse transcriptase was added to each sample (except –RT controls). Reactions 
were incubated at 42oC for 50 minutes before being terminated by incubation at 
70oC for 15 minutes. Samples were collected by centrifugation and 1µl of 
RNAaseH added to each one. These were incubated at 37oC for 20 minutes and 
then stored at –20oC until used for PCR amplification. 
2.1.20 Polymerase Chain Reaction (PCR) 
PCR for all applications was performed using a NewEngland Biolabs master mix. . 
Reaction mix for PCR was as follows: 2x NewEngland Biolabs master mix (12.5 
µL), 10µM 5’ primer (2 µL), 10µM 3’ primer (2 µL), approximately 1 µg cDNA and 
distilled water (up to 25 µL volume). All reactions were mixed well by pipetting 
before being placed in a thermocycler. 
Appropriate thermocycler programs were used according to the application: 
Amplification of cDNA: Initial denaturation: 94°C 5 mins, (denaturation: 94°C 1 
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min, annealing: 60°C 30 sec, extension: 72°C 1 min) x 35, final extension: 72°C 10 
min, final hold: 4°C; PCR products were then analysed by agarose gel 
electrophoresis as described below. 
2.1.21 Agarose Gel Electrophoresis 
1.2% of agarose was prepared in 100 ml of 1xTAE buffer and melted by heating in 
a microwave for 2 minutes, followed by gentle mixing until completely dissolved. 
2 µL of ethidium bromide (10 mg/mL) was added to 100 mL of cooled agarose 
solution, mixed and slowly poured in an appropriate tank. Required combs were 
placed into the gel and any air bubbles were removed. Gel was left to set for 30-60 
minutes. 1x TAE buffer (running buffer) was added to an appropriate gel running 
tank. The gel was then placed in the tank and the comb removed. PCR products 
were mixed with 6 x gel loading buffer and loaded on to the gel alongside with 
DNA ladder. Electrophoresis was preformed at 90V in the TAE running buffer until 
bromophenol blue (from the loading buffer) has run 3/4 the length of the gel. After 
that point gel (preferably within its holder) was carefully transferred to visualise 
and photograph PCR products on the UV transluminator with photo camera build. 
2.1.22 In Vitro Cell Migration Assay 
The ChemoTx System is a disposable 96-well format migration assay. The system 
is set up with the appropriate agonists in the lower wells, over which a 5µm pore 
size filter is placed, through which the cell migrate. This filter is designed to mirror 
the 96 well plate structure beneath. Surrounding each well on the filter is a 
hydrophobic material that focuses the cell suspension directly over the ligand 
below, eliminating the need for the upper chambers. Following the incubation time, 
the migrated cells were collect and counted. 
2.1.23 Chemotaxis 
Chemotaxis assays were performed in 96-well chemotaxis chambers with 
polycarbonate membranes (5µm pore size). The lower chambers were filled with 
29µl of chemokine diluted in RPMI-1640, 0.1% BSA and carefully overlaid with the 
polycarbonate membrane. Cells were washed twice in RPMI-1640 and re-
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suspended in RPMI-1640, 0.1% BSA at a concentration of 3.2x106 cells/ml. 25µl of 
the cell suspension was loaded on top of the filter. 
Migration was performed at 37oC, 5% CO2 for 180 minutes, after which non-
migrated cell on the top of the filter were rinsed off with PBS. Following 
centrifugation (350g, 10 minutes) the filter was removed and the migrated cells 
were re-suspended in 300µl PBS, 0.1% BSA. Analysis of migration was performed 
using FACS Canto (BD Biosciences, UK). Samples were performed in triplicate 
with each being analysed for 60 seconds. Data is expressed as chemotactic index. 
2.1.24 Chemotactic Index 
The chemotatic index was calculated as follows: Number of cells migrated/basal 
levels of migration. 
2.1.25 Actin Polymerisation 
1 x 106 of primary mast cells or THP-1 cells per point were washed twice in RPMI 
1640 and incubated at 37oC in serum free RMPI 1640 for 60 minutes. When the 
effects of inhibitors were examined, these, or controls, were added 30 min prior to 
stimulation with chemokine. Cells were or were not stimulated with specific 
chemokine diluted in RPMI 0.1% BSA at a specific time period. After stimulation 
cells were fixed in 4% paraformaldehyde (w/v) for 10 minutes at room temperature 
before centrifuged at 10,000 rpm for 10 seconds before resuspended in 0.2% 
Triton X-100 (v/v) at room temperature for 5 min to permeabilise the samples. 
After washing three times with PBS, the samples were blocked in 1% FBS in PBS 
for 30 min at 37°C and then incubated with TRITC-conjugated phallodin (0.1 µg/ml 
for 1 h at room temperature. Cells were washed twice in PBS 5% FBS and re-
suspended in 300µl for analysis. Flow cytometric analysis using a Becton 
Dickinson FACS Canto flow cytometer and analysed using FACSDiva software. 
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2.1.26 Ca2+ via Flex Station 
Mast cells were loaded with Fluo-4 AM and [Ca2+]i was measured as described 
previously in conjunction with a fluorometric imaging plate reader (FLIPR; 
Molecular Devices Ltd., Wokingham, UK) (Cronshaw et al., 2006). Mature mast 
cells or THP-1 cells were washed twice and resuspended at 10 x 106 cells/ml in 5 
ml loading buffer (RPMI without phenol Red indicator supplemented with 10% 
FCS, 2.5mM probenecid and 20 mM HEPES). This cell suspension was loaded 
with 5 mM Fluo-4 AM in the dark for 1 hour at 37oC. Cells were washed twice in 
assay buffer (Hanks’ balanced saline solution/20 mM HEPES without phenol Red 
indicator) and resuspended at 7 x 106/ml. Cell suspension (50 µl; 350,000 cells) 
was added to each well of a black-walled, clear-bottomed plate (Corning Costar 
UK Ltd., High Wycombe). After loading, the plate was centrifuged at 1200 
revolutions per minute for 5 min at room temperature and then incubated at 37oC 
for 1 hour. The cell plate was then loaded into the FLIPR instrument. The cells 
were then excited at 488 nm using the FLIPR laser, and the fluorescence emission 
wavelength was at 525nm. Fluorescence readings were taken at 1-s intervals for 
times indicate. Agonist (50 ml) was added (dispense speed, 30 ml/s) after 1 min 
using the FLIPR. Raw fluorescence data were exported for each well and 
tabulated versus time within Microsoft Excel (Microsoft Corp). 
Figure 2.1 – FlexStation 3 Microplate used to measure automated calcium 
responses. Picture taken from Bucher Biotech. 
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2.2Materials 
2.2.1 Antibodies and Secondary Detection Reagents 
Antibody Species Conjugate Supplier Country 
Anti-phospho-S6 
ribosomal protein 
Rabbit N/A Cell Signalling 
Technologies 
Hitchin, UK 
S6 Ribosomal Protein 
(5G10) 
Rabbit N/A Cell Signalling 
Technologies 
Hitchin, UK 
Anti-phospho-Akt Rabbit N/A Cell Signalling 
Technologies 
Hitchin, UK 
Pan Akt Goat N/A Santa Cruz Wembley, UK 
Anti-ERK1/2(p42/p44) Rabbit N/A Cell Signalling 
Technologies 
Hitchin, UK 
Anti-Human Mast Cell 
Tryptase 
Mouse N/A Dako Cambridge, UK 
mouse IgG1 Mouse N/A Dako Cambridge, UK 
Chimeric human Fc 
anti-4-hydroxy-3-
nitrophenylacetyl 
(NP)-specific IgE 
N/A AbD Serotec Oxford, UK 
Anti-human CCR1 Mouse PE R and D Abingdon, UK 
Anti-human CCR2 Mouse PE R and D Abingdon, UK 
Anti-human CCR3 Mouse PE R and D Abingdon, UK 
Anti-human CCR5 Mouse PE R and D Abingdon, UK 
Anti-human CCR7 Mouse FITC R and D Abingdon, UK 
Anti-human CXCR3 Mouse PE R and D Abingdon, UK 
Anti-human CXCR3 Mouse N/A R and D Abingdon, UK 
Anti-human CXCR4 Mouse FITC R and D Abingdon, UK 
Anti-human CXCR6 Mouse PE R and D Abingdon, UK 
Anti-human CXCR7 Mouse PE R and D Abingdon, UK 
Anti-human CXCR7 Mouse N/A R and D Abingdon, UK 
Mouse IgG1 isotype Mouse PE R and D Abingdon, UK 
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control 
Mouse IgG2a isotype 
control 
Mouse PE R and D Abingdon, UK 
Mouse IgG2a isotype 
control 
Mouse FITC R and D Abingdon, UK 
Anti-human CD133 Mouse PE Miltenyi Biotec Surrey, UK 
Anti-human CD13 Mouse PE Beckon 
Dickenson 
Oxford, UK 
Anti-human CD54 Mouse PE Beckon 
Dickenson 
Oxford, UK 
Anti-human CD117 Mouse PE Beckon 
Dickenson 
Oxford, UK 
Anti-human CD63 Mouse PE Beckon 
Dickenson 
Oxford, UK 
Anti-human CD203c Mouse PE Miltenyi Biotec Watford, UK 
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2.2.2 Cell Culture 
Item/Reagent Supplier Country 
10ml plastic pipettes Greiner Bio-one Stonehouse, UK 
25ml plastic pipettes Greiner Bio-one Stonehouse, UK 
50ml tubes Greiner Bio-one Stonehouse, UK 
Pasteur Pipette Fisher Scientific Loughborough, UK 
200mM L-Glutamine Invitrogen Paisley, UK 
6 well tissue culture plates Nunc(Fisher Scientific) Loughborough, UK 
96 microwell plates Nunc(Fisher Scientific) Loughborough, UK 
Cryotubes Nunc(Fisher Scientific) Loughborough, UK 
RPMI-1640 Gibco Paisley, UK 
Foetal Bovine Serum Gibco Paisley, UK 
IMDM Gibco Paisley, UK 
Penicillan/Streptomycin Gibco Paisley, UK 
Sterile Phosphate buffered 
saline(PBS) 
Gibco Paisley, UK 
Stem-Pro Invitrogen Paisley, UK 
IL-3 Novartis Institutes for 
Biomedical Research 
(NIBR) Vienna 
Vienna, Austria 
IL-6 Novartis Institutes for 
Biomedical Research 
(NIBR) Vienna 
Vienna, Austria 
SCF Novartis Institutes for 
Biomedical Research 
(NIBR) Vienna 
Vienna, Austria 
IL-4 Novartis Institutes for 
Biomedical Research 
(NIBR) Vienna 
Vienna, Austria 
Cord Blood CD133+ Cells Stem Cell Technologies Grenoble, France 
THP-1 Sigma-Aldrich Poole, UK 
HMC-1 Mayo Foundation for Rochester, USA 
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Medical Education and 
Research. 
175cm2 tissue culture flasks Nunc(Fisher Scientific) Loughborough, UK 
75cm2 tissue culture flasks Nunc(Fisher Scientific) Loughborough, UK 
RPMI-1640 w/o Phenol Red Gibco Paisley, UK 
Polysine Slides VWR International West Sussex, UK 
SuperPap Pen Zymed Laboratories 
(Invitrogen) 
Paisley, UK 
May-Grunwald’s eosine-
methylene blue solution 
modified 
Merck (VWR 
International) 
West Sussex, UK 
Giemsa’s azur eosin 
methylene blue solution 
Merck(VWR 
International) 
West Sussex, UK 
96-well chemotaxis 
chambers 
Neuro Probe (Receptor 
Technologies) 
Leamington Spa, UK 
2.2.3 Chemokines

Chemokine Supplier Country 
Human recombinant CXCL4 Peprotech London, UK 
Human recombinant CXCL9 Peprotech London, UK 
Human recombinant 
CXCL10 
Peprotech London, UK 
Human recombinant 
CXCL11 
Peprotech London, UK 
Human recombinant 
CXCL12 
Peprotech London, UK 
Human recombinant 
CXCL16 
Peprotech London, UK 
Human recombinant CCL2 Peprotech London, UK 
Human recombinant CCL5 Peprotech London, UK 
Human recombinant CCL11 Peprotech London, UK 
Human recombinant CCL22 Peprotech London, UK 
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2.2.4 Chemicals 
Chemical Supplier Country 
Bromophenol Blue BDH-International Leicestershire, UK 
Bovine Serum Albumin Sigma-Aldrich Poole, UK 
Dimethyl sulfoxide Sigma-Aldrich Poole, UK 
EGTA Sigma-Aldrich Poole, UK 
Ethanol Fisher Scientific Loughborough, UK 
Methanol Fisher Scientific Loughborough, UK 
Glycerol Sigma-Aldrich Poole, UK 
Tris-HCL Sigma-Aldrich Poole, UK 
Trizol Reagent Invitrogen Paisley, UK 
Tween-20 Sigma-Aldrich Poole, UK 
Triton-X Sigma-Aldrich Poole, UK 
Phallodin Sigma-Aldrich Poole, UK 
Sodium Azide Sigma-Aldrich Poole, UK 
Paraformaldehyde Sigma-Aldrich Poole, UK 
4-Nitrophenyl n-acetly-B-D-
Glucosaminide 
Sigma-Aldrich Poole, UK 
NP-BSA Biosearch Technologies Novato, CA, USA 
Fluo-4-AM Invitrogen Paisley, UK 
Sodium Hydroxide Sigma-Aldrich Poole, UK 
Sodium dodecyl sulphate Sigma-Aldrich Poole, UK 
Precision protein all blue 
standards 
Biorad Hemel Hempsted, UK 
ECL Advance western 
blotting detection reagent 
GE Healthcare Slough, UK 
X-Ray Film Fuji Bedfordshire, UK 
Pertussis toxin Calbiochem Leicestershire, UK 
ZSTK-474 Axxora Platform Nottingham, UK 
T487 UCB Cambridge, UK 
NBI-74330 UCB Cambridge, UK 
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N-oxide metabolite of NBI-
74330 
UCB Cambridge, UK 
AS605240 Echelon Bioscience 
(Tebu-bio) 
Le Perray en Yvelines 
Cedex, France 
IC87114 Symansis 
(Caltagmedsystems) 
Buckingham, UK 
PIK75 Axon Medchem Groningen, The 
Netherlands 
TGX-221 Cayman Chemical Michigan, USA 
TGX-121 Novartis Institutes for 
Biomedical Research 
(NIBR) Vienna 
Vienna, Austria 
U73122 Calbiochem Leicestershire, UK 
U73343 Calbiochem Leicestershire, UK 
Y27632 Sigma-Aldrich Poole, UK 
2-APB Cayman Chemical Michigan, USA 
2.2.5 PCR Sequences

Oligo Sequence 5’ to 3’ 
CXCR3A/Alt CCAAGTGCTAAATGACGCCG 
CXCR3B GACAGTTATAGGAGGAGCTGCTC 
CXCR7 GCCGTCATTTGATTGCCCGC 
Β-Actin ATGGATGATGATATCGCCGCG 
CXCR3A/Alt GCAAGAGCAGCATCCACATC 
CXCR3B CAGTGTCAGCACCAGCAGC 
CXCR7 CGAAGAGGTTGATGGAGAAG 
Β-Actin CTAGAAGCATTTGCGGTGGAC 
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3	 Characterisation of Mast Cell Models 
3.1	 HMC­1 as a Model for Investigation of CXCR3 Signalling and 
Function on Mast Cells 
3.1.1 Introduction to Study 
HMC-1 is a unique human mast cell line which can serve as a resource for mast cell 
proteins including granule proteins and mast cell genetic material (DNA and RNA). 
The HMC-1 line was derived from a patient with mast cell leukaemia and it is believed 
it is comprised of immature mast cells. These cells may respond in different ways 
compared to mature mast cells. HMC-1 cells lack a functional IgE receptor and have 
two point mutations in the intracellular juxtamemberane domain (Val560Gly) and in 
the catalytic domain (Asp816Val) of the c-Kit receptor (Furitsu et al., 1993). 
3.1.2 CXCR3 Expression and Signalling on HMC­1 Cell Line 
To investigate if the HMC-1 cell line was an appropriate model to study responses 
induced by CXCR3 agonists, mRNA and cell surface expression of CXCR3 and its 
variants were examined. Figure 3.1a reveals that only 2 variants of CXCR3 are 
present within the HMC-1 cells. CXCR3A and CXCR3B mRNA were detectable but 
there was no expression of CXCR3-alt (Figure 3.1a). At least one of these variants is 
translated to a protein level. Use of a non-isoform discriminating antibody revealed 
expression of CXCR3 at a surface level (Figure 3.1b) 
Biochemical signals robustly activated by chemokine agonists include 
phosphorylation and activation of Akt (a downstream readout for PI3K activation) and 
the ribosomal protein S6. HMC-1 cells are a poor model for investigating 
phosphorylation events due to very high basal levels of phosphorylation (Figure 3.1c). 
Using CXCL9 as a representative agonist of CXCR3 basal levels of phosphorylation, 
it was not possible to determine elevation of phosphorylation of these proteins above 
basal levels by CXCL9 (Figure 3.1c). 
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CXCR3A 
CXCR3­Alt 
CXCR3B 
CXCR7 
CXCR3 
Figure 3.1: Expression and signalling of CXCR3 on HMC­1. a) mRNA expression 
of CXCR3 variants in HMC-1 cells. mRNA (5µg) from 5 x 106 HMC-1 was extracted 
and reverse transcribed in the presence (+) or absence (–) of reverse transcriptase to 
ensure that samples were not contaminated with genomic DNA. mRNA levels of 
CXCR3 variants and CXCR7 were examined using specific primers as described in 
materials and methods. Arrows point to bands of mRNA expression for each CXCR3 
variant or CXCR7 respectively. b) Cell surface expression of CXCR3 (orange) on 
HMC-1 cells. Briefly 1x106 cells were washed in PBS and incubated with the 
respective PE conjugated antibody at 4oC, cells were washed in PBS and analysed 
on a FACS Calibre using Cell Quest software. Unstained (purple) and non-specific 
isotype stained (green) populations were used as negative controls. c) CXCL9 
signalling in HMC-1 cells. Aliquots of HMC-1 (1×106 cells/ml) were left untreated or 
stimulated at 37 °C with CXCL9 for 1-5 min and lysed by the addition of 1× sample 
buffer. Cell lysates were resolved by SDS-PAGE, transferred to nitrocellulose 
membranes and immunoblotted with a phospho-specific Akt or S6 Ab and proteins 
were visualised with ECL. The blots were stripped and reprobed with anti-S6 Ab to 
verify equal loading and efficiency of protein transfer (lower panel). The data are 
representative of three other experiments. 
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3.1.3 CXCR3 Agonists Fail to Induce Migration of HMC­1 Cells

To further evaluate if HMC-1 could act as an appropriate mast cell model I examined 
their function by investigating if CXCR3 agonists could induce migration of HMC-1 
cells. Figure 3.2 demonstrates that all four CXCR3 agonists failed to induce migration 
of HMC-1 cells. It was possible to induce migration of HMC-1 cells to the mast cell 
growth factor SCF. The migration observed was induced at 10nM, peaked at 100nM 
and started to decrease at 300nM (Figure 3.2a). The THP-1 cell line was utilised 
through out this thesis to act as a comparison of CXCR3 responses during evaluation 
of the mast cell model. In THP-1 cells, all CXCR3 agonists were capable of inducing 
chemotactic responses (Figure 3.2b). It was notable that CCL2 was a more potent 
chemotactic agent than the CXCR3 agonists in inducing migration of THP-1 cells. 
Figure 3.2b reveals that the peak response was 7.8 on the chemotactic index, clearly 
demonstrating a stronger response compared to the greatest response induced by 
CXCR3 agonists. 
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a) 
b) 
Figure 3.2: Migration of HMC­1 or THP­1 to different stimuli. a) HMC-1 cells or b) 
THP-1 cells (8x104/25µl) were placed on the upper membrane of a 96-well 
chemotaxis plate above lower chambers containing varying concentrations of CXCR3 
agonists or SCF. Chemotaxis across a 5µm pore size membrane was determined 
after 3 hour incubation at 37oC in 5% CO2 as described in material and methods. 
Data shown is derived from a single experiment performed in triplicate; data is 
representative of three experiments. 
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3.2 Generation of Primary Mast Cell Model 
3.2.1	 Generation and Characterisation of Human Cord Blood Derived 
Mast Cells 
CD133+ progenitor cells were differentiated into human mature mast cells by growing 
CD133+ progenitor cells in serum-free Stempro medium in the presence of SCF and 
IL-6 for 8 weeks. In addition IL-3 was added for the first 2 weeks to induce 
proliferation and IL-4 and serum were added to this cocktail after the initial 8-week 
period had passed. This method of initial serum-free conditions, followed by a 
subsequent serum supplementation has previously been reported to support the 
formation of functional human mast cells (Dahl et al., 2002). Figure 3.3 demonstrates 
the expression of surface markers that indicate the differentiation of CD133+ cells into 
mature mast cells. Precursors (0 – 2 wks) stained positive for the myeloid antigen 
CD13, the mast cell growth receptor CD117, CD133 (the progenitor marker used to 
isolate the cells) and IL-3R a growth marker for myeloid cells. Precursor cells 
however did not stain positive for the FcεRIa receptor commonly associated with 
mature mast cells. During differentiation and maturation a loss of CD133 and IL-3R 
expression is observed and accompanied by an upregulation of the FcεRIa. Mature 
mast cells (>9 wks) are observed to have total loss of CD133 and IL-3R expression, 
whereas the FcεRIa is highly expressed, which is a key characteristic of mature mast 
cells. 
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CD13 
(aminopeptidase) 
CD117 (c­kit) FceRIaCD123 
(IL­3R) 
CD133 
Precursor 
Immature 
Mature 
cε Ia 
Figure 3.3: Expression markers on CD133+ progenitors through to mature mast 
cells. Representative surface expression profiles of CD13, CD117, CD133 CD123 
and FcεRIa on precursors (0-2 weeks), immature (~2-9 weeks) and mature (9 weeks 
+) cells. The respective immunoglobulin isotype controls are shown in blue. Briefly 
1x106 cells were washed in PBS and incubated with the respective PE conjugated 
antibody at 4oC, cells were washed in PBS and analysed on a FACS Calibre using 
Cell Quest software. 
Further to the expression of these cells surface markers the mature cells were 
observed to display typical phenotypic features of mature mast cells such as 
metachromasia and the abundant expression of granular mast cell tryptase (Figure 
3.4). Tryptase was detected in both immature and mature cells. However the mild 
staining observed in the precursor stage was thought to be due to non-specific 
binding of the substrate system. Staining was visually more intense in the mature 
cells compared to immature cells, with 90 % of the mature population staining positive 
for human mast cell tryptase (Figure 3.4). 
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Figure 3.4: Characteristic tryptase staining of CD133+ precursors. 
Representative images demonstrating characteristic tryptase staining throughout 
development of CD133+ progenitor cells into mature human mast cells. Briefly 1 x 105 
of primary mast cells were washed twice in RPMI and centrifuged onto poly-L-lysine-
coated glass slides in a cytospin3 cytocentrifuge at 250g. The resulting smears were 
air-dried and fixed by submersion in an acetone-methanol solution for 1 min. The 
smears were then carefully washed in TBS buffer (pH 7.6) and 100µl of anti-human 
mast cell tryptase mAb was added to the appropriate smear and incubated at 4oC 
overnight. To visualise the presence of tryptase within human mast cells, prepared 
smears were stained using the alkaline phosphatase/anti-alkaline phosphatase 
(APAAP) method according to the manufacturer's instructions. Magnification is at x20 
A further defining characteristic of a mature mast cell is the ability to release a vast 
range of pre-formed and newly formed mediators. Using a light microscopy and a 
May-Grunwald/Giemsa stain (Figure 3.5). I was able to demonstrate that CD133+ 
cells have a large nucleus but little sign of any preformed granules. Immature cells 
have faint granule staining which is in contrast to the heave staining of the mature 
mast cells stain, displaying the presence of a wide range of mediators stored within 
the cytoplasm of these mast cells. 
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Figure 3.5: Characteristic May­Grunwald/Giemsa staining of CD133+ 
precursors. Representative images demonstrating, characteristic May 
Grunwald/Giemsa staining throughout the development of CD133+ progenitor cells 
into mature human mast cells. Briefly 1 x 105 of primary mast cells were washed twice 
and centrifuged onto poly-L-lysine-coated glass slides at 250g. The resulting smears 
were then air-dried and fixed by submersion in an acetone: methanol solution (1:1) for 
1 minute. Smears were then air-dried before submersion in May-Grunwald’s eosine-
methylene blue solution modified for 1 minute. Smears were rinsed with dH2O and air-
dried. Smears were then submersed in Giemsa’s azur eosin methylene blue solution 
for 1 minute. After the incubation period, the excess stain was washed off using dH2O 
and again left to air dry. Magnification is 40x. 
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Finally, in the characterisation of mast cells, ultra-thin slices were taken at different 
stages of differentiation. These slices were analysed by TEM and revealed that 
precursors have a large nucleus and little else present in their cytoplasm (Figure 3.6). 
The immature mast cells were observed to have clear compartments where the 
granules of the mast cells are stored. Whereas the mature mast cells have developed 
larger compartments, which are filled with dark stained matter indicative of the 
presence of granules. 
Figure 3.6: TEM pictures of mast cells at different stages of differentiation and 
maturation. Examples of mast cells from different stages of development were 
prepared for imaging under TEM as described in Materials and Methods. Each stage 
has two different mast cells pictured under TEM. Measurement bar is 1µm. 
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3.3 Characterisation of Primary Mast Cell Model 
3.3.1 Introduction to Study 
Prior to investigating CXCR3 expression and function of this primary mast cell model 
it was important to validate this human cord-blood derived primary mast cell model. 
The cross-linking of the IgE-loaded high-affinity IgE receptor by multivalent antigens 
has been demonstrated to result in mast cell activation and subsequent release of 
multiple pro-inflammatory mediators. Other membrane activation events can either 
prime mast cells for subsequent degranulation or can act in synergy with FcεRI signal 
transduction. 
An allergen is able to bind to antigen-binding sites, situated on the variable regions of 
the IgE molecules on the mast cell surface allowing the clustering of the intracellular 
domains of the cell-bound Fc receptors, which are associated with the cross-linked 
IgE molecules. This induces a complex sequence of reactions inside the mast cell 
that lead to its activation. The dose-response curve for FcεRI-mediated degranulation 
is bell-shaped regardless of whether the IgE or the Ag concentration is varied. 
Moreover, certain early signalling events continue to increase whereas degranulation 
drops under sub-optimal conditions (Gimborn et al., 2005). 
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3.3.2 Antigen Induces Degranulation in Dose Dependent Manner 
Treatment of mature mast cells with NP-BSA (0.1 – 1000 ng ml-1 , 2 hrs, 37oC?) 
resulted in a dose-dependent increase in beta-hexaminidase release (Figure 3.7) This 
was observed to reach maximal release using 100 ng ml-1 NP-BSA with 
concentrations greater than this resulting in lesser beta-hexaminidase release. The 
curve generated from this dose response treatment started to exhibit bell-shaped 
characteristics similar to results previously discovered in other studies. 
Figure 3.7: IgE/Ag dose response. Mature mast cells (1x106/ml) were treated 
overnight with chimeric human Fc anti-4-hydroxy-3-nitrophenylacetyl (NP)-specific IgE 
(1 µg/ml). Cells were stimulated with NP-BSA for 2 hours. Samples were centrifuged 
for 10mins and supernatants transferred to new wells before addition of β-
hexosaminidase substrate for 1.5 hours to measure β-hexosaminidase release. Data 
are expressed as % the total β-hexosaminidase release. Results are expressed as 
mean ± SEM of 4 experiments performed in triplicate. 
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3.3.3	 Investigating the Mechanism of IgE Cross­Linking Induced 
Degranulation. 
PI3K has recently been described as a key-signalling molecule in the degranulation 
mechanism in mast cells (Wymann et al., 2003). Therefore it was important in this 
study to evaluate the role of the PI3K family in mast cell degranulation induced by 
cross-linking of FcεRI. 
FcεRI initiate their signalling processes via activation of tyrosine kinases, either 
intrinsically or by recruitment of cytosolic kinases (Gilfillan and Tkaczyk, 2006; 
Roskoski, 2005). They have been demonstrated to utilise the class 1A PI3Ks to 
mediate subsequent downstream signalling events. GPCRs, such as those for 
adenosine, prostaglandin (PG)E2, sphingosine 1 phosphate (S1P) and complement 
component C3a, mediate their responses via class 1B PI3K. (Wymann et al., 2003). 
Utilising the general isoform non-selective inhibitor of the PI3K family, ZSTK474, 
revealed that at least one isoform of PI3K is involved in the degranulation of mast 
cells by cross linking of IgE by treatment with 100 ng/ml of antigen (Figure 3.8). Pre-
treatment with concentrations < 1 µM demonstrated little inhibition of degranulation 
whilst concentrations > 1 µM, demonstrated clear inhibition of degranulation induced 
by treatment with antigen. 100% inhibition was only achieved at 10 µM with an IC50 of 
1.15 µM. This is above the IC50 of the compound to be specific for PI3K indicating the 
involvement of other signalling molecules in the mechanism of degranulation. 
ZSTK474 IC50 for PI3K is between 10 and 50 nM. 
109

Chapter 3 – Characterisation of Mast Cell Models

Figure 3.8 – Cross­linking of IgE/Ag induced degranulation is PI3K dependent. 
Mature mast cells (1x106/ml) were treated overnight with chimeric human Fc anti-4-
hydroxy-3-nitrophenylacetyl (NP)-specific IgE (1µg/ml). Cells were treated with 
ZSTK474 at concentrations indicated for 30mins before stimulation with 100 ng/ml 
NP-BSA for 2 hours. Samples were centrifuged for 10mins and supernatants 
transferred to new wells before addition of β-hexosaminidase substrate for 1.5 hours 
to measure β-hexosaminidase release. Data are expressed as % inhibition compared 
to the control IgE/Ag response. Results are expressed as mean ± SEM of 4 
experiments performed in triplicate. 
110

Chapter 3 – Characterisation of Mast Cell Models 
3.3.4	 The Role of Specific PI3K isoforms in Degranulation by Cross­
Linking of IgE. 
PI3K can be considered a central regulator of critical downstream signalling 
processes for receptor-mediated mast cell responses. Evidence from murine studies 
appears to indicate that in vitro studies both p110δ and p110γ are required for FcεR1-
driven mast cell degranulation, whereas in vivo, p110δ (but not p110γ) is 
indispensable for allergic responsiveness (Ali et al., 2004; Ali et al., 2008; Laffargue et 
al., 2002). The role of PI3K in human mast cells has yet to be fully elicited. This study 
aims to highlight potential key PI3K isoforms in FcεRI induced degranulation in the 
human mast cell model. 
Isoform specific PI3K inhibitors were used to investigate the role of individual PI3K 
catalytic isoforms in IgE/Ag-induced degranulation. A recent comprehensive analysis 
of inhibitor selectivity revealed that the most selective compounds include the 
quinazolinone purine inhibitors of PI3K such as IC87114 which targets PI3Kδ , the 
chromones that preferentially target PI3Kβ/δ (TGX-121), the 
pyridinylfuranopyrrimidine that preferentially targets PI3Kα (PIK75) and the 
thiazolidinediones that preferentially target PI3Kγ (AS605240) (Knight et al., 2006; 
Smith et al., 2007). At least one compound from each of these chemotypes exhibits 
10-100-fold selectivity between their primary target(s) versus other class I PI3Ks 
(Table 3.1). 
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Class I PI3K isoforms 
IC50(�M) 
α β γ δ 
IC50 F.S IC50 F.S IC50 F.S IC50 F.S 
PIK75 0.0078 1 0.343 44 n/a n/a 0.907 116 
TGX-221 5 714 0.007 1 3.5 500 0.1 14 
IC87114 > 200 >1539 16 123 61 469 0.13 1 
TGX-121 >5 >100 0.05 1 >50 >1000 0.05 1 
AS605240 0.06 7.5 0.27 34 0.008 1 0.3 38 
ZSTK474 n/a n/a 0.012 2 0.053 9 0.006 1 
Table 3.1: IC50 values (µM) for isoform­discriminating PI3K inhibitors. All values 
are based on in vitro assays of inhibitor activity against purified protein activity. F.S 
represents the fold selectively of each inhibitor. (Knight et al., 2006; Smith et al., 
2007). 
PIK75 which displays around 116-fold selectivity against PI3Kα versus the δ isoform 
respectively had no inhibitory effect on mast cell degranulation at concentrations 
known to be specific for p110α (Figure 3.9a). It is notable however that inhibition of 
degranulation by PIK75 starts to occur at concentrations predicated to impinge on 
other PI3K isoforms. In rank order of potency target, p110δ is the next isoform 
inhibited, indicating a potential role for p110δ in IgE/Ag induced degranulation. 
Use of TGX-221, which has approximately 10-fold selectivity for p110β versus p110δ 
(Knight et al., 2006), had no effect on degranulation responses to IgE/Ag, even at 
concentrations predicted to impinge on p110δ activity (Figure 3.9b). It is notable, 
however, that inhibition of degranulation by TGX-221 starts to occur at concentrations 
predicated to impinge on other PI3K isoforms. In rank of order-of-potency target, 
p110δ is the next isoform inhibited, again highlighted as a potential role for p110δ. 
Interestingly, the p110δ-discriminating inhibitor IC87114 inhibits IgE/Ag-induced 
degranulation with an IC50 of 10-20 µM (Figure 3.9d) markedly higher than its 
reported IC50 for p110δ obtained against purified enzyme (Table 3.1). This is 
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surprising as there is usually good concordance between IC50’s obtained for IC87114 
against p110δ using purified enzyme (Crabbe et al., 2007; Knight et al., 2006; Smith 
et al., 2007), versus IC50’s derived from cell based assays. Given the reported IC50 for 
IC87114 versus p110β is 16 µM, it was important to assess the role of p110β in 
IgE/Ag agonist-stimulated mast cell degranulation. This was further investigated using 
2 inhibitors known to target p110β. Firstly, TGX-121 displays equipotency against 
p110β and p110δ with approximately 100-fold selectivity against these isoforms 
versus p110α and p110γ. TGX-121 inhibited IgE/Ag degranulation, (Figure 3.8c). 
The IC50 for TGX-121 is comparable to that predicted for inhibition of p110β and 
p110δ (Table 3.1). 
AS605240 displays around 10-fold selectivity against PI3Kγ versus α isoforms but 
approximately 35-fold selectivity vs. δ/β. AS605240 inhibited IgE/Ag agonist induced 
β-hexosaminidase release with an IC50 comparable to reported its IC50 for p110γ 
(Figure 3.9e). Possible concerns about off-target effects of AS606240 on p110α at 
concentrations >60nM seem unfounded, as the p110α-targeting inhibitor PIK75 had 
no effect on degranulation until ranges which are known to impinge on other PI3K 
isoforms (Figure 3.9e). 
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Figure 3.9: PI3K Isoform Specific IgE/Ag induced degranulation. Mature mast 
cells (1x106/ml) were treated overnight with chimeric human Fc anti-4-hydroxy-3-
nitrophenylacetyl (NP)-specific IgE (1µg/ml). Cells were treated with specific PI3K 
inhibitor at concentration indicated for 30mins before stimulation with 100 ng/ml NP-
BSA for 2 hours. Samples were centrifuged for 10mins and supernatants transferred 
to new wells before addition of β-hexosaminidase substrate for 1.5 hours to measure 
β-hexosaminidase release. Data are expressed as % inhibition compared to the 
control IgE/Ag response. Results are expressed as mean ± SEM of 4 experiments 
performed in triplicate. 
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3.3.5 The Role of Rho Kinase in IgE/Antigen Induced Degranulation 
Signalling by the FcεRI receptor manages the cytoskeletal re-arrangements which are 
associated with degranulation of mature mast cells. There are two important features 
of the microtubles in the degranulation of mast cells. Firstly, tubulin polymerisation-
inhibiting agents have been shown to inhibit the crosslinking of FcεRI (Martin-
Verdeaux et al., 2003; Nielsen and Johansen, 1986; Tasaka et al., 1991). Secondly, 
the mobilisation of granules by FcεRI induced activation has been demonstrated in 
the mast cell line RBL to be dependent on the microtubles (Smith et al., 2003), 
highlighting a crucial role of cytoskeletal re-arrangements in mast cell degranulation. 
One such pathway which has been implicated as key to the cytoskeletal 
rearragnement is the Rho kinase pathway (Nishida et al., 2005). Rho-kinase is an 
effector molecule of RhoA, a monomeric GTP-binding protein causing Ca2+ 
sensitization via inactivation of myosin phosphatase. The major physiological 
functions of Rho-kinase include contraction, migration and proliferation in cells. These 
actions are thought to be related to the pathophysiological features of asthma, i.e., 
airflow limitation, airway hyper-responsiveness, β-adrenergic desensitization, 
eosinophil recruitment and airway remodeling. (Kume, 2008). This study aimed to 
investigate the role of Rho kinase in degranulation induced by cross-linking of the 
FcεRI by IgE/Antigen complexes. 
Figure 3.10 indicates that Rho kinases play a key role in the degranulation of human 
mature mast cells induced by IgE/Antigen complexes. Pre-treatment of mast cells 
with the inhibitor Rho kinase Y27632 was observed to inhibited degranulation by 90 
%. This suggests that Rho kinase plays a major role in mast cell degranulation; 
however other signalling pathways could be involved. 
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Figure 3.10: Involvement of Rho kinase in Antigen induced degranulation. 
Mature mast cells (1x106/ml) were treated overnight with chimeric human Fc anti-4-
hydroxy-3-nitrophenylacetyl (NP)-specific IgE (1µg/ml). Cells were treated with 
Y27632 at concentration indicated for 30mins before stimulation with 100ng/ml NP-
BSA for 2 hours. Samples were centrifuged for 10mins and supernatants transferred 
to new wells before addition of β-hexosaminidase substrate for 1.5 hours to measure 
β-hexosaminidase release. Data are expressed as % inhibition compared to the 
control IgE/Ag response. Results are expressed as mean ± SEM of 4 experiments 
performed in triplicate. 
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3.3.6	 The Role of PLC in Mast Cell Induced Degranulation of Mast Cell by 
Antigen 
Mast cell degranulation following FcεRI-aggregation is generally believed to be 
dependent on PI3K mediated PLCγ activation. Mast cells are one of the few cell types 
that express both PLCγ1 and PLCγ2 isoforms (Barker et al., 1998). In primary 
cultures of human mast cells, FcεRI aggregation induced a rapid translocation and 
phosphorylation of PLCγ1, and subsequent IP3 production that preceded PI3K related 
signals (Tkaczyk et al., 2006). Therefore with different subsets of mast cells 
portraying different characteristics it was of interest to investigate if PLC is as crucial 
a signalling molecule in cross-linking of FcεRI to induce degranulation in human cord 
blood derived mast cells. 
Figure 3.11 demonstrates that PLC plays a key role in degranulation of cord blood 
derived mast cells by aggregation of FcεRI. Pre-treatment of cells with the 
aminosteroid U73122 which is reported to act as a specific inhibitor of PLC was 
observed to inhibit mast cell degranulation whereas use of the inactive analogue 
U73343 in the same concentration range failed to inhibit degranulation. 
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Figure 3.11: Role of PLC in IgE/Ag induced degranulation. Mature mast cells 
(1x106/ml) were treated overnight with chimeric human Fc anti-4-hydroxy-3-
nitrophenylacetyl (NP)-specific IgE (1µg/ml). Cells were treated with specific PLC 
inhibitor at concentration indicated for 30mins before stimulation with 100ng/ml NP-
BSA for 2 hours. Samples were centrifuged for 10mins and supernatants transferred 
to new wells before addition of β-hexosaminidase substrate for 1.5 hours to measure 
β-hexosaminidase release. Data are expressed as % inhibition compared to the 
control IgE/Ag response. Results are expressed as mean ± SEM of 4 experiments 
performed in triplicate. 
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3.3.7 IP3 in Mast Cell Induced Degranulation 
The activation of mast cells by aggregation of the FcεRI increases levels of IP3 due to 
the activation of phospholipases. This in turn increases the calcium flux which triggers 
the movement of intracellular secretary molecules towards the plasma membrane and 
subsequent fusion of the granular membrane with the plasma membrane. This is a 
key process in the degranulation process. 
Figure 3.12 reveals that IP3 is critical to the degranulation of mast cells by FcεRI. Pre-
treatment of mature mast cells with the IP3 inhibitor 2-AB strongly inhibits mast cell 
degranulation induced by aggregation of FcεRI. 
Figure 3.12: Generation of IP3 is critical for FcεRI aggregation induced 
degranulation. Mature mast cells (1x106/ml) were treated overnight with chimeric 
human Fc anti-4-hydroxy-3-nitrophenylacetyl (NP)-specific IgE (1µg/ml). Cells were 
treated with specific IP3 inhibitor, 2-AB at concentration indicated for 30mins before 
stimulation with 100ng/ml NP-BSA for 2 hours. Samples were centrifuged for 10mins 
and supernatants transferred to new wells before addition of β-hexosaminidase 
substrate for 1.5 hours to measure β-hexosaminidase release. Data are expressed as 
% inhibition compared to the control IgE/Ag response. Results are expressed as 
mean ± SEM of 4 experiments performed in triplicate. 
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3.3.8 Calcium Influx is Key to Mast Cell Degranulation 
Evidence exists for the importance of calcium dependent and independent pathways 
both being critical for mast cell degranulation by FcεRI. It was therefore essential to 
investigate if the role of calcium in the extracellular medium and its importance in 
FcεRI aggregation induced degranulation. Figure 3.13 reveals that the absence of 
calcium in the extracellular medium strongly restricts the degranulatory response 
induced by aggregation of FcεRI. Aggregation of FcεRI in medium without Ca2+ only 
induced minimal release of β-hexaminidase above basal levels. In completely calcium 
free conditions, calcium free media was pre-treated with 1mM EGTA to sequester any 
remaining calcium ions, only trace amount of β-hexaminidase release were 
detectable above basal levels. These findings clearly indicate the importance of 
calcium in the extracellular media to induce degranulation. 
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Figure 3.13: Varying Ca2+ conditions in FcεRI aggregation induced 
degranulation. Mature mast cells (1x106/ml) were treated overnight with chimeric 
human Fc anti-4-hydroxy-3-nitrophenylacetyl (NP)-specific IgE (1µg/ml). 1x106 
human mature cord blood-derived mast cells in appropriate buffer, (RPMI,RPMI 
without Ca2+ or RPMI without Ca2+and 1mM EGTA) and before stimulation with 
100ng/ml NP-BSA for 2 hours. Samples were centrifuged for 10mins and 
supernatants transferred to new wells before addition of β-hexosaminidase substrate 
for 1.5 hours to measure β-hexosaminidase release. Data is expressed as % of total 
β-hexosaminidase content. Results are expressed as mean ± SEM of 4 experiments 
performed in triplicate. 
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3.3.9 Summary 
�	 FcεRI aggregation by antigen induces degranulation of mature human mast 
cells derived from cord blood in a dose dependent manner. 
�	 FcεRI aggregation induced degranulation of mast cells is dependent on the γ, 
β and δ isoforms of PI3K. 
�	 PLC is a key signalling molecule needed to be activated in order to induce 
mast cell degranulation via FcεRI aggregation. 
�	 This activation results in the formation of IP3 which is highlighted as another 
key signalling molecule required in mast cell degranulation 
�	 Calcium mobilisation is crucial to mast cell activation. 
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3.4 Discussion 
The aim of this study was to successfully evaluate a mast cell model to investigate 
CXCR3 expression and its function. Two mast cell models were evaluated: HMC-1 
and primary human mast cell derived from human CD133 precursor cell isolated from 
cord blood. Investigations began by characterising the HMC-1 cell line as an 
appropriate mast cell model. 
3.4.1	 HMC­1 Cell Line makes a Poor Mast Cell Model for Investigating 
CXCR3 Function. 
The HMC-1 cell line was derived from a patient with mast cell leukaemia which is 
comprised mostly of immature mast cells. Far from being ideal as a model for 
investigating mast cell function the cells may respond very differently to mature mast 
cells. HMC-1 cells lack a functional IgE receptor and have mutations in the coding 
sequence of the c-Kit proto oncogene (Furitsu et al., 1993). The benefits of utilising a 
cell line are in the numbers that can be generated and maintenance of a cell line is far 
less than the cost of the primary mast cell line utilised in this study. Under normal 
circumstances, SCF binds to c-Kit, inducing homodimerization of the receptor that 
leads to intrinsic kinase activity and results in autophosphorylation of tyrosine 
residues (Blechman et al., 1993). c-Kit then becomes the docking site for various Src 
homology domain 2 (SH2) domain signalling molecules. The mutations in the coding 
sequence produce high spontaneous tyrosine phosphorylation of c-Kit resulting in 
phosphorylation of down stream signalling proteins (Ma et al., 1999). Although 
CXCR3 was expressed at an mRNA and surface level, the mutation in the c-Kit 
results in the high basal activation of many down stream signalling proteins exposed 
the HMC-1 model as an inappropriate mast cell model to study CXCR3 signalling 
events. 
Despite the mutated c-Kit, in other studies and in this study, SCF through the binding 
of c-Kit is able to induce a chemotactic response in HMC-1 cells. SCF falls into the 
growth factor category with receptors endowed with tyrosine kinase activity that also 
stimulate cell migration. Stimulation of c-Kit with SCF induces dimerisation and 
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activation of its intrinsic tyrosine kinase activity, leading to auto-phosphorylation and 
to the phosphorylation of a number of substrates (Blume-Jensen et al., 1991; Herbst 
et al., 1991; Lev et al., 1991). In this pathway is protein kinase C, a serine/threonine 
kinase that is involved in the control of cell proliferation, differentiation, and motility 
(Nishizuka, 1988). It was discovered, however, that CXCR3 agonists failed to induce 
the migration of HMC-1 cell line. This inability to induce the migration of HMC-1 has 
also been noted in response to other chemokine agonists (Nilsson et al., 1994). 
3.4.2 Chemokine Receptors and Mast Cell Migration 
Chemokine receptors whose expression is inducible rather than constitutive, such as 
CCR1, CCR2 (receptor for monocyte chemoattractant protein 1 [MCP-1], also 
designated CCL2), CCR5, and CXCR3 agonists are known to play a prevalent role in 
the control of inflammation (Amoura et al., 2003). Airway inflammation is 
characterised by selective recruitment of mononuclear and granulocytic cells. This 
recruitment is mediated by the action of chemotactic cytokines, such as chemokines. 
A number of chemokines and their receptors have been identified and proposed as 
potential therapeutic targets to help resolve allergic airway inflammation. Chemokines 
that have been associated with allergic inflammatory diseases such as asthma and 
allergic rhinitis are CXCR3 and CCR2 agonists. 
It is widely recognised that members of the CC subfamily of the chemokine family 
exert strong chemoattractant activities on monocytes, T cells and natural killer cells 
(Rollins, 1996). This study clearly demonstrated the functional responses of CCL2 in 
the monocyte cell line, THP-1 with functional response seen in both Ca2+ mobilisation 
and chemotatic assay. 
In addition to promoting the transmigration of circulating monocytes into tissues, 
CCL2 has been shown to exert various effect on monocytes, including superoxide 
anion induction, chemotaxis, and calcium flux (Rollins, 1996). CCL2 plays a critical 
role in the regulation of human monocyte function and has largely been associated 
with modulating monocyte migration in response to inflammation (Rollins et al., 1991). 
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CCL2 also induced characteristic monocyte responses, such as Ca2+ mobilisation and 
respiratory burst (Rollins, 1996)., thus making this specific chemokine an appropriate 
positive control in this study. 
3.4.3 Development of Mast Cell Culture Systems 
Since the HMC-1 cell line model proved to be an inappropriate mast cell model to 
study CXCR3 signalling and function, the focus of this study moved to evaluate a 
primary mast cell model. The utilisation of these primary mast cell models has 
allowed the discovery of how mast cells responded to a wide range of different 
physiological and pathological mediators. These models have also allowed the 
understanding the role of mast cells in inflammatory responses. This study utilised the 
cord blood derived model to generate large volumes of mast cells to allow the study 
of the function of CXCR3 on mast cells. The first challenge of this study was to 
generate large enough volumes of mature mast cells to determine if this cord blood 
derived model was appropriate. The results in this study have shown that it was 
possible to generate pure populations of mature mast cells. However the drawbacks 
to this model were the cost of maintaining the cells throughout the maturation and 
differentiation. Also lack of cord blood availability in the local area resulted in this 
study buying CD133+ precursors which further added to the cost of this cell model. As 
a result of the cost of this model slight limitations were placed on the amount of 
experiments that were able to be performed. 
3.4.4 Evaluation of Cord Blood Derived Mast Cell Model 
This investigation began by characterising the optimal concentration of antigen that 
induces the maximal degranulatory response from cord blood derived mast cells. IgE 
antibodies bind to the antigens of allergens. These allergen-bound IgE molecules 
interact with Fcε receptors on the surface of mast cells. Activation of mast cells 
following engagement of FcεRI results in degranulation of mast cells in a dose 
dependent manner. 
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The process of degranulation via aggregation of FcεRI involves many different 
signalling molecules. Many of the signalling networks identified as being involved in 
mast cell degranulation have been dervied from the analysis of mast cells from gene-
targeted mice. Murine models have been instrumental in defining the basic 
mechanisms of anti-tumor immunity. Most of these mechanisms have since been 
shown to operate in humans as well. In common with other animal species murine 
models also have limitations. Mice do not spontaneously develop asthma and no 
model mimics the entire asthma phenotype making it critical in diseases linked to 
mast cells to also study human models (Kips et al., 2003). 
3.4.5 Role of PI3K Isoforms in Mast Cell Degranulation 
Mast cells express the class 1A PI3K, p85α, p85β and p50β regulatory subunit 
isoforms (Lu-Kuo et al., 2000; Tkaczyk et al., 2003). In addition to all three classes 1A 
PI3K catalytic subunit isoforms, p110α, p110β, and p110δ and the class 1B p110γ 
catalytic subunit (Ali et al., 2004; Okkenhaug et al., 2007). As c-Kit and the FcεRI 
initiate their signalling processes via activation of tyrosine kinases, either intrinsically 
or by recruitment of cytosolic kinases (Gilfillan and Tkaczyk, 2006; Roskoski, 2005). 
They use class 1A PI3Ks to mediate subsequent downstream signalling events. It is 
understood that GPCRs, such as adenosine, PGE2, S1P and complement 
component C3a, mediate their responses via class 1B PI3K (Gilfillan and Tkaczyk, 
2006). 
The activation of PI3K in mast cells by FcεRI aggregation induces the recruitment of 
the AKT to the plasma membrane resulting in phosphorylation of AKT by the 
serine/theronine kinase PDK-1 (Vanhaesebroeck and Alessi, 2000). Although 
activation of Akt seems to be crucial for mast cell function, the exact role of Akt in 
mast cells is not yet clear. Evidence suggests that PDK1-AKT may contribute to the 
PI3K-dependent signalling events regulating mast cell growth, homeostasis and 
cytokine production. This has been highlighted by the inhibition of PDK1 activation, 
resulting in the apoptosis of SCF-maintained mast cells (Sawamukai et al., 2007). 
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It is has been proved from gene targeting approaches in mice that gene knock-out of 
individual PI3K isoforms can alter the expression of other non-targeted isoforms and 
this is a likely complication of siRNA-based strategies. Knock-out mice lacking PI3K 
protein expression exhibit a different phenotype from knock-in mice displaying PI3K 
mutants that lack kinase activity. Such studies, in comparison of pharmacological and 
gene targeting of PI3K isoforms have revealed that PI3K isoforms have scaffolding 
roles in addition to their catalytic roles (Shaywitz et al., 2008; Vanhaesebroeck et al., 
2004). Give that this thesis has used a range of novel inhibitors with differing 
selectivity profiles, the pharmacological analysis is actually more accurate and 
reliable that the siRNA strategy. 
3.4.6	 Role of Signalling PLC in Mast cell Degranulation by Aggregation 
of FcεRI 
Upon cross-linking of FcεRI with IgE/cognate antigen complexes, the aggregation of 
multiple FcεRI complexes results in transphosphorylation of the ITAM regions of the β 
and γ-chains by Lyn, a src family protein tyrosine kinase (PTK) that is constitutively 
associated with the β-chain (Jouvin et al., 1994; Pribluda et al., 1994). After activation 
of mast cells by aggregation of FcεRI, this event recruits Lyn kinase to the 
phosphorylated β–chains and the phosphorylation of the ITAM regions present on the 
γ-chain resulting in a docking site for the spleen tyrosine kinase (SYK) (Kimura et al., 
1996; Shiue et al., 1995). The activation of the SYK has been shown to be an 
indispensable initial signal for mast cell activation by FcεRI aggregation. Studies in 
SYK-deficient mast cell lines and primary mast cells taken from SYK-deficient fetal 
liver have lacked all the features of mast cell activation, including degranulation and 
leukotriene and cytokine release (Costello et al., 1996; Zhang et al., 1996). 
Lyn is a kinase upstream of SYK activation. Lyn was the major src PTK that 
phosphorylates SYK and the FcεRI β and γ-chains. One particular study has 
demonstrated that in passive systemic anaphylaxis (PSA) in Lyn-deficient mice, PSA 
is severely diminished (Hibbs et al., 1995). This initial study has been contradicted by 
the findings in vitro that where mast cells were deficient of Lyn that degranulation was 
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unaffected or potentially enhanced in these cells (Hernandez-Hansen et al., 2004; 
Odom et al., 2004). The discrepancy in these studies was due to a difference in the 
age of mice used; leading to the conclusion that Lyn plays a key role in mast cells of 
the young but loses its importance as the mice age. 
Activation of SYK results in the phosphorylation of several adaptor molecules. One of 
these is PLCγ, shown in this thesis and in other studies to be crucial for 
degranulation. The downstream phosphorylation of PLCγ and Vav was completely 
absent in Syk-deficient mast cells. Mast cells have been shown to express both 
isoforms of PLCγ (Wilde and Watson, 2001). The generation of IP3 by activation of 
PLC leads to mobilisation of intracellular Ca2+ , resulting in a sustained Ca2+ flux 
response that is maintained by an influx of extracellular Ca2+ (Hoth and Penner, 
1992). This study has demonstrated the key role of IP3 in mast cell degranulation 
further unraveling the signalling profile of mast cell degranulation in cord blood 
derived mast cells. Activation of mast cells by aggregation of FcεRI it is known to, in 
conjunction with DAG, the increase in intracellular calcium levels causes downstream 
activation of PKC and Ras guanyl nucleotide- releasing protein (RasGRP), known to 
contribute to the release of cytokines from mast cells (Dower et al., 2000; Ebinu et al., 
2000), further enhancing the important of PLC activation in mast cells demonstrated 
in this study. 
Further proof PLC is a key player in mast cell degranulation was the findings that both 
PLCγ1 and PLCγ2 isoforms are phosphorylated in FcεRI aggregation. This is, 
however, drastically reduced in SLP-76 and LAT-deficient mast cells. The use of 
PLCγ1 deficient mast cells has not proved a successful model to date to investigate 
PLC’s role in the mast cell due to the early embryonic lethality of PLCγ1-deficient 
mice, (Ji et al., 1997) mast cells from PLCγ2-deficient mice display reduced Ca2+ flux 
and degranulation(Wen et al., 2002). 
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3.4.7 Reliance of Calcium Influx for Mast Cell Degranulation 
This study highlighted the importance of calcium influx to the degranulatory response. 
Removal of calcium from the extracellular medium completely blocked the 
degranulation response. STIM1 has been demonstrated to be key in promoting the 
Ca2+ influx that is essential for FcεRI-mediated mast cell activation and anaphylaxis 
(Baba et al., 2008). Mast cells lacking STIM1 also had much less degranulation and 
cytokine production after FcεRI I stimulation (Baba et al., 2008). Another key 
component that has been identified is the role CRAC channels in mast cell 
degranulation. Mast cells derived from CRACM1-deficient mice showed grossly 
defective degranulation and cytokine secretion, and the allergic reactions elicited in 
vivo were inhibited in CRACM1-deficient mice (Vig et al., 2008). These studies fit in 
with the data in this thesis, as activation of PLC drive STIM1 expression from the ER 
resulting in the opening on the CRAC allowing influx of Ca2+ driving the degranulation 
response forward. 
3.4.8	 Rho Kinase is Crucial to Mast Cell Degranulation by FcεRI 
Aggregation 
This thesis has shown the dependence on activation of Rho kinase in the induced 
degranulation of mature cord blood derived mast cells by FcεRI aggregation. It has 
also indicated a key role for the influx of calcium in mast cells. It has been 
demonstrated however that in studies of exocytosis of mast cells that members of the 
SNARE family, including SNAP-23, synaptotagmin, syntaxin (t-SNARE), and 
molecules of the VAMPs family (v-SNARE) regulate granule-to-plasma or granule-to-
granule membrane fusion in response to elevated cytosolic calcium concentrations 
(Castle et al., 2002). 
It has also been highlighted that calcium independent pathways are just as crucial to 
the degranulatory process. (Nishida et al., 2005) demonstrating a key involvement of 
the Fyn/Gab2/RhoA signalling and are required for granule translocation to the 
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plasma membrane. This study concluded that FcεRI stimulation induced the formation 
of microtubules and that this was independent of calcium; Fyn/Gab2/RhoA signalling 
was not only involved in microtubule formation but was also required for 
degranulation and the translocation of granules to the plasma membrane. 
The presence of a calcium independent pathway has also been noted in studies with 
Fyn-deficient bone marrow derived mast cells in which degranulation after FcεRI 
aggregation was impaired, despite the presence of a functional calcium flux 
(Parravicini et al., 2002). It is believed that the requirement of 2 pathways, one 
dependent, the other independent of calcium, is required to mobilise the translocation 
of granules to the plasma membrane (calcium dependent pathway), where the 
calcium independent pathway is required for the fusions of the granules with the 
plasma membrane (Nishida et al., 2005). This study and others highlights the 
importance of Rho kinase in mast cell degranulation. 
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Chapter 4 – Role of CXCR3 in Cord Blood Derived Mast Cells. 
4.1 CXCR3 Function in Human Cord Blood Derived Mast Cells 
4.1.1 Introduction to the Study 
The findings so far in this study have demonstrated that primary human mast 
cells derived from cord blood create a suitable model to study CXCR3 
responses in mast cells. It is already established that a range of mediators 
other than IgE cross-linking can activate mast cells (Kuehn and Gilfillan, 2007; 
Nishida et al., 2005; Tkaczyk et al., 2002), however the role of chemokines in 
mast cell activation has not yet been widely studied. Evidence has 
demonstrated that certain chemokines are capable of inducing augmentation 
of antigen-induced degranulation, for example CCL3 and CCL5 are capable of 
augmenting antigen-induced degranulation in a non-additive manner 
(Laffargue et al., 2002). However it has yet to be demonstrated that 
chemokines are capable of mediating granule release from mast cells via 
degranulation.Therefore it was of interest to discover the expression profile of 
chemokine receptors on the mast cell model utilised in this study and potential 
functions of chemokine receptors on mast cells. 
4.1.2	 Chemokine Expression Profile on Mature Human Cord 
Blood Derived Mast Cells 
There is considerable heterogeneity in the chemokine receptor expression 
profile of mast cells according to species, how they are derived (cord-blood 
versus bone marrow) and their final anatomical location. It was therefore 
important to establish a comprehensive chemokine expression profile for the 
mature human cord blood derived mast cells. 
CCR2 and CCR3 were found to be the most highly expressed chemokine 
receptors present on mature cord blood derived mast cells. CCR1, CXCR3 
and CXCR6 were detected in much lower levels to those found previously 
with CCR2 and CCR3. CCR5, CXCR4 and CXCR7 were present in very low 
levels whereas CCR7 was not detectable at surface levels on mature cord 
blood derived mast cells (Figure 4.1). 
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The aim of this thesis was to investigate the role of CXCR3 agonists in 
degranulation and biochemical signalling responses in mature (approximately 
over 8 week old) human cord blood derived mast cells. In a physiological 
setting CXCR3 agonists have been implicated in a range of inflammatory 
diseases. It is possible therefore that CXCR3 plays a key role in amplification 
of mast cell responses in inflammatory diseases. Of interest was to 
investigate if the inflammatory CXCR3 chemokines were also capable of 
inducing this augmentation of IgE/Ag induced degranulation. 
Figure 4.1 revealed that low levels of CXCR3 were expressed on the surface 
of mature mast cells but with currently 3 known variants of CXCR3 in 
existence it was imperative to try and decipher which variants were expressed 
on the primary mast cell model used in this study. 
Figure 4.1: Chemokine receptor expression profile on mature mast cells. 
Mature mast cells (1 x 106) were stained (40 min, 4 oC) with a specific mouse 
PE or FITC-conjugated anti-chemokine mAb or with appropriately isotype 
matched PE or FITC-conjugated mouse IgG control at the same concentration 
Chemokine receptor expression was determined by flow cytometry as 
described in Materials and Methods. Data is presented as percentage of 
positive staining above isotype control from three different donors. Error bars 
are ± S.E.M 
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4.1.3	 Expression of CXCR3 Variants and CXCR7 on CD133+ 
during Differentiation and Maturation 
Analysis by RT-PCR of CXCR3A, CXCR3B and CXCR3-alt expression during 
differentiation/ maturation of CD133+ cells revealed that mRNA of all CXCR3 
variants was detectable at every stage of differentiation (Fig 4.2). Analysis of 
surface protein expression of CXCR3 revealed low expression in all stages of 
differentiation and maturation of CD133+ cells. Due to the inability of 
commercially available antibodies to CXCR3 to reliably distinguish between 
the different forms of CXCR3, it is impossible to determine which variants are 
present at the surface. The THP-1 cell line was utilised as a comparison of 
CXCR3 variant expression (Figure 4.2). Analysis by RT-PCR of CXCR7 
revealed only progenitor cells possess mRNA for CXCR7. Equal loading of 
mRNA was confirmed by the analysis of the “house-keeping” gene β-actin. 
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Figure 4.2: Expression of CXCR3 variants and CXCR7 at the mRNA in 
different stages of mast cell development. mRNA (5µg) from 5 x 106 
human mast cells or THP-1 was extracted and reverse transcribed in the 
presence (+) or the absence (–) of reverse transcriptase to ensure that 
samples were not contaminated with genomic DNA. mRNA of CXCR3 
variants and CXCR7 was examined using specific primers as described in 
materials and methods. Arrows indicate mRNA expression for each CXCR3 
variant or CXCR7 respectively. Each channel represents a different donor at 
different stages of mast cell maturation/development. Figure below each 
channel represents surface expression at time of extraction as measured 
using FACS. m ; mature, i ; immature, p ; precursor. 
All variants of CXCR3 were expressed at the mRNA level but only low levels 
of protein were detected on the surface. Further investigation throughout the 
differentiation/maturation of CD133+ cells found protein expression of CXCR3 
had robust intracellular expression, but much lower cell surface expression. 
However, intracellular levels of CXCR3 were markedly down-regulated during 
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the differentiation/maturation process, with little change in surface levels 
(Figure 4.3). 
Figure 4.3: Effect of differentiation/maturation on CXCR3 expression in 
mast cells. Mast cells (1 x 106) were sampled at weekly intervals over a 
specific time period of 9 weeks. Samples were stained with a specific mouse 
PE-conjugated anti-CXCR3 mAb or with isotype matched PE-conjugated 
mouse IgG control at the same concentration, and examined by flow 
cytometry as described in Materials and Methods. Data is presented as 
percentage of positive staining above isotype control from three different 
donors, mean ± S.E.M. 
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Further investigation of CXCR3 protein levels in different stages of CD133+ 
differentiation/maturation via western blotting reveal CXCR3 was clearly 
present at all stages of differentiation (Figure 4.4a). Surprisingly, the bands in 
more mature cells became more diffuse, suggesting the possibility of post-
translational modification of CXCR3 by for example glycosylation. 
Although current commercial antibodies do not reliably distinguish between 
variants of CXCR3B, one antibody claims to be specific to CXCR3B. Western 
blotting revealed that at any stage of differentiation, CD133+ cells do not 
express CXCR3B at the predicted molecular weight of ~44kDa (Figure 4.4b). 
In the precursor stage there was a clear band at ~65kDa suggesting that a 
modified form of CXCR3B may be present at this stage. The THP-1 cell line 
was used as a positive control and reveals two bands, one at the expected 
molecular weight for CXCR3B and a higher band that was also found in the 
precursors (Figure 4.4b). Probing for CXCR7 revealed no protein expression 
in either cell model (Figure 4.4c). The proposed molecular weight of CXCR7 is 
41kDa, however as this is only one experiment, further experiments are 
needed to prove that the lack off expression is not only due to non binding of 
the anti-CXCR7 antibody. 
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Figure 4.4: Expression of CXCR3 variants and CXCR7 via western blots. 
Mast cells or THP-1 (1×106 cells/ml) taken from different stages of 
maturation/development were lysed by the addition of 1× sample buffer. Cell 
lysates were resolved by SDS-PAGE, transferred to nitrocellulose 
membranes, and immunoblotted with antibodies specific for a) CXCR3, b) 
CXCR3-B and c) CXCR7. Proteins were visualised with ECL and blots were 
stripped and reprobed with anti-actin Ab to verify equal loading and efficiency 
of protein transfer (lower panel). Panels a and b are representative of three 
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other experiments, panal c is derived from a single experiment. W; no of 
weeks in culture. 
To further explore the possible expression of CXCR3B, we utilised the specific 
CXCR3B antibody to investigate surface expression of CXCR3B. There was 
no detectable surface expression of CXCR3B through any stage of 
differentiation/maturation. THP-1 cells utilised as a positive control only 
demonstrated moderate levels of CXCR3B on the surface (Figure 4.5). 
Figure 4.5: FACS expression of CXCR3B. Mast cells or THP-1 (1 x 106) 
were stained with a specific mouse anti-CXCR3B mAb or with isotype 
matched PE-conjugated mouse IgG control at the same concentration for 30 
mins. Excess primary antibody was washed off and incubated with an anti-
mouse PE-conjugated secondary antibody and examined by flow cytometry 
as described in Materials and Methods. Data is representative of FACS 
staining from 2 different donors at different stages of maturation. 
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4.1.4	 CXCR3 Agonists Induce Phosphorylation of the Protein Akt 
and ERK1/2 
A range of biochemical signals are robustly induced by chemokine agonists; 
including the activation of PI3K and MAPK pathways. Therefore biochemical 
studies focused on establishing whether CXCR3 agonists could activate either 
of these pathways in the mature mast cells. To establish whether PI3K was 
activated in response to CXCR3 receptor stimulation, the phosphorylation of 
Akt was monitored. Akt is a serine/threonine kinase, whose recruitment; 
phosphorylation and subsequent activation are entirely dependent upon the 
lipid products produce by induction of the PI3K pathway. For MAPK activity 
the phosphorylation of ERK1/2 was monitored as this has been observed to 
be the major pathway preferentially activated by chemokines. All the CXCR3 
agonists were observed to induce phosphorylation of Akt and ERK1/2 (Figure 
4.6). 
Figure 4.6: CXCR3 agonists induce phosphorylation of the protein Akt 
and ERK1/2. Mature mast cells (1×106 cells/ml) were left untreated or 
stimulated at 37 °C with CXCR3 agonist for indicated time period and lysed by 
the addition of 1× sample buffer. Cell lysates were resolved by SDS-PAGE, 
transferred to nitrocellulose membranes and immunoblotted with a phospho-
specific Erk or Akt Ab and proteins were visualised with ECL. The blots were 
stripped and reprobed with anti-Akt Ab to verify equal loading and efficiency of 
protein transfer (lower panel). The data is representative of three other 
experiments. 
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4.1.5	 CXCR3 Induced Partial Degranulation of Cord Blood 
Derived Mast Cells 
Before studying whether CXCR3 agonists were able to effect antigen induced 
mast cell degranulation, it was assessed whether treatment with CXCR3 
agonists alone were able to induce degranulation of mature mast cells. Mast 
cell degranulation was assessed by measurement of β-hexosaminidase 
release. At concentrations <10nM, CXCR3 agonists were unable to induce 
release β-hexosaminidase above basal levels. However, at concentrations 
>100nM each agonist elicited partial degranulation, which represented around 
40-45% of control ionomycin induced β-hexosaminidase release (Fig 4.7a). 
The peak response of degranulation mediated by all CXCR3 agonists was 
detected after 1 min post stimulation (Fig 4.7b). Interestingly, CXCL4 induced 
significant degranulation comparable to the classical CXCR3 agonists. 
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Figure 4.7: Effect of CXCL9, CXCL10, CXCL11 and CXCL4 on mast cell 
degranulation. Mature mast cells (1x106/ml) were treated overnight with 
chimeric human Fc anti-4-hydroxy-3-nitrophenylacetyl (NP)-specific IgE 
(1µg/ml). The cells were then treated with a) CXCL9, CXCL10, CXCL11 or 
CXCL4 at concentration indicated or 100ng/ml NP-BSA(IgE/Ag) for 1.5 hours 
or b) indicated time period at 100nM of agonist. Control in b) was treated for 
1.5 hours. Samples were centrifuged for 10 mins and supernatant transferred 
to a new wells before addition of β-hexosaminidase substrate for 1.5 hours to 
measure β-hexosaminidase release. Data are expressed as % total β-
hexosaminidase content. Results are expressed as mean ± SEM of 4 
experiments performed in triplicate. 
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The induction of partial degranulation in the absence of antigen by CXCR3 
agonists was a surprising finding. Therefore it was important to investigate the 
role of other chemokine receptors in this process. Using human cord blood 
derived mast cells as a model, it emerged that several chemokines operating 
through different chemokine receptors such as CCR3 and CCR2 can induce 
partial degranulation of mature mast cells in the absence of antigen (Fig 4.8). 
Figure 4.8: Several chemokines induce partial degranulation of human 
mast cells. Mature mast cells (1x106/ml) were treated overnight with chimeric 
human Fc anti-4-hydroxy-3-nitrophenylacetyl (NP)-specific IgE (1µg/ml). Cells 
were treated with specific chemokine at concentration of 100nM for 1.5hours. 
Samples were centrifuged for 10 mins and supernatants transferred to new 
wells before addition of β-hexosaminidase substrate for 1.5 hours to measure 
β-hexosaminidase release. Data are expressed as % total β-hexosaminidase 
content. Results are expressed as mean ± SEM of 4 experiments performed 
in triplicate. 
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4.1.6	 CXCR3 Induced Partial Degranulation of Human Mast Cells 
is PTX Sensitive 
Previous studies have found that CXCR3A and CXCR3-alt-mediated 
responses are PTX sensitive indicating that they couple to Gαi/o, whereas 
CXCR3B responses are PTX insensitive. It was interesting that in the 
presented thesis observed a biochemical and functional response from 
CXCL4, despite no detectable expression of CXCR3B - the only known 
chemokine receptor for CXCL4 to date. Pre-treatment of mature mast cells 
for 16 hours with 10ng/ml PTX inhibited the partial degranulation observed in 
response to CXCL9, CXCL10 and CXCL11 (Figure 4.9). This suggests that 
the responses are mediated by a Gαi/o-coupled form of CXCR3. However in 
direct conflict with the study by blah et al the partial degranulation induced by 
the CXCR3B agonist; CXCL4 was also inhibited by pre-treatment of cells with 
PTX (Figure 4.9). 
Figure 4.9: Effect of PTX treatment on CXCR3 agonist induced partial 
degranulation. Mature mast cells (1x106/ml) were treated overnight with 
chimeric human Fc anti-4-hydroxy-3-nitrophenylacetyl (NP)-specific IgE 
(1µg/ml). Cells were stimulated with 100nM of appropriate CXCR3 agonist for 
1 hour in presence or absence of PTX 10ng/ml pre-treatment for 16hrs. 
Samples were centrifuged for 10mins and supernatants transferred to new 
wells before addition of β-hexosaminidase substrate for 1.5 hours to measure 
β-hexosaminidase release. Data are expressed as % total β-hexosaminidase 
content. Results are expressed as mean ± SEM of 4 experiments performed 
in triplicate. 
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4.1.7	 CXCR3 Agonist­ Induced Degranulation is CXCR3 
Dependent. 
With the surprising finding that chemokines could induce partial degranulation 
of cord blood mature mast cells, it was important to verify that the partial 
degranulation induced by CXCL9 CXCL10, CXCL11 and CXCL4 was indeed 
mediated by CXCR3. It was possible that the response observed was due to 
potential contamination of the CXCR3 ligands with LPS, or that the ligands 
could be potentially mediating the effect via another chemokine receptor. 
Therefore it was important to clarify that CXCR3 was responsible for 
activating these responses. 
In recent years several classes of small-molecule compounds targeting 
CXCR3 have recently been described, including 4-N-aryl- [1,4] diazepane 
ureas (Cole et al., 2006), 1-aryl-3-piperidin- 4-yl-urea derivatives (Allen et al., 
2007), quinazolin-4-one, 3H-pyrido[2,3-d]pyrimidin-4-one derivatives (Heise et 
al., 2005; Storelli et al., 2005) (Johnson et al., 2007; Storelli et al., 2007), and 
quaternary ammonium anilide TAK-779 which also shares affinity for CCR5, 
CCR2b, (Gao et al., 2003). 
This study utilised three of these small non-peptide, non-competitive CXCR3 
antagonists namely, T487 (reported IC50 – 8nM), NBI-74330 (reported IC50 7– 
18 nM) and N-Oxide metabolite NBI-74330. Accordingly, both T487 (Fig 
4.10a) and NBI-74330 (Fig 4.10b) potently inhibited the degranulation induced 
by CXCR3 agonists. N-Oxide metabolite NBI-74330 was less potent than the 
other compounds but still demonstrated clear inhibition of CXCR3 induced 
degranulation (Figure 4.10c) In contrast, all three compounds were unable to 
inhibit partial degranulation that was induced by CCL2, a known agonist for 
CCR2 (Fig 4.10 a, b and c). 
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Figure 4.10: Effect of CXCR3 antagonist on CXCR3 and CCR2 induced 
partial degranulation. Mature mast cells (1x106/ml) were treated overnight 
with chimeric human Fc anti-4-hydroxy-3-nitrophenylacetyl (NP)-specific IgE 
(1µg/ml). Mast cells were treated with a selective CXCR3 antagonist at 
concentration indicated for 30 mins before stimulation with CXCR3 or CCR2 
agonist for 1 hour. Samples were centrifuged for 10 mins and supernatants 
transferred to new wells before addition of β-hexosaminidase substrate for 1.5 
hours to measure β-hexosaminidase release. Data are expressed as % 
inhibition of chemokine agonist response. Results are expressed as mean ± 
SEM of 4 experiments performed in triplicate. 
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4.1.8	 CXCR3 Induced Biochemical ignalling are CXCR3 
Dependent 
As demonstrated previously, CXCR3 agonists are able to induce robust 
biochemical signalling responses as demonstrated by the phosphorylation of 
ERK1/2 and Akt. To determine that these responses are mediated by 
activation of CXCR3; mast cells were pre-treated with 300 nM of either T487 
or NBI-74330 for 30 mins before stimulation with agonists. Both compounds 
were able to block phosphorylation of ERK1/2 and Akt induced by CXCL9, 
CXCL10, CXCL11 and CXCL4 (Fig 4.11). However Akt and ERK1/2 
phosphorylation induced by the CCR2 and CCR4 ligand CCL2 was unaffected 
by pre-treatment with either inhibitor. 
Figure 4.11: CXCR3 agonist dependent signalling. Mature mast cells 
(1×106 cells/ml) were treated with a selective CXCR3 antagonist at 
concentration indicated for 30 mins before stimulation with CXCR3 agonist for 
2 min and lysed by the addition of 1× sample buffer. Cell lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and 
immunoblotted with a phospho-specific Erk1/2 or Akt Ab and proteins were 
visualised with ECL. The blots were stripped and reprobed with anti-Akt Ab to 
verify equal loading and efficiency of protein transfer (lowest panel). The data 
is representative of three other experiments. 
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4.1.9 CCL2 Induced Partial Degranulation is CCR2 Dependent. 
CCL2 induced degranulation of mature cord blood derived mast cells was not 
inhibited by any of the CXCR3 antagonists utilised in this study. It was 
therefore important to investigate which chemokine receptor that this 
response was mediated by as CCL2 is a known agonist for CCR2. 
Accordingly this study utilised the CCR2 antagonist, RS102895 to investigate 
the CCL2 induced degranulation response. Figure 3.24 reveals that CCL2 
induced degranulation of mature cord blood mast cells was inhibited by pre-
treatment with RS102895. This compound was unable to inhibit CXCR3 
agonist induced degranulation indicating that the CXCR3 induced responses 
are not dependent on CCR2 (Figure 4.12). 
Figure 4.12: Effect of CCR2 antagonist on CXCR3 and CCR2 agonist 
induced partial degranulation. Mature mast cells (1x106/ml) were treated 
overnight with chimeric human Fc anti-4-hydroxy-3-nitrophenylacetyl (NP)-
specific IgE (1µg/ml). Mast cells were treated with a selective CCR2 
antagonist, RO102895, at concentration indicated for 30 mins before 
stimulation with CXCR3 or CCR2 agonist for 1 hour. Samples were 
centrifuged for 10 mins and supernatant transferred to new well before 
addition of β-hexosaminidase substrate for 1.5 hours to measure β-
hexosaminidase release. Data is expressed as % inhibition compared to each 
agonist response. Results are expressed as mean ± SEM of 4 experiments 
performed in triplicate. 
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4.1.10 Other	 Chemokines unable to Elicit Degranulation 
Responses are still able to Stimulate Biochemical Responses. 
The induction of partial degranulation in the absence of antigen by a range of 
different chemokine receptor agonists was a surprising finding. Although not 
all the chemokine agonists utilised in this study were capable of inducing the 
partial degranulation. CXCL12 and CXCL16, agonists for CXCR4 and CXCR6 
respectively did not induce partial degranulation of human mature cord blood 
derived mast cells (Figure 4.8). This led to the question can chemokines 
induce biochemical signals such as PI3K and MAPK, without inducing partial 
degranulation. CXCL16 did not induce activation of Akt or ERK1/2 in mature 
mast cells. However CXCL12 did induce phosphorylation of ERK1/2 and Akt 
(Figure 4.13) indicating that activation of these pathways alone is not 
sufficient to induce degranulation. Therefore other signalling pathways would 
be hypothesised to be involved in chemokine receptor induced degranulation. 
Figure 4.13: CXCL12 elicits biochemical responses in mast cells. Mature 
mast cells (1×106 cells/ml) were left untreated or stimulated at 37 °C with 
CXCL12 or CXCL16 for indicated time period and lysed by the addition of 1× 
sample buffer. Cell lysates were resolved by SDS-PAGE, transferred to 
nitrocellulose membranes, and immunoblotted with a phospho-specific Erk or 
Akt Ab and proteins were visualised with ECL. The blots were stripped and 
reprobed with anti-Akt Ab to verify equal loading and efficiency of protein 
transfer (lower panel). The data is representative of three other experiments. 
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4.1.11 CXCR3	 Agonists Augment Sub­Optimal Ag Induced 
Degranulation 
The surprising finding that CXCR3 agonists induce partial degranulation of 
mature human cord blood derived mast cells made it crucial to re-visit the 
original hypothesis and idea behind this study that CXCR3 agonists could 
induce augmentation of sub-optimal Ag induced degranulation. 
Figure 4.14: CXCR3 augmentation of sub­optimal IgE/Ag. Mature mast 
cells (1x106/ml) were treated overnight with chimeric human Fc anti-4-
hydroxy-3-nitrophenylacetyl (NP)-specific IgE (1µg/ml). Mature mast cells 
were treated overnight with chimeric human Fc anti-4-hydroxy-3-
nitrophenylacetyl (NP)-specific IgE (1µg/ml). Cells were stimulated with 
10ng/ml Ag for 1 min before stimulation with CXCR3 or CCR2 agonist for 1 
hour. Samples were centrifuged for 10mins and supernatants transferred to 
new wells before addition of β-hexosaminidase substrate for 1.5 hours to 
measure β-hexosaminidase release. Data are expressed as % total β-
hexosaminidase release. Results are expressed as mean ± SEM of 4 
experiments performed in triplicate. 
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Figure 4.14 revealed that all CXCR3 agonists are capable of augmenting sub-
optimal degranulation induced by sub-optimal concentrations of antigen (as 
determined in Figure 3.7). Sub-optimal concentrations of Ag or treatment with 
CXCR3 agonists alone induced partial degranulation; this ranged from 25-
35% of total β-hexosaminidase release (Figure 4.14). This could imply that 
the augmentation observed is more than a purely additive effect of the two 
individual stimulations. 
The augmentation of sub-optimal Ag induced degranulation by CXCR3 
agonists was CXCR3 dependent. Pre-treatment of mature human cord blood 
derived mast cells with either T487 or NBI-74330 inhibited the potentiation in 
degranulation seen with CXCR3 ligand treatment (Figure 4.15 a and b). The 
CXCR3 antagonists were unable to fully inhibit the degranulation responses 
indicating that these antagonists are unable to inhibit degranulation induced 
by sub-optimal concentrations of Ag (Figure 4.15 a and b). The respective 
IC50s for each antagonist to each CXCR3 agonist are shown in figure 4.15c. 
150

Chapter 4 – Role of CXCR3 in Cord Blood Derived Mast Cells.

Figure 4.15: CXCR3 augmentation of sub­optimal IgE/Ag is CXCR3 
dependent. Mature mast cells (1x106/ml) were treated overnight with chimeric 
human Fc anti-4-hydroxy-3-nitrophenylacetyl (NP)-specific IgE (1µg/ml). Cells 
were treated with a selective CXCR3 antagonist at concentrations indicated 
for 30 mins before stimulation with 10ng/ml Ag for 1 min followed by 
stimulation with a CXCR3 or CCR2 agonist for 1 hour. Samples were 
centrifuged for 10mins and supernatants transferred to new wells before 
addition of β-hexosaminidase substrate for 1.5 hours to measure β-
hexosaminidase release. Data are expressed as % of the total β-
hexosaminidase release. Results are expressed as mean ± SEM of 4 
experiments performed in triplicate. 
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4.1.12 Up­regulation	 of Mast Cell Markers Stored within the 
Granules 
Granule translocation to the plasma membrane is a key process for mast cells 
to degranulate. Two such markers that are utilised to investigate activation of 
myeloid linage cells are CD63 and CD203c; which are both upregulated in 
response to allergen challenge. CD63 is a 53-kDa glycoprotein present on the 
lysosome membrane of various cells. It has been reported to be able to 
translocate to the plasma membrane after activation in a wide variety of cell 
types (Jaiswal et al., 2002) and plays an important role in intracellular 
trafficking, recycling of plasma membrane components and integrin-
dependent post-adhesion functions. It has been previously demonstrated to 
be expressed at a high density on activated basophil membrane (Metzelaar et 
al., 1991). Furthermore in the mast cell RBL model, CD63 has been shown to 
colocalise with SNARE proteins syntaxin 3 and VAMP7, which are involved in 
fusion of secretary granules with plasma membranes (Puri et al., 2003). 
CD203c expression among hematopoietic cells is restricted to basophils, mast 
cells and their precursors and has been described as specific for this lineage 
(Bühring et al., 1999). Due to its restricted expression pattern, CD203c is 
used as a specific marker to monitor the allergen-induced activation of mast 
cells. 
Previously reported in this study was the induction of partial degranulation by 
CXCR3 agonists. By inducing degranulation it was possible that the fusing of 
the membrane and the granules could lead to an upregulation of the markers 
CD63 and CD203c. Figure 4.16 demonstrates that both CD63 and CD203c 
are up-regulated after activation of mature mast cells derived from cord blood 
in response to CXCR3 ligands. The number of cells expressing positive 
staining for each of these molecules after stimulation by CXCR3 agonists was 
approximately 50% of the levels induced by treatment with the calcium 
ionophores; ionomycin. This finding is consistent with previous data in this 
study; demonstrating that CXCR3 induced degranulation is only half the level 
observed with ionomycin treatment. 
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a) 
b) 
CD63 
CD203c 
Figure 4.16: Expression of CD63 and CD203c after CXCR3 activation­
Mature mast cells (1x106/ml) were treated with CXCR3 specific agonists 
(100nM) or ionomycin (1µM) for 1.5 hours. Samples were centrifuged for 10 
mins and supernatant removed and remaining cells were collected. Mature 
mast cells (1 x 106) were stained with a specific mouse-conjugated anti-CD63 
(a) or CD203c (b) mAb or with appropriately isotype matched PE or FITC-
conjugated mouse IgG control at the same concentration. Antibodies were 
incubated for 40 mins at 4oC and staining examined by flow cytometry as 
described in Materials and Methods. Data is presented as percentage of 
positive staining above isotype control from three different donors. N = 3, 
mean ± S.E.M 
153

Chapter 4 – Role of CXCR3 in Cord Blood Derived Mast Cells. 
4.1.13 Reorganisation	 of the cell membrane is critical for 
degranulation 
Several studies have suggested the involvement of cytoskeletal 
rearrangements in mast cell degranulation. Actin polymerisation-inhibiting 
agents increase both the rate and extent of FcεRI-induced degranulation 
(Frigeri and Apgar, 1999; Oka et al., 2002) and biochemical studies indicated 
that FcεRI stimulation causes a rapid increase in the level of F-actin in RBL 
mast cells (Frigeri and Apgar, 1999; Pfeiffer et al., 1985). Furthermore, 
activation-induced rearrangement of microtubules is observed in rat peritoneal 
mast cells while tubulin polymerisation inhibiting agents block degranulation 
(Martin-Verdeaux et al., 2003; Nielsen and Johansen, 1986; Tasaka et al., 
1991). The precise roles of the cytoskeletal rearrangements in the mast cell 
degranulation process have not been established. 
With the finding in this study that CXCR3 agonists can induce the partial 
degranulation of mature cord blood derived mast cells, it was therefore likely 
CXCR3 agonists were inducing the re-organisation of the cytoskeleton in 
order to mediate the release of granules from mature mast cells. The three 
“classical” CXCR3 ligands previously have been shown to induce actin 
reorganization in intestinal myofibroblasts (Kouroumalis et al., 2005). 
Figure 4.17 demonstrates that all four CXCR3 agonists can induce an 
increase in phalloidin binding indicative of actin polymerisation. Maximal actin 
polymerisation was observed for each agonist around 1-2 mins after 
stimulation with the levels of F-actin present decreasing back to basal after a 
10 min stimulation (Fig 4.17). 
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Figure 4.17: CXCR3 agonists induce actin polymerisation in mature cord 
blood derived mast cells. Human mature cord blood derived mast cells 
(1x106) were stimulated with CXCR3 agonists (100 nM) for the time periods 
indicated. Cells were fixed in 4% paraformaldehyde and permeabilised using 
1% TRITON-X. Cells were stained with 0.3µM phallodin for 40mins at 4oC. 
Samples were washed and re-suspended and analysed using a FACs canto. 
Data is presented as percentage of positive staining above negative control 
from three different donors. N = 3, mean ± S.E.M. 
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4.1.14 Polymerisation	 of Actin by CXCR3 Agonists is CXCR3 
Dependent 
The reorganisation of actin by CXCR3 agonists further supported the 
evidence that CXCR3 agonists are capable of releasing mediators from 
mature mast cells. Figure 4.18 demonstrates that pre-treatment of human 
cord blood derived mast cells with the CXCR3 antagonists; T487 or NBI-
74330 blocked CXCR3 but not CCR2 agonist induced actin reorganisation. 
This indicates that the CXCR3 agonists are only utilising a form of CXCR3 
able to induce the reorganisation of the cellular membrane. 
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Figure 4.18: CXCR3 agonists reorganise actin filaments in mature cord 
blood derived mast cells in a CXCR3 dependent manner. Human mature 
cord blood derived mast cells (1x106) were incubated in the presence or 
absence of either T487 (300 nM, 30mins) or NBI-74330 (300 nM, 30mins) 
before stimulation with CXCR3 agonists (100nM, 2 min) Cells were fixed in 
4% paraformaldehyde and permeabilised using 1% TRITONX. Cells were 
stained with 0.3µM phallodin for 40mins at 4oC. Samples were washed and 
re-suspended and analysed using a FACs canto. Data is presented as 
percentage of positive staining above negative control ± S.E.M. taken from 3 
different donors. 
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4.1.15 Involvement of Rho kinase in Actin Reorganisation

Localised disassembly of cortical F-actin has long been considered necessary 
for facilitation of exocytosis. Exposure of permeabilised mast cells to 
calcium/ATP induces cortical F-actin disassembly (calmodulin-dependent) and 
secretion (calmodulin-independent) (Sullivan et al., 1999). The signals that 
generate the actin filament reorganization are often mediated by several 
theronine kinases such as Rho kinase (ROCK). Pre-treatment of human mast 
cells with the ROCK inhibitor Y27632 completely inhibited the partial 
degranulatory response induced by all of the CXCR3 agonists (Figure 4.19). 
Figure 4.19 – Inhibitory effect of Rho kinase inhibitor on CXCR3 induced 
partial degranulation. Human mast cells (1x106) were pre-treated with 
Y27632 (30 min) at the concentrations indicated, before stimulation with 
CXCR3 agonists (100nM, 1hr). Samples were centrifuged for 10mins and 
supernatant transferred to new wells before addition of β-hexosaminidase 
substrate for 1.5 hours to measure β-hexosaminidase release. Data are 
expressed as % inhibition of agonist response. Results are expressed as 
mean ± SEM of 4 experiments performed in triplicate. 
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There is an overlap in cellular functions regulated by Rac and class I PI3K. 
CXCR3 can activate Rac via PIP3-dependent Rac guanine nucleotide 
exchange factors (GEFS) (Wang et al., 2002). With the discovery that both 
Rho kinase and PI3K were involved in the mechanism behind CXCR3 
induced partial degranulation, it was important to determine if both kinases 
were activated at different times. The reorganisation of actin occurs in the 
latter stages of the degranulation process in order to mediate the release of 
the mast cell mediators. Figure 4.20 reveals that ROCK but not PI3K is 
involved in the polymerisation of actin filaments suggesting that PI3K is 
involved in a much earlier stage of the degranulation mechanism, possibly in 
the mobilisation, but not the release of mast cell mediators. 
1µM 
10µM 
1µM 
10µM 
1µM 
10µM 
1µM 
10µM 
Figure 4.20 – Reorganisation of actin filaments in mature cord blood 
derived mast cells is RHO kinase but not PI3K dependent. Human 
mature cord blood derived mast cells (1x106) were incubated in the presence 
or absence of either a PI3K (ZSTK474, 1 µM, 30mins) or ROCK (Y27632, 10 
µM, 30mins) inhibitor before stimulation with CXCR3 agonists (100nM, 2 
mins). Cells were fixed in 4% paraformaldehyde and permeabilised using 1% 
TRITONX. Cells were stained with 0.3µM phallodin for 40mins at 4oC. 
Samples were washed and re-suspended and analysed using a FACs canto. 
Results are expressed as mean ± SEM of 4 experiments performed in 
triplicate. 
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4.1.16 CXCR3	 Agonists do not Induce Calcium Mobilisation in 
Mature Mast Cells 
Elevation of cytosolic calcium levels is one of the most robust biochemical 
signals elicited by chemokine agonists (Heise et al., 2005). Interestingly, 
treatment of mature mast cells with all of the CXCR3 agonists at a 
concentration of 100nM failed to induce an increase in cytosolic calcium 
(Figure 4.21). Treatment of mature mast cells with 100ng/ml Ag did induced 
prolonged increases in cytosolic calcium concentrations in mature mast cells. 
Figure 4.21: Cytosolic Ca2+ levels do not increase in mast cells 
stimulated with CXCR3 agonists. Mature mast cells (50µl; 350,000 cells) 
were prepared and treated as described in the Material\Methods section. 
CXCR3 agonist (100 nM) or Ag (NP-BSA) (100 ng/ml) were applied to FLUO-
4 AM loaded mast cells and fluorescence levels were recorded using a 
FLEXstation. Traces are representative of 3 different experiments. 
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Although no increases in intracellular Ca2+ was detectable in mast cells, figure 
4.22 clearly demonstrates that Ca2+ is required for induction of mast cell 
degranulation. Treatment of mature mast cell with CXCR3 agonists in either 
Ca2+ free buffer or in the presence of 1mM EGTA failed to induce 
degranulation of mature cord blood derived mast cells. 
Figure 4.22: Effect of different extracellular Ca2+ conditions on mast cell 
degranulation. Human mature cord blood derived mast cells (1x106) in 
indicated buffers (See Materials and Methods) were stimulated CXCR3 
agonists (100 nM, 1hr). Samples were centrifuged for 10mins and supernatant 
transferred to new wells before addition of β-hexosaminidase substrate for 1.5 
hours to measure β-hexosaminidase release. Data are expressed as % total 
β-hexosaminidase release. Results are expressed as mean ± SEM of 4 
experiments performed in triplicate. 
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4.1.17 The	 Role of PLC of CXCR3 Induced Mast Cell 
Degranulation. 
The signalling cascade involved in inducing mast cell degranulation requires 
the recruitment and activation of many different kinases and other signalling 
proteins. One pivotal step is the activation of phospholipase Cγ1 and 2 
(PLCγ1/2), leading to hydrolysis of the lipid substrate PIP2 resulting in the 
formation of two key signalling intermediates, diacylgylercol (DAG) and 
inositol 1,4,5-triphosphate (IP3). DAG is the physiological activator of PKC and 
IP3 the ligand for the IP3 channel receptor (Berridge et al., 2003). 
One of the major mechanisms by which calcium is mobilised from intracellular 
stores is via the binding of IP3 on to its receptor located on the endoplasmic 
reticulum (ER) resulting in the release of Ca2+ from the ER into the cytoplasm. 
PLCß can be activated by the Gßγ sub-units after chemokine receptor ligation 
(Jiang et al., 1997; Wu et al., 1992). To determine whether the increase in 
[Ca2+]i following ligation of the CXCR3 receptor requires the enzymatic 
function of PLC isoforms, the use of U73122 a broad spectrum 
pharmacological inhibitor of PLC isoforms was emplyed. U73122 is reported 
to have an IC50 between 500 nM and 2.1 µM (Smith et al., 1996). 
CXCR3-agonist induced degranulation was abolished by U73122 but not by 
its inactive derivative U73343 indicating that PLC plays a role in the induction 
of CXCR3 induced partial degranulation of human cord blood derived mast 
‘ cells (Figure 4.23 a-d). The respective IC50 s for each agonist are shown in 
Figure 4.23e. 
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Figure 4.23: Effect of PLC inhibitors on CXCR3 mediated degranulation. 
Human mast cells (1x106) were treated with either U73122 or U73343 (30 
min) at concentrations indicated before stimulation with CXCR3 agonists (100 
nM, 1hr). Samples were centrifuged for 10mins and supernatant transferred to 
new wells before addition of β-hexosaminidase substrate for 1.5 hours to 
measure β-hexosaminidase release. Data are expressed as % inhibition of 
agonist response. Results are expressed as mean ± SEM of 4 experiments 
performed in triplicate. 
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The compound 2-aminoethyl diphenylborate (2-APB: also blocks TRP 
channels), an inhibitor of IP3 receptors in some cell types, has been used to 
assess the role of IP3R mediated increases in intracellular Ca2+ (Ma et al., 
2001). 2-APB has been described as an inhibitor of calcium release from IP3 
stores without affecting binding of IP3 to IP3R and has a reported IC50 of 42 
µM (Ascher-Landsberg et al., 1999). The data presented in this study 
suggests that the mobilisation of intracellular Ca2+ is required in the 
degranulation process. Figure 4.24a reveals that pre-treatment with the IP3R 
inhibitor 2-APB strongly inhibits CXCR3 induced degranulation. The 
respective IC50s for each agonist are shown in Figure 4.24b. 
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Log[2­APB] 
Degranulation IC50(µM) 
2­APB 
CXCL9 57.3 
CXCL10 34.9 
CXCL11 33.5 
CXCL4 18.6 
Figure 4.24: Effect of IP3 inhibition on CXCR3 induced degranulation. 
Human mast cells (1x106) were treated with 2-APB (30 min) at concentrations 
indicated before stimulation with CXCR3 agonist (100nM, 1 hr). Samples were 
centrifuged for 10mins and supernatant transferred to new wells before 
addition of β-hexosaminidase substrate for 1.5 hours to measure β-
hexosaminidase release. Data are expressed as % inhibition of agonist 
response. Results are expressed as mean ± SEM of 4 experiments performed 
in triplicate. 
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4.2 The Role of PI3K in CXCR3 Induced Degranulation

The signalling mechanism that induces the degranulation of mature mast cells 
is a complex process involving a wide range of different signalling molecules. 
With the reported role of PI3K isoforms in IgE/Ag-mediated mast activation 
and degranulation, the role of PI3K in the degranulation of human cord blood 
derived mast cells by CXCR3 agonists was assessed. This was evaluated by 
inducing degranulation by CXCR3 agonists in the presence of increasing 
concentrations of the PI3K inhibitor ZSTK474. Pre-treatment of mast cells 
with ZSTK474 was observed to induce dose-dependent inhibition of CXCR3 
agonist induced-degranulation of mast cells (Fig 4.25). 
Figure 4.25: Effect of PI3K inhibitor on CXCR3 agonist degranulation. 
Human mast cells (1x106) were pre-treated with increasing concentrations of 
ZSTK474 (30mins) followed by stimulation with CXCR3 agonists (conc, 1hr). 
Samples were centrifuged for 10mins and supernatant transferred to new 
wells before addition of β-hexosaminidase substrate for 1.5 hours to measure 
β-hexosaminidase release. Data are expressed as % inhibition of agonist 
response. Results are expressed as mean ± SEM of 4 experiments performed 
in triplicate. 
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In the last decade, evidence has suggested that the PI3K catalytic subunit 
p110γ may play a role in mast cell hyperactivation. This is thought to occur via 
an auto/paracrine mechanism, whereby GPCR agonists released FcεRI 
activated mast cells can relieve PI3K negative regulation by antagonising the 
lipid phosphatases SHIP and PTEN (Harris et al., 2008). Recent studies 
employing the use of murine models demonstrated that both the PI3K 
isoforms p110γ and p110δ are required for FcεRI-driven mast cell 
degranulation in vitro, however in vivo p110 γ is required whereas p110δ is 
dispensable for allergic responsiveness (Ali et al., 2004; Ali et al., 2008; 
Laffargue et al., 2002). 
Isoform-specific PI3K inhibitors were employed to investigate the role of 
individual PI3K catalytic isoforms in CXCR3-induced degranulation. The 
inhibitors utilised were IC87114 for PI3Kδ, TGX-221 for p110β , TGX-121 for 
PI3Kβ/PI3Kδ, PIK75 for PI3Kα and AS605240 for PI3Kγ. 
PIK75, which displays around 116-fold selectivity against PI3Kα versus the δ 
isoform, was observed at concentrations around the predicted IC50 to have no 
effect on mast cell degranulation induced by CXCR3 agonists (Figure 4.26a). 
Figure 4.26b reveals that at the predicted IC50 for p110β inhibitor TGX-221 
there is no inhibition of CXCR3 agonist induced degranulation. Whereas the 
equipotent inhibitor of p110β and p110δ; TGX-121 was observed to have a 
strong inhibitory effect on CXCR3 induced degranulation (Figure 4.26c). The 
IC50 for TGX-121 on CXCR3 induced degranulation is well below the 
predicted impingement of the next PI3K isoform. This would suggest that 
p110δ is the dominant isoform involved in CXCR3 induced degranulation 
however the p110δ -discriminating inhibitor IC87114 only partially inhibits 
CXCR3 agonist induced degranulation at the quoted IC50 for the p110δ 
isoform (Figure 4.26d). Furthermore there is only any notable inhibition of 
CXCR3 agonist induced degranulation when the inhibitor concentration 
reaches levels expected to impinge on p110β. This therefore suggests a 
synergy between the p110β and p110δ catalytic isoforms of PI3K in promoting 
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CXCR3 evoked mast cell degranulation. These findings compares to my 
previous observation that IgE/Ag induced degranulation that reported a good 
correlation between IC50’s obtained for IC87114 against p110δ using purified 
enzyme versus IC50’s derived from cell based assays (Crabbe et al., 2007; 
Knight et al., 2006; Smith et al., 2007). 
AS605240 displays around 10-fold selectivity against p110γ versus α 
isoforms but approximately 35-fold selectivity vs δ/β. AS605240 inhibited 
CXCR3 agonist induced β-hexosaminidase release with an IC50 comparable 
to its reported IC50 for p110γ (Figure 4.26e) and possible concerns about off-
target effects of AS606240 on p110α at concentrations >10 nM seem 
unfounded, as the p110α-targeting inhibitor PIK75 had no effect on 
degranulation (Figure 4.26e). Table 4.1 lists the IC50 values of each PI3K 
isoform inhibitor against degranulation induced by each CXCR3 agonist. 
Similar IC50’s for each inhibitor where observed against each CXCR3 agonist. 
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Figure 4.26: Effect of PI3K isoform specific inhibitors on CXCR3 agonist 
induced degranulation. Human mast cells (1x106) were pre-treated with 
increasing concentrations of PI3K isoform-discriminating inhibitors (30 min) 
before stimulation with CXCR3 agonist (100nM, 1hour). Samples were 
centrifuged for 10mins and supernatant transferred to new wells before 
addition of β-hexosaminidase substrate for 1.5 hours to measure β-
hexosaminidase release. Data are expressed as % inhibition of chemokine 
agonist responses. Results are expressed as mean ± SEM of 4 experiments 
performed in triplicate. 
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IC50 (�M) 
CXCL9 CXCL10 
CXCL11 
CXCL4 IgE/Ag 
PIK75 >0.1 >0.1 >0.1 >0.1 0.65 
TGX-221 >0.1 >0.1 >0.1 >0.1 0.44 
TGX-121 0.046 0.028 0.033 0.026 0.031 
IC87114 10.66 15.49 16.65 19.92 4.81 
AS605240 0.0101 0.0124 0.0151 0.0105 0.0228 
ZSTK474 0.003 0.064 0.108 0.124 0.637 
Table 4.1 ­ IC50 values for inhibition of degranulation induced by CXCR3 
agonists and IgE/Ag were obtained by comparing concentration-dependent 
effects of individual inhibitors against optimal degranulation in response to 
100 nM of specific chemokines or 100ng/ml NP-BSA(Ag). N = 4. 
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4.2.1	 Further Assessing the Role of p110δ and p110β in Mast Cell 
Degranulation 
The finding that IC87114 and TGX-221 did not inhibit degranulation induced 
by both IgE/Antigen and CXCR3 agonists at their predicted IC50 values, yet 
TGX-121 inhibited CXCR3 induced degranulation responses, suggested the 
potential synergy of the delta and beta isoforms of PI3K. To evaluate this 
hypothesis mast cells were treated with approximate IC50 concentrations of 
IC87114 and TGX-221 in combination. A combined treatment of TGX-221 and 
IC87114 resulted in full inhibition of CXCR3 induced degranulation (Fig 4.27). 
This observation further supports the idea that the p110β and p110δ catalytic 
isoforms of PI3K act in synergy to promoting CXCR3 evoked mast cell 
degranulation. 
Figure 4.27 – Combination of PI3K isoform inhibitors on CXCR3 
degranulation. Human mast cells (1x106) were pre-treated with either TGX-
221 (10 nM, 30 min) and/or IC87114 (1µM, 30 min) before stimulation with 
CXCR3 agonists (1 hr). Samples were centrifuged for 10mins and 
supernatant transferred to new wells before addition of β-hexosaminidase 
substrate for 1.5 hours to measure β-hexosaminidase release. Data are 
expressed as % inhibition of control agonist responses. Results are 
expressed as mean ± SEM of 4 experiments performed in triplicate. 
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Activation of PI3K leads to the formation of 3- phosphorylated 
phosphoinositides which are able to recruit various signalling molecules to 
cellular membranes, once located at the membrane these signalling 
molecules can be phosphorylated by there activating kinases. Therefore 
measurement of the phosphorylation of these signalling molecules is a useful 
method to assess PI3K activity. One such signalling molecule is the protein 
AKT which is phosphorylated by PDK1 (T308) and MTORC2 (S473). 
In order to determine which PI3K isoforms are activated downstream of 
CXCR3; the effect of the isoform specific PI3K inhibitors on AKT 
phosphorylation was assessed by western blot. Stimulating mast cells with 
CXCL9 in the presence of the class I PI3K inhibitor ZSTK474 resulted in a 
loss of AKT phosphorylation (Figure 4.28a). The p110α inhibitor PIK75 had 
no effect on CXCL9-stimulated Akt phosphorylation (Fig 4.28b). The p110-γ 
targeting AS605240 resulted in partial inhibition of Akt phosphorylation (Figure 
4.28b). The inhibition by AS605240 was incomplete even at concentrations 
well above the reported IC50 values (Figure 4.28b). Similar to the results 
obtained for degranulation responses, the dual p110β/δ-targeting TGX-121 
completely inhibited Akt phosphorylation (Fig 4.28e). Furthermore the 
combined (but not individual) treatment of TGX-221 and IC87114, at 
concentrations predicted to be selective for β and δ isoforms respectively, 
also inhibited CXCL9-stimulated Akt phosphorylation (Fig 4.28c-e). 
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Figure 4.28: Effect of PI3K inhibitors on CXCL9, CXCL10, CXCL11, and 
CXCL4 induced phosphorylation of Akt. (A­E) Mature mast cells (1×106 
cells/ml) were pre-treated with vehicle or PI3K isoform-discriminating inhibitor 
at concentrations indicated (30 mins) before stimulation with CXCL9 (100 nM, 
2 min) and lysed by the addition of 1× sample buffer. Cell lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and 
immunoblotted with a phospho-specific Akt Ab with affinity for the active 
Ser473-phosphorylated form of Akt and proteins were visualised with ECL. 
The blots were stripped and reprobed with anti-Akt Ab to verify equal loading 
and efficiency of protein transfer (lower panel). The data are representative of 
two experiments. 
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4.2.2 Summary 
�	 CXCR3 agonists induced partial degranulation of cord blood derived 
mast cells in a CXCR3 and PTX dependent manner. 
�	 CXCL4 induced responses were PTX insensitive therefore suggesting 
that it is not limited to mediating its effect via the PTX insensitive 
CXCR3-B receptor. 
�	 Other inflammatory chemokines induce partial degranulation of mature 
mast cells. 
�	 CXCR3 agonists are capable of inducing the phosphorylation of ERK 
and Akt in mast cells. 
�	 The phosphorylation of ERK and AKT by all tested CXCR3 agonists 
was PTX sensitive. 
�	 CXCR3 mediated effects in mast cells are PI3K dependent. 
�	 The PI3K isoforms suggested to be involved in these responses are 
p110γ and p110β in synergy with p110δ isoforms. 
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4.3 Discussion 
4.3.1	 Expression of CXCR3 Variants in Cord Blood Derived Mast 
Cells 
The cord blood derived mast cell model appeared to be an appropriate model 
to study CXCR3 expression and function on mast cells. All variants of CXCR3 
were expressed at the mRNA level and proteins expression of at least one 
CXCR3 variant was detectable upon the surface. It was notable that protein 
levels of CXCR3 decrease as CD133+ precursors differentiate and mature 
into mast cells. This down regulation of CXCR3 was surprising as all variants 
of CXCR3 were detectable at the mRNA throughout the maturation process. 
There are several possible explanations for the apparent disparity between 
detection of CXCR3 mRNA and lack of detectable protein expression. 
Firstly, the CXCR3 receptor could become post translationally modified which 
interferes with the ability of commercial available antibodies to recognise this 
receptor. Indeed, previous reports have shown that some human chemokine 
receptors are alleged to be sulphated and/or glycosylated at their N-terminal 
extracellular domains, (Colvin et al., 2006; Neel et al., 2005). Secondly, 
CXCR3 variants maybe expressed at the mRNA level but may either not be 
translated to protein or rapidly degraded post-translationally. In this instance, 
a novel receptor expressed on human cord blood derived mast cells may be 
responsible for the biochemical and functional responses observed. 
4.3.2	 Up­Regulation of Chemokine Receptors after Mast Cell 
activation. 
The presented study reveals that levels of CXCR3 were highly expressed 
intracellularly at the progenitor stage. Despite degradation of CXCR3 as the 
cells mature, intracellular levels of CXCR3 were equal to or higher, than was 
expressed on the surface. The chemokine receptor expression profile 
expressed on mat cell is thought to be mainly expressed within cytoplasmic 
granules. Consequently it is believed upon allergic activation, chemokine 
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receptors, especially CCR3 expression is increased on the cell surface 
(Juremalm and Nilsson, 2005). It is possible that this could apply to CXCR3. 
The CXCR3 expression data presented in this thesis is in contrast to other 
studies of CXCR3 in mast cells. Other investigations have reported that in 
human bone marrow-derived precursors, expression of CXCR3 at a protein 
level is low and upon maturation, protein levels of CXCR3 are up-regulated 
(Brightling et al., 2005). Brightling et al, (2005) reports a receptor profile on 
cord blood derived mast cells including CCR1, CCR2, CCR3, CCR7, CXCR1, 
CXCR4, with CXCR3 being the most highly expressed. The differences 
between these studies and the work presented in this thesis highlight that 
mast cells derived from different sources have differing chemokine receptor 
expression profile. 
Human mast cells differentiated from cord blood developed by cytokine 
control have found to be comparable to human mast cells in the lung and gut 
mucosa by similarities found in the sub-structural granule patterns of the cells 
and that the mature cells contained only tryptase (Mitsui et al., 1993). There 
appears to be a consider heterogeneity in the chemokine receptor expression 
profile of mast cells according to species. This is dependent on whether they 
are cord blood derived or bone marrow derived and their final anatomical 
location (Juremalm and Nilsson, 2005). Hence, a mast cells chemokine 
receptor profile is most likely chaped by the cytokine milieu present at the 
relevant progenitor stage. The chemokine receptor profile will be crucial in 
determining the homing progenitor and mature mast cells. 
4.3.3	 Chemokine Agonists Induce Partial Degranulation of 
Human Mature Mast Cells 
To investigate the functional role of CXCR3 agonists within mature mast cell 
degranulation and potential mechanisms behind this degranulation process, 
functional and biochemical studies were performed following stimulation with 
CXCR3 agonists. The work began by carrying out the control experiments 
with the intention of studying the potential of CXCR3 augmentation of sub-
optimal antigen induced degranulation of mature mast cells. Previous studies 
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in mast cells have shown that GPCR agonists such as CCL5 and CCL3 are 
capable of augmenting antigen-induced degranulation in a non-additive 
manner (Laffargue et al., 2002). The evidence presented in this study using 
human cord blood derived mast cells as a model indicates that several 
chemokines operating through different chemokine receptors such as CXCR3, 
CCR3 and CCR2 can induce partial degranulation of mature mast cells in the 
absence of antigen. 
Evidence presented in this thesis highlights that not all chemokines are 
capable of inducing partial degranulation of human mast cells but are still able 
to induce biochemical signals. The data demonstrated that other chemokines, 
for example, CXCL12, can elicit signalling events but this is not sufficient to 
elicit partial degranulation. This suggests that inflammatory chemokines, and 
not homeostatic chemokines, are capable of inducing the partial degranulation 
observed. CXCR3 agonists are classed as inflammatory chemokines due to 
their nature of being all released after IFN-γ stimulation. With the inflammatory 
nature of CXCR3 agonists, they are implicated in a wide range of 
inflammatory diseases. 
One of the hallmarks of allergic inflammatory disorders is the accumulation of 
an abnormally large number of leukocytes including eosinophils, neutrophils, 
lymphocytes, basophils and macrophages in the lung (Bousquet et al., 1990). 
Another distinguishing feature that defines allergic inflammatory disorders is 
the activation of leukocytes by the release of biologically active mediators 
from such cells as mast cells (Rothenberg et al., 1999). Chemokines are key 
mediators in the recruitment of leukocytes to the site of inflammation and the 
subsequent release of a further wide range of mediators. Consequently 
chemokines are a key component in the pathogenesis of inflammatory 
responses in many allergic diseases such as asthma (Baggiolini and 
Dahinden, 1994). The data presented here could provide new insight in to the 
role of chemokines in inflammatory disease. 
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All the chemokines observed in this study induced the partial degranualtion of 
mature mast cells. To date they have been named “inflammatory” 
chemokines. The only chemokine not to induce degranulation, yet still able to 
elicit biochemical signals in this mast cell model was CXCL12, a so- called 
“homeostatic” chemokine. This revelation could provide a new role for 
chemokines in inflammatory disorders. If chemokines are capable of inducing 
the release of mediators from mature mast cells, this in turn will trigger further 
immune responses, initating an immune cascade that could result in damage 
to the host. 
The data presented in this study is in contrast to other research using murine 
bone marrow-derived mast cells, where it was found several chemokines 
(CCL2, CCL5, CXCL10 and CXCL4), are incapable of inducing partial 
degranulation of mast cells (Taub et al., 1995). This serves to underline the 
view that there is considerable heterogeneity in mast cell responsiveness and 
phenotype according to species. The purpose of this chemokine-mediated 
partial degranulation in response to higher concentrations of chemokine 
agonists is likely to function to optimise mast cell activation and tailor it 
according to the local inflammatory context. Since CXCR3 agonists have 
been reported to be present in high levels of allegic inflammatory diseases 
(Widney et al., 2000; Woodman et al., 2006),the data portrayed here indicates 
that CXCR3 agonists can contribute to, and possibly perpetuate, the allergic 
response by inducing partial mast cell degranulation. 
4.3.4 The Role of CXCL4 in Mast Cells 
CXCL4 was previously reported to bind with high affinity to the receptor 
CXCR3B, the first known chemokine receptor to be accredited to CXCL4, 
despite being the first chemokine discovered. Lasagni et al., (2003) 
demonstrated that CXCL4 binds with low nanomolar affinty to CXCR3 B but 
not CXCR3A. This study also demonstrated that this was a functional receptor 
capable of intracellular signalling but was unable to induce migratory 
responses. Recent reports challenge the findings of this particular study. 
Mueller et al., (2008) demonstrated that in L1.2 cell expressing individual 
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isoforms of CXCR3 A or B, CXCL4 was able to bind both isoforms with low 
affinty and was able to induce chemotactic responses via both receptors. This 
highlights the possiblity that CXCL4 can mediate effects through other forms 
of CXCR3 similar to the findings observed in the work presented here. 
The original study that discovered CXCR3B reported microvascular 
endothelial transfectants expressing CXCR3B were coupled to Gαs proteins. 
This is contrast to the other isoforms which are reported to bind to the Gαi 
protein. Unlike Gαi, Gαs is not reported to be sensitive to PTX. Mueller et al., 
(2008) reports that CXCL4 mediates response in CXCR3B transfectants in a 
PTX sensitive manner indicating the presence of a form of CXCR3 that is 
Gαi/o bound. It is understood that CXCL4 can play a wide role in inflammatory 
responses. Recent data has suggested that it can contribute to immune 
activation and T cell trafficking as part of the pathogenesis of ECM in 
experimental cerebral malaria models (Srivastava et al., 2008). The high 
concentrations of CXCL4 reported to be released by activated platelets might 
suggest that CXCL4 could play a role in the subsequent recruitment of 
lymphocytes into the tissues. Based on the data in this thesis the activation of 
mast cells by CXCL4 could result in the large amplification of the immune 
response suggesting it is possible that the blockade of the CXCR3/CXCL4 
axis could be a good target in atherosclerosis (Mueller et al., 2008). 
This investigation only detected the presence of CXCR3B at an mRNA level 
with no detectable presence of protein suggesting that CXCR3B did not play a 
role in the responses observed. The roles of CXCR3A and CXCR3B have 
posed interesting questions. One proposal is that CXCR3A and CXCR3B 
have opposite regulatory effects. This model was proposed by Romagnani et 
al., (2005) who examined the opposite regulatory effects of CXCL10 and 
CXCL4 on human Th1/Th2 polarisation. Luster and Ravetch, (1987) 
demonstrated the Th1-polarising activity of CXCL10 providing a positive 
amplification loop with IFN-γ which is its major inducer. A line of thought 
developed whereby the generation of CXCR3 agonists could help in the 
protection of Th2-mediated allergic inflammatory responses by amplifying the 
TH1 mediated responses against environmental allergens (Gangur et al., 
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1998). CXCL4, however, in its physiological role, is a cationic protein stored 
in the granules and secreted upon platelet activation (McLaren et al.1993). 
With regard to allergic disease increased expression of CXCL4 has been 
detected in human asthmatic subjects (Averill et al., 1992; Yamamoto et al., 
1993), indicating a role of CXCL4 in Th2 diseases. 
The data in this thesis provides a new avenue to be explored in examining the 
role of CXCL4 in allergic disease. The release of CXCL4 by platelets is 
providing key signalling in the amplification of inflammatory diseases by 
mediating granule release from mature mast cells present in the airways. 
4.3.5 CXCR3 Agonists Induce a Short Signalling Profile 
This study investigated biochemical signalling of CXCR3 agonists on mature 
mast cells concentrating specifically on the phosphorylation of the protein Akt 
and Erk1/2. The signalling profile of all CXCR3 agonists is fairly similar in 
length. The signalling profile of CXCR3 agonists varies depending on cell 
type. It has been observed that in intestinal myofibroblasts the signalling 
profile of CXCR3 agonists is longer than observed in this particular study, 
whereas the signalling profile in peripheral blood mononuclear cells is quite 
similar to the signalling prolife in mast cells observed in this thesis 
(Kouroumalis et al., 2005). This may reflect differences in the expression of 
regulatory components such as phosphatases between the different cell 
types. The robustness and duration of the activation of a given signalling 
pathway have far-reaching biological consequences. 
Studies of CXCR3 activation by CXCL11 leads to sustained phosphorylation 
of Akt in T cells that is similar to that previously observed for CXCL12 and 
CXCR4 but distinct from other chemokine receptors (Smit et al., 2003). This 
is in contrast to the data presented in this thesis, which demonstrates that in 
mast cells activation is similar for each ligand and not sustained. Persistent 
activation of Akt by CXCL12 has been explained by the fact CXCR4 is 
involved in homeostasis rather than inflammation. Therefore sustained 
activation could protect CXCR4+ cells from undergoing apoptosis- a process 
that is critical for the activation of T cells (Tilton et al., 2000). 
180

Chapter 4 – Role of CXCR3 in Cord Blood Derived Mast Cells. 
In the case of CXCR3, sustained activation of Akt has only been observed at 
low concentrations, whereas higher concentrations of the activation of Akt is 
transient (Smit et al., 2003). It is proposed that the chemokine signalling 
profile can induce different properties in different cell types. Vlahakis et al., 
(2002) demonstrated that CXCR4 activation in CD4 T cells by CXCL12 led to 
the activation of the prosurvival secondary messengers, Akt and extracellular 
signal-regulated protein kinase. In contrast Akt activation through CXCR4 by 
SDF1alpha interactions is necessary to confer resistance to apoptosis. 
4.3.6 CXCR3 Specificity of the CXCR3 Agonists 
The recent discovery of CXCL11 binding to another chemokine receptor 
CXCR7 raised the question of the specificity (is this a word) of the CXCL11 
responses noted in this study. CXCR7 is another high affinity receptor for the 
inflammatory chemokine CXCL11 and the homestatic chemokine CXCL12. 
Despite binding these two chemokines, it is thought that the CXCR7 signalling 
pathway is distinct from the typical GPCR mechanism of other CXC 
chemokine receptors (Burns et al., 2006). It is still believed that CXCR7 
provides an advantage in growth and survival and evidence suggests CXCR7 
is constitutively active in tumour cells (Burns et al., 2006; Meijer et al., 2008; 
Miao et al., 2007). These studies demonstrate that CXCR7 is a key factor in 
the growth and expression of tumour cells in breast and lung cancer and 
could play a role in other malignancies. Treatment with a small molecule 
weight antagonist against CXCR7 limits growth in syngenic and xenograft 
models thus highlighting further a key role in potential cancer diseases (Burns 
et al., 2006). 
Many atypical receptors exist in the chemokine system. The most studied are 
DARC and D6 whose defined roles are the scavenging of chemokines from 
the system. It has recently been proven that CXCR7 can scavenge the 
chemokine CXCL12. Investigations have suggested a regulated expression of 
CXCR7 and CXCR4 in migrating cells of the primordium,CXCR7 is found 
predominantly in trailing cells and CXCR4 in the front cells (Dambly-
Chaudière et al., 2007; Valentin et al., 2007). This evidence suggests that 
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CXCR7 is an atypical receptor. CXCR7 shares many features similar to 
DARC and D6. Mutations in the DRYLAIV motif and the glycine associated 
with the NxxPY motif is much further down stream than in other chemokine 
receptors similar to D6. 
A more recent investigation has discovered further evidence of CXCR7 as a 
decoy receptor (Boldajipour et al., 2008). This study discovered the enhanced 
internalisation of CXCR7 in somatic cells suggesting that CXCR7 acts as a 
sink for SDF-1a, thus allowing the dynamic changes in the transcription of 
SDF-1a to be mirrored by similar dynamics at the protein level. 
Based on recent research it is now understood that the differential expression 
of CXCR4 and CXCR7 might provide a fine-tuning of CXCL12-migration. This 
view is also supported by the concept that CXCR7 acts as a scavenger 
receptor but does not exclude the possibility that the receptor also activates 
signalling pathways. It is possible that this role of CXCR7 and CXCL12 also 
applies for CXCL11 with CXCR7 tailoring CXCL11 responses to specific 
situations. No obvious or visible protein levels of CXCR7 were detected in this 
study suggesting that other receptors must act as scavenger receptors of 
CXCL11 induced responses. 
4.3.7	 CXCR3 Augmentation of Sub­Optimal Degranulatory 
Responses. 
This research has proved that all CXCR3 agonists are capable of inducing 
augmentation of sub-optimal Antigen induced degranulation of human mast 
cells. This augmentation process has been noted with other GPCRs. The 
degranulation of mast cells by GPCRs in the absence of antigen was first 
observed by (Tilley et al., 2000). It was then subsequently reported by 
(Laffargue et al., 2002) that CCL5 and CCL3 as well as other GPCR agonists 
like ATP, ADP, inosine and LPA were capable of augmenting antigen-induced 
calcium influx and mast cell granule release. All these investigations, 
including this one, highlighted the role of GPCR agonists in mast cell 
activation and involvement in many immune reactions: for example- system 
182

Chapter 4 – Role of CXCR3 in Cord Blood Derived Mast Cells. 
anaphylaxis. A variety of research models has shown the activation of mast 
cells by chemokines both in vitro and in vivo (Alam et al., 1992; Alam et al., 
1994; Conti et al., 1995) further emphasising a key role of a wide range of 
chemokines in mast cell activation. This further endorses the role of 
chemokines in many allergic and inflammatory diseases by the accumulation 
of chemokines at many disease sites (Alam et al., 1996; Gerard and Rollins, 
2001; Gordon, 2000; Luster and Rothenberg, 1997). 
4.3.8 Role of Activation Markers in Mast Cells 
It was clearly demonstrated in this thesis that upon activation of mast cells by 
CXCR3 agonists, the activation markers CD63 and CD203c were up-
regulated. It is understood that membrane complexes containing CD63 and 
CD203c control mast cell adhesion and induced degranulation by a shared 
pathway. The translocation of granules to the cell membrane is vital to the 
exocytosis of mast cell granules. (Nishida et al., 2005) observed the 
translocation of CD63-containing granules to the plasma membrane in the 
absence of calcium. In these particular conditions they did not observe FcåRI-
induced increase of cell surface expression of CD63 by FACS analysis. It is 
considered that the membrane fusion is calcium dependent in general (Lin 
and Scheller, 2000). (Kraft et al., 2005) demonstrated that CD63, is 
associated to signalling components that are key to the formation of the 
membrane complexes containing CD63. They also established that inhibiting 
CD63 impairs the Gab2–PI3K pathway known to be essential for both 
degranulation and adhesion (Kraft et al., 2005). 
4.3.9 Pharmacological Investigations into the PI3K Family 
Following clarification of the function and biochemical effects of the CXCR3 
agonists, attention was then focused on investigating the mechanism of 
CXCR3 induced degranulation. Initial interest was on the PI3K family utilising 
inhibitors to dissect the role of the class 1 isoforms on degranulation and 
signalling. Cross-linking of the FcεRI by antigen is known to activate a Tyr 
kinase signalling cascade which provides a direct molecular link to class IA 
PI3K signalling (Deane and Fruman, 2004; Okkenhaug et al., 2007). Genetic 
or pharmacological inactivation of p110δ has been shown to lead to a 
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substantial, but not complete, block in the allergic responses in mice (Ali et al., 
2004; Lee et al., 2006; Nashed et al., 2007). Worthy of note is the fact that 
genetic inactivation of p110γ in mice has been reported to lead to a complete 
block in passive cutaneous and systemic anaphylaxis responses in vivo 
(Laffargue et al., 2002). 
This is quite remarkable given that the FcεRI Tyr kinase signalling pathway 
does not appear to provide a direct molecular link to this GPCR coupled PI3K. 
Evidence based largely on the use of in vitro cultured mast cells suggested 
that p110γ may be part of an auto/paracrine mechanism whereby exocytosed 
mast cell-derived GPCR agonists, initially released by an FcεRI-dependent 
pathway, promote hyperactivation of mast cells through GPCR signalling to 
overcome inhibition by lipid phosphatases such as SHIP and PTEN, which 
antagonize PI3K signalling (Harris et al., 2008). Recent experiments in 
murine models have shown that in vitro both p110δ and p110γ are required 
for FcεRI-driven mast cell degranulation, whereas in vivo, p110γ (but not 
p110δ) is dispensable for allergic responsiveness (Ali et al., 2004; Ali et al., 
2008; Laffargue et al., 2002). 
4.3.10 A Critical Role for PI3Kγ in CXCR3 Agonists Induced Partial 
Degranulation 
In common with all pharmacological tools to unequivocally attribute function to 
a particular isoform, it was important to establish the respective selectivity for 
these compounds. The PI3K inhibitors utilised in this study, exhibit selectivity 
between their primary isoform target and the other membranes of the family 
(Table 1). As anticipated, the data presented in this study using the p110γ-
discriminating PI3K inhibitor AS605240 indicates that p110γ makes a 
significant contribution to the signalling events that underpin CXCR3 agonist-
induced mast cell degranulation. This was also observed in signalling through 
inhibition of Akt in responses to CXCR3 agonists. The discovery that p110γ 
plays a key role in mast cell responses is supported in both in vivo and in vitro 
studies (Laffargue et al., 2002; Wymann et al., 2003). The inhibition by 
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AS605240 recorded in this study was incomplete even at concentrations well 
above the reported IC50 values, suggesting the presence of other PI3K 
isoforms. 
4.3.11 What is the contribution of other Class 1 PI3K isoforms to 
CXCR3 Agonist­Induced Mast Cell Degranulation? 
The inhibitor PIK75 was utilised in this thesis to investigate the role of PI3K 
class 1A. This inhibitor is selective for the α member of the PI3K family with 
an IC50 for this isoform at approximately 8nM and had no effect on CXCR3 
induced degranulation, even at concentrations above its IC50, especially at the 
concentrations it is predicted to impinge on p110γ. This implies reduced cell 
permeability and bioavailability of this compound in comparison to the other 
PI3K isoform-discriminating inhibitors undertaken in this thesis 
Other kinases (most notably DNA-PK) have been reported to be inhibited by 
PIK75. This occurs at an IC50, at an even lower concentration, than that 
predicted for p110α. The evidence presented in this study would suggest that 
this kinase has no role to play in mast cells degranulation by CXCR3 agonists. 
The role of PI3K has become clearer over the last few years Recent genetic 
knock-in and pharmacological approaches have suggested that, of class IA, it 
is the p110α  isoform (PIK3CA) that plays the predominant role in insulin 
signalling (Chaussade et al., 2007). 
4.3.12 A Potential Synergy between p110δ and p110β 
Combined (but not individual) treatment of both p110β and p110δ 
discriminating inhibitors attenuated degranulation responses and 
phosphorylation of Akt in response to CXCR3 agonists. Compounds that 
inhibit p110β tend also to inhibit p110δ isoforms (Crabbe et al., 2007; Knight 
et al., 2006; Smith et al., 2007). Consequently these isoforms have been 
termed pharmalogs. Carefully controlled experiments with a panel of PI3K 
isoform-discriminating inhibitors with differing selectivities suggest a hitherto 
unrecognised functional relationship between p110β and p110δ. 
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Evidence has previously been presented for the coupling of p110β to GPCRs 
either by in vitro studies that documented activation of p110β by Gβγ subunits 
(Kurosu et al., 1997; Maier et al., 1999) or in cellular experiments where 
p110β function was probed by microinjection of neutralising Ab to p110β 
(Graness et al., 1998; Roche et al., 1998), RNAi against p110β (Graness et 
al., 1998) or expression of p110β (Kubo et al., 2005; Yart et al., 2002), all 
highlight activation of p110β by GPCRs. Recent evidence using cells derived 
from mice with conditional genetic inactivation of p110β has revealed that 
p110β and p110γ can couple redundantly to the same GPCRs including some 
chemokines receptors (Guillermet-Guibert et al., 2008). The work presented 
in this thesis would suggest that, at least in human mast cells, p110β operates 
in tandem with p110δ and provides a conduit for agonist-induced 
degranulation. 
4.3.13 Class1A and 1B PI3K dependent degranulation 
This thesis implicates a key role for the p110γ as well as p110delta in 
combination with p110β in CXCR3 mediated partial degranulation of human 
mast cells. Other studies have highlighted a role for both the class 1A and 1B 
PI3Ks. Dependence on PI3K has been listed in a number of systems with 
migratory processes being the most widely studied. 
Throughout the presented thesis, it was highlighted that p110γ played a key 
role in chemokine-mediated degranulation. The importance of 110 γ in other 
studies has also been emphasised) These studies focused particular attention 
on the role of p110γ with neutrophils (Hannigan et al., 2002; Hirsch et al., 
2000; Sasaki et al., 2000). The p110γ knock out murine models also revealed 
that in neutrophils, no PtdIns(3,4,5)P3 production was detected, therefore 
suggesting a role for the class 1B PI3Ks within the generation of 
PtdIns(3,4,5)P3 in these knockout murine models (Li et al., 2000). 
The biphasic generation of PtdIns(3,4,5)P3 has been shown to be dependent 
on both classes of PI3K. The first phase is dependent on p110γ, whereas the 
second is determined largely by the class1A, mostly through p110δ, but to 
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some extent influenced by p110α and p110β. This points to a potential dual 
role of the distinct classes of PI3K as both classes are seen to be crucial to 
the induction of mast cell degranulation. It is possible that the two activation 
stages of PtdIns(3,4,5)P3 by the classes of PI3K are critical to the activation 
of mast cells whereas one activation is not enough to generate degranulation. 
4.3.14 CXCR3 Reorganises the Actin Cytoskeleton. 
Initial studies on the adrenal chromaffin cell highlight that reorganisation of the 
cortical actin network is necessary to allow granules to reach exocytotic sites 
in stimulated cells. This reorganisation may involve changes in actin filament 
cross-linking, assembly and interactions with secretory granules and plasma 
membranes (Burgoyne) et al., 1987). Localised disassembly of cortical F-actin 
has long been considered necessary for the facilitation of exocytosis. Several 
studies have proved that the reorganisation of actin increases both the rate 
and extent of FcεRI-induced degranulation (Frigeri and Apgar, 1999; Oka et 
al., 2002). Biochemical studies indicate that FcεRI stimulation causes a rapid 
increase in the level of F-actin in RBL cells (Frigeri and Apgar, 1999; Pfeiffer 
et al., 1985). The precise roles of the cytoskeletal re-arrangements in the mast 
cell degranulation process have not been established. 
Chemokine signalling induces re-modelling of cytoskeleton such as the 
reorganisation of F-actin filaments that allows the cells to flatten and attain 
cellular polarisation. The classical CXCR3 agonists, CXCL9, CXCL10 and 
CXCL11 have been previously shown to promote actin reorganization 
(Kouroumalis et al., 2005). It is now well established that the dynamics of 
actin cytoskeleton are closely regulated by the activation of members of the 
Rho GTPase family including RhoA and Rac1 and their activities control mast 
cell degranulation. Rho, in particular, has been associated with stress fibre 
formation and cell contractility (Ridley and Hall, 1992). Several proteins have 
been identified as putative Rho effectors on the basis of their selective 
interaction with GTP-bound Rho. The ROCK family of kinases has been 
shown to be involved in Rho-induced formation of actin stress fibres and focal 
adhesions (Amano et al., 1997; Leung et al., 1996; Leung et al., 1995). In 
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association with this pre-treatment of human mast cells with Y27632 abolished 
CXCR3 agonist-induced actin polymerisation. 
Regulation of actin polymerization, downstream from G protein-coupled 
receptors, was originally thought to depend on PI3K activation and involves 
the activation of PKB and the GTPases Cdc42 and Rac2 (Pollard et al., 2000). 
Recently an alternative PI3K-independent mechanism for actin polymerization 
in human neutrophils has been proposed (Chodniewicz and Zhelev, 2003). 
This PI3K-independent pathway in neutrophils has been shown to be 
dependent on Src tyrosine kinases, NADPH oxidase and protein kinase A, as 
well as RhoA and ROCK. Further evidence supports the existence of a PI3K-
independent pathway. The discovery that LY294002 did not appear to have 
any effect on CXCL9-, CXCL10-, or CXCL11-induced actin polymerisation 
(Kouroumalis et al., 2005) supports the presence of a PI3K independent 
pathway of the reorganisation actin by CXCR3 agonists is PI3K independent. 
4.3.15 Clinical importance of CXCR3 Agonists 
CXCR3 and its four agonists, CXCL9, CXCL10, CXCL11 and CXCL4 play a 
role in a wide range of cellular functions and diseases. Considerable interest 
in this chemokine receptor and its agonists has raised many questions about 
its importance in a clinical setting. Clinical and pre-clinical studies suggest that 
CXCR3 and its ligands significantly contribute to the cellular infiltration that 
result in heart, lung and skin allograft rejection (Agostini et al., 2001; Belperio 
et al., 2002; Belperio et al., 2003; Hancock et al., 2000; Koga et al., 1999; 
Miura et al., 2001). 
The role of CXCR3 agonists is dependent on the diseases setting, or in many 
cases, the experimental model used (Belperio et al., 2002; Fahmy et al., 
2003; Kao et al., 2003; Zhao et al., 2002). One example of this is the role of 
CXCL9 and CXCL10 having an involvement in bronchiolitis obliterans 
syndrome after lung transplantation whereas CXCL11 plays no part (Belperio 
et al., 2003). This pattern has also been observed in acute cardiac allograft 
rejection (Zhang et al., 2004; Zhao et al., 2002). 
188

Chapter 4 – Role of CXCR3 in Cord Blood Derived Mast Cells.

CXCR3 is known to be a key target in the treatment against graft rejection. 
High levels of CXCL10 have been shown to directly correlate with instances of 
heart and lung rejection in human tissue (Agostini et al., 2001; Melter et al., 
2001). CXCL9 has been identified as the dominant factor directing CXCR3+ T 
cells into both cardiac and tracheal allografts in murine models (Belperio et al., 
2003; Miura et al., 2001). The data presented in this thesis has further 
highlighted the potential clinical importance of CXCR3 by presenting evidence 
that CXCR3 agonists are important in any immune response involving mast 
cells. Inhibition of the amplification of degranulation reponses could help 
reduce many recognised diseases such as rheumatoid arthritis, allowing 
easier resolution of imflammatory responses. 
4.3.16 Cytosolic Ca2+ not require for CXCR3 Function in Mast Cells 
In most, but not all cells, activation of chemokine receptors induces an 
increase in cytosolic calcium. In this thesis, not all CXCR3 agonists changed 
cytosolic calcium levels in mature mast cells. These results differ from studies 
in other mast cell models where CXCR3 agonists increased Ca2+(Brightling et 
al., 2005). Of notable interest is the absence of a Ca2+ which has been 
associated with other chemokine receptors and their agonists. For example, 
RANTES/CCL5 induces CCR5-mediated T-lymphocyte chemotaxis without 
changing cytosolic Ca2+ (Turner et al., 1995). Furthermore, IL-8/CXCL2 
induces CXCR2-mediated neutrophil migration without an increase in Ca2+ in 
cells from PLC-β2/β3 knockout mice (Li et al., 2000). The absence of calcium 
mobilisation in response to chemokine agonists ,despite the ability to induce a 
functional response, has also been highlighted by CXCR3 agonists. CXCR3 
agonists induced chemotaxis in human airway epithelial cells without 
mobilising cytosolic calcium (Shahabuddin et al., 2006). Coupled with the data 
presented in this study, this suggests that changes in Ca2+ are not always 
necessary for directional sensing and cell shape change. 
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4.3.17 Role of PLC in Degranulation 
This study and many other studies have shown the dependence of PI3K in 
mast cell degranulation. It has been recently highlighted that the presence of 
a PLC dependent but PI3K independent pathway leads to mast cell activation 
(Kuehn and Gilfillan, 2007). PLC-mediated hydrolysis is required for mast cell 
exocytosis. On the onset of exocytosis, PtdIns(4,5)P2 is eliminated from the 
extra cellular membrane. PLC is essential to the process of removal of 
PtdIns(4,5)P2 from the plasma membrane. PLC is required to initiate the Ca
2+ 
signal at the onset of exocytosis yet Ca2+ is necessary for PLC activity. PLC 
depletes PtdIns(4,5)P2 from incipient phagosomes causing breakdown of the 
surrounding F-actin (Scott et al., 2005). It has also been proven that mast 
cells containing an F-actin cortex break down at the onset of degranulation 
(Nishida et al., 2005; Price et al., 1995). Disruption of this cortex is seen to 
enhance degranulation (Borovikov et al., 1995; Martin-Verdeaux et al., 2003). 
A fair conclusion would be that PtdIns(4,5)P2 breakdown is associated with 
the breakdown of the cortical actin cytoskeleton. Hammond et al., (2006) 
discovered that PLC is required for exocytosis, independent of the Ins(1,4,5)-
P3–Ca2+ pathway by eliminating PtdIns(4,5)P2 from the plasma membrane. 
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Figure 4.29: Proposed model for PI3K signalling role in cord blood mast 
cell degranulation. Stimulation of CXCR3 by its agonists leads 
predominantly to activation of p110γ leading to the accumulation of 
PI(3,4,5)P3 at levels sufficient to initiate activation of downstream effectors 
such PLC and drive degranulation. CXCR3 agonists also lead to the 
activation of the G protein coupled p110β isoform, though the levels of 
PI(3,4,5)P3 formed by activation of this PI3K isoform alone are insufficient to 
promote downstream effectors and initiate degranulation and/or redundant 
with p110γ-derived PI(3,4,5)P3. However, the PI(3,4,5)P3 formed by p110β 
leads instead to the recruitment of PH domain-containing adaptor proteins 
which, in turn, lead to the recruitment and activation of p110δ, via SRC by 
GPCRs, contributing to the formation of PI(3,4,5)P3. The pool of PI(3,4,5)P3 
which is formed by the combined actions of p110β and p110δ is sufficient to 
evoke PI3K effectors and elicit degranulation responses. This model allows 
for discrete and critical differences in the spatio-temporal regulation of 
PI(3,4,5)P3 accumulation by distinct PI3Ks that ensure optimal mast cell 
responses to activating stimuli. 
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4.4 Future Work 
4.4.1	 The Role of CXCR3 in Precursor and Immature Mast Cell 
Stages. 
As this study demonstrated in immature mast cells, CXCR3 agonists are 
functional at least at a biochemical signalling level. With the reported down-
regulation of CXCR3 in this investigation it would be of interest to further 
investigate the function of CXCR3 at earlier stages than the mature mast cell 
stage explored here. This study has focussed on the potential role of CXCR3 
in the migration of precursors to blood and the migration of immature mast 
cells from the blood to the tissues. It would be of considerable interest to 
further investigate the migratory role of CXCR3 agonist in these stages of 
mast cell development. 
4.4.1.1 Clarifying the Synergy of the PI3K Isoforms. 
This study highlighted the importance of PI3K isoforms in the degranulatory 
mechanism of mast cells by both CXCR3 and FcεRI induced degranulation, 
focusing essentially on the role of the synergy between the β and δ isoforms. 
With the emerging role of PI3K isoforms in mast cell degranulation it would be 
prudent to further investigate the potential synergy between the β and δ 
isoforms of PI3K. The data demonstrates the activation of signalling and 
degranulation. 
The evidence for the PI3K isoforms however is only based on the use of 
inhibitors. Therefore utilising other technologies such as siRNA interference 
to provide further evidence of the synergy of the PI3K isoforms involved in 
mast cell degranulation would be useful 
4.4.1.2 Other Mast Cell Models 
The evidence presented in this study looked specifically at a mast cell model 
derived from cord blood precursor cells. It is widely known that the differences 
in mast cells are dependent upon their final anatomical location. It would 
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therefore be of considerable interest to investigate if the key findings in this 
study are mirrored in other primary human mast cell models. 
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5. Summary 
The presented work characterises the role of the chemokine receptor CXCR3 
and its spliced variants, namely CXCR3B and CXCR3-alt, in different human 
mast cell model. In the investigation of CXCR3 in HMC-1 cell line, only 
variants CXCR3A and CXCR3B were detected while on the primary mast cell 
model all variants of CXCR3 were detected at the mRNA level. This thesis 
concludes that the HMC-1 cell line make a poor model for CXCR3 studies in 
mast cells. This is due to the mutation in the SCF receptor resulting in the 
constitutive activation of downstream signalling proteins, making signalling 
events induces by CXCR3 impossible to determine. No functional responses 
by any of the CXCR3 agonist were detected in HMC-1 in this thesis. 
The work presented in this thesis highlights the downregulation CXCR3 in the 
differentiation and maturation of CD133+ precursors into mature mast cells. 
This is in direct contrast to other studies which report the upregulation of 
CXCR3 in mast cell maturation process. It is proposed in this thesis that the 
cytokine mileu that the precursors are exposed to will determine the subtype 
of mast cells that they will eventually differentiate into. Therefore this thesis 
has also proposed that the role of CXCR3 in mast cell precursors derived 
from cord blood is to induce the migration into the tissues, the place where 
mast cells will mature. 
This thesis reports for the first time the induction of degranulation, albeit 
partial, of human mast cells by CXCR3 agonists. It has previously been 
shown that GPCRs can augment the sub-optimal antigen/FcεRI induced 
release, but never the direct release of mediators from mast cells after 
CXCR3 activation. This response was further surprising with respect to 
CXCL4, as the only current known receptor for CXCR3B which was 
undetectable at a protein level in cord blood derived mast cells. Therefore it is 
proposed in this thesis that CXCL4 could bind isoforms other than CXCR3 or 
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that CXCR3B becomes post-translationally modified making it undetectable 
by currently available commercial antibodies. 
This result highlights a new role for chemokines in mast cells never before 
reported. With this finding of direct induced degranulation of human mast cells 
by CXCR3, this study focused on how closely this responses mirrored 
antigen/FcεRI responses. 
This thesis demonstrated that pathways involved in both antigen 
degranulation and CXCR3 degranulation were identical. The pathways 
highlighted in this thesis that are critical to the degranulation response were 
the PLC and PI3K pathways. 
It is presented in this thesis that activation of individual PI3K isoforms are key 
to the degranulation response. All CXCR3 agonists induced degranulation 
that was dependent on the p110γ isoform of PI3K. However, for the first time, 
it is also reported in this thesis that p110δ isoform in synergy with p110β 
isoform are also key to induction of the degranulation response. This finding 
was observed utilising a of wide range of PI3K isoform specific inhibitors. This 
synergy was not only observed in degranulation responses but also in Akt 
phosphorylation where both p110δ and p110β isoforms were needed to be 
inhibited before complete attenuation of Akt responses. 
In summary, despite only low levels of detectable CXCR3 expression, I have 
demonstrated biochemical and functional mast cell responses to CXCR3 
agonists that are inhibited by PTX and selective CXCR3 antagonists. I provide 
the first evidence that chemokine induced partial degranulation of human cord 
blood derived mast cells responses are dependent not only on p110γ, but also 
on an unexpected p110δ and p110β synergy. These findings provide a novel 
insight into problems and opportunities to selective target of PI3K isoforms in 
allergic disease settings and general manipulation of the immune system with 
such tools. 
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6. Appendix 
6.1Buffers and Solutions 
6.1.1 Solutions and buffers for SDS­PAGE and western blotting 
Lysis Buffer 4x Resolving Gel Buffer 
1.5M Trizma base pH 8.8 
0.4 % (w/v) SDS 
MilliQ Water 
1% (v/v) Nonidet P-40 
150nM NaCl 
50mM Tris pH 7.5 
5mM EDTA 
10mM Sodium Fluoride* 
1mM Phenylmethylsulfonyl fluoride* 
10µg ml-1Leupeptin* 
10µg ml-1Aprtinin* 
1µg ml-1Soybean Trypsin Inhibitor* 
1µg ml-1Pepstatin A* 
1mM Sodium Orthovanadate* 
1mM Sodium Molybdate 
MilliQ Water 
N.B * Denotes added on the day of use 
SDS-PAGE Running Buffer 5 x SDS-Sample Buffer 
25mM Trizma Base 
192mM Glycine 
0.1%(w/v) SDS 
MilliQ Water 
5% SDS 
50% Glycerol 
200mM Tris-HCl pH 6.8 
MilliQ Water 
4 x Stacking Gel Buffer 
0.5 M Trizma Base pH 6.8 
0.4% (w/v) SDS 
MilliQ Water 
Bromophenol Blue 
5% 2-mercaptoethanol 
Semi-Dry Transfer Buffer Tris-Buffered Saline(TBS) 
29mM Glycine 
48mM Trizma Base 
0.0375% SDS 
20mM Tris-HCl pH 7.5 
150mM NaCl 
MilliQ Water 
20% (v/v) Methanol 
MilliQ Water 
Tris-Buffered Saline-Tween (TBST) Stripping Buffer 
TBS + 0.1% (v/v) Tween-20 62.5mM Tris-HCL pH 6.8 
2% (w/v) SDS 
100mM 2-mercaptoethanol 
MilliQ Water 
Appendix 
6.1.2 Recipes for SDS­PAGE Gels 
Resolving Gel Stacking Gel 
10% 4X 
4x Resolving Buffer or 5 5 
Stacking Buffer (ml) 
MilliQ Water (ml) 8.17 6.85 
Acrylamide (ml) 6.67 2.0 
APS(10%) (µl) 150 150 
TEMED (µl) 15 15 
6.1.3 Immunoblotting Conditions for Specific Primary Antibodies

Secondary 
Antibody 
Concentration3 
Molecule Targeted By 
Primary Antibody 
Primary 
Antibody 
Species (kDa) Concentration2 
Molecular 
Weight 
Blocking 
Buffer1 Antibody 
Primary 
PhosphorSer473-Akt Rabbit 60 5% 1:1000 1:10000 
Akt1 Goat 60 5% 1:1000 1:10000 
phosphoThr402/Tyr404 Rabbit 42/44 5% 1:1000 1:10000 
ERK1/2 
phosphoSer236/236S6 Rabbit 32 5% 1:1000 1:10000 
CXCR3 Mouse 42 5% 1:100 1:10000 
CXCR7 Mouse 40 5% 1:100 1:10000 
1 Expressed as percentage (w/v) non-fat milk diluted w/v in TBST 
2 Diluted v:v in 0.01%(w/v) Sodium Azide TBST 
3 Dilution v:v in 1% (w/v) non-fat milk in TBST 
6.1.4 Recipes for Buffers in Flexstation Ca2+ Readings 
Master Buffer Assay Buffer 
500ml HPSS (w/o Ca2+) 198mls Master Buffer 
750µl CaCl2 1M 2mls Probenecid (250mM) 
10ml HEPES 1M (pH 7.3) 
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